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A B S T R A C T
Background
Adrenaline and vasopressin are widely used to treat people with cardiac arrest, but there is uncertainty about the safety, effectiveness
and the optimal dose.
Objectives
To determine whether adrenaline or vasopressin, or both, administered during cardiac arrest, afford any survival benefit.
Search methods
We searched the Cochrane Central Register of Controlled Trials, MEDLINE, Embase and DARE from their inception to 8 May
2018, and the International Liaison Committee on Resuscitation 2015 Advanced Life Support Consensus on Science and Treatment
Recommendations. We also searched four trial registers on 5 September 2018 and checked the reference lists of the included studies
and review papers to identify potential papers for review.
Selection criteria
Any randomised controlled trial comparing: standard-dose adrenaline versus placebo; standard-dose adrenaline versus high-dose
adrenaline; and adrenaline versus vasopressin, in any setting, due to any cause of cardiac arrest, in adults and children. There were no
language restrictions.
Data collection and analysis
Two review authors independently identified trials for review, assessed risks of bias and extracted data, resolving disagreements through
re-examination of the trial reports and by discussion. We used risk ratios (RRs) with 95% confidence intervals (CIs) to compare
dichotomous outcomes for clinical events. There were no continuous outcomes reported.We examined groups of trials for heterogeneity.
We report the quality of evidence for each outcome, using the GRADE approach.
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Main results
We included 26 studies (21,704 participants).
Moderate-quality evidence found that adrenaline increased survival to hospital discharge compared to placebo (RR 1.44, 95% CI 1.11
to 1.86; 2 studies, 8538 participants; an increase from 23 to 32 per 1000, 95% CI 25 to 42). We are uncertain about survival to hospital
discharge for high-dose compared to standard-dose adrenaline (RR 1.10, 95% CI 0.75 to 1.62; participants = 6274; studies = 10); an
increase from 33 to 36 per 1000, 95% CI 24 to 53); standard-dose adrenaline versus vasopressin (RR 1.25, 95% CI 0.84 to 1.85; 6
studies; 2511 participants; an increase from 72 to 90 per 1000, 95% CI 60 to 133); and standard-dose adrenaline versus vasopressin
plus adrenaline (RR 0.76, 95% CI 0.47 to 1.22; 3 studies; 3242 participants; a possible decrease from 24 to 18 per 1000, 95% CI 11
to 29), due to very low-quality evidence.
Moderate-quality evidence found that adrenaline compared with placebo increased survival to hospital admission (RR 2.51, 95% CI
1.67 to 3.76; 2 studies, 8489 participants; an increase from 83 to 209 per 1000, 95% CI 139 to 313). We are uncertain about survival
to hospital admission when comparing standard-dose with high-dose adrenaline, due to very low-quality evidence. Vasopressin may
improve survival to hospital admission when compared with standard-dose adrenaline (RR 1.27, 95% CI 1.04 to 1.54; 3 studies, 1953
participants; low-quality evidence; an increase from 260 to 330 per 1000, 95% CI 270 to 400), and may make little or no difference
when compared to standard-dose adrenaline plus vasopressin (RR 0.95, 95% CI 0.83 to 1.08; 3 studies; 3249 participants; low-quality
evidence; a decrease from 218 to 207 per 1000 (95% CI 181 to 236).
There was no evidence that adrenaline (any dose) or vasopressin improved neurological outcomes.
The rate of return of spontaneous circulation (ROSC) was higher for standard-dose adrenaline versus placebo (RR 2.86, 95% CI 2.21
to 3.71; participants = 8663; studies = 3); moderate-quality evidence; an increase from 115 to 329 per 1000, 95% CI 254 to 427). We
are uncertain about the effect on ROSC for the comparison of standard-dose versus high-dose adrenaline and standard-does adrenaline
compared to vasopressin, due to very low-quality evidence. Standard-dose adrenaline may make little or no difference to ROSC when
compared to standard-dose adrenaline plus vasopressin (RR 0.97, 95% CI 0.87 to 1.08; 3 studies, 3249 participants; low-quality
evidence; a possible decrease from 299 to 290 per 1000, 95% CI 260 to 323).
The source of funding was not stated in 11 of the 26 studies. The study drugs were provided by the manufacturer in four of the 26
studies, but neither drug represents a profitable commercial option. The other 11 studies were funded by organisations such as research
foundations and government funding bodies.
Authors’ conclusions
This review provides moderate-quality evidence that standard-dose adrenaline compared to placebo improves return of spontaneous
circulation, survival to hospital admission and survival to hospital discharge, but low-quality evidence that it did not affect survival with
a favourable neurological outcome. Very low -quality evidence found that high-dose adrenaline compared to standard-dose adrenaline
improved return of spontaneous circulation and survival to admission. Vasopressin compared to standard dose adrenaline improved
survival to admission but not return of spontaneous circulation, whilst the combination of adrenaline and vasopressin compared with
adrenaline alone had no effect on these outcomes. Neither standard dose adrenaline, high-dose adrenaline,vasopressin nor a combination
of adrenaline and vasopressin improved survival with a favourable neurological outcome. Many of these studies were conducted more
than 20 years ago. Treatment has changed in recent years, so the findings from older studies may not reflect current practice.
P L A I N L A N G U A G E S U M M A R Y
Adrenaline and vasopressin for cardiac arrest
Review question
Do the drugs adrenaline or vasopressin improve survival in cardiac arrest.
Background
Cardiac arrest occurswhen someone’s heart unexpectedly stops beating.Without any treatment, death occurswithinminutes. Treatments
that are proven to work in cardiac arrest include cardiopulmonary resuscitation and giving an electric shock (defibrillation). If these
treatments do not work, drugs such as adrenaline and vasopressin are injected (usually into a vein) to try to restart the heart. The early
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scientific evidence which led to their use came largely from small studies in animals. Whilst some human studies have shown that these
drugs can help restart the heart initially, research also suggests they may have harmful effects on the brain.
Search date
The last search was conducted on 8 May 2018.
Study Characteristics
We identified 26 randomised controlled trials, involving 21,704 participants, that examined the effect of adrenaline or vasopressin
on survival after cardiac arrest that occurred in and out of hospital and in adults and children. Some studies compared adrenaline in
standard doses with placebo (dummy medication); some examined standard-dose versus high-dose adrenaline; and others compared
vasopressin alone or vasopressin plus adrenaline to standard doses of adrenaline.
Study funding sources
The source of funding was not stated in 11 of the 26 studies. The study drugs were provided by the manufacturer in four of the 26
studies, but neither drug represents a profitable commercial option. The other 11 studies were funded by organisations such as research
foundations and government funding bodies.
Key results
The studies found evidence that adrenaline was effective at restarting the heart and helping people recover enough to go home from
hospital. However, there was no evidence that any of the drugs improved survival with a good neurological outcome.
Quality of the evidence
The overall quality of evidence ranged from low to moderate (for studies comparing adrenaline to placebo), but mainly low or very
low for the other comparisons, due to risks of bias within the studies. Many of these studies were conducted more than 20 years ago.
Treatment has changed in recent years, so the findings from older studies may not reflect current practice. The studies examined the
drugs in many different situations (in and outside of hospitals, at different dosages, and in both adults and children), which may make
combining findings misleading.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Standard-dose adrenaline (SDA) compared to placebo for cardiac arrest
Patient or population: people suf fering cardiac arrest
Setting: either outside of hospital (OHCA) or during hospitalisat ion (IHCA)
Intervention: standard-dose adrenaline (SDA)
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with standard-
dose adrenaline
Survival to hospital dis-
charge
Study populat ion RR 1.44
(1.11 to 1.86)
8538
(2 RCTs)
⊕⊕⊕©
MODERATEa
OHCA only
23 per 1000 32 per 1000
(25 to 42)
Survival to hospital ad-
mission
Study populat ion RR 2.51
(1.67 to 3.76)
8489
(2 RCTs)
⊕⊕⊕©
MODERATEa
OHCA only
83 per 1000 209 per 1000
(139 to 313)
Favourable neurologi-
cal outcomes
Study populat ion RR 1.21
(0.90 to 1.62)
8535
(2 RCTs)
⊕⊕©©
LOWa,b
Favourable neurologi-
cal outcomes were de-
f ined as a CPC score of
< 3 or mRS < 4
OHCA only
19 per 1000 22 per 1000
(17 to 30)
Return of spontaneous
circulat ion
Study populat ion RR 2.86
(2.21 to 3.71)
8663
(3 RCTs)
⊕⊕⊕©
MODERATEc
OHCA and IHCA
115 per 1000 329 per 1000
(254 to 427)
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; CPC: cerebral performance category; mRs: modif ied Rankin score
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level as one study at high risk of bias for incomplete outcome data
bDowngraded by one level for imprecision. The CI crosses the clinical decision threshold.
cDowngraded one level as two studies at high risk of bias for incomplete outcome data
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B A C K G R O U N D
Description of the condition
Sudden cardiac arrest is defined by the absence of signs of cir-
culation (Utstein 2015). Each year, globally, hundreds of thou-
sands of people sustain a cardiac arrest from which fewer then one
in ten survive if the arrest occurs outside a hospital (Beck 2018;
Daya 2015; Grasner 2016; PAROS 2015) and around one in five
if the arrest occurs inside a hospital (Girotra 2014; Nolan 2014).
Key treatments associatedwith survival are high-quality cardiopul-
monary resuscitation (CPR) (Hasselqvist-Ax 2015; Sasson 2010;
Wik 2016) and early defibrillation (Sandroni 2007; Sasson 2010).
The initial goal of resuscitation is to restart the heart, described
as achieving return of spontaneous circulation (ROSC). However
amongst those people in whom ROSC is achieved, only about
25% to 50% survive to go home from hospital. The main causes
of hospital deaths are severe brain injury and multi-organ failure
(Laver 2004). Thus overall survival rates to hospital discharge are
low, in the range of 0.6% to 25% (Berdowski 2010).
A significant proportion of those who survive to leave hospital
are left with significant brain damage (Corrada 2013; Kim 2016;
Scales 2016). Even those with apparently good overall recovery
may be left with subtle cognitive impairment (Nolan 2015a).
Description of the intervention
Pharmacological agents were a central part of early resuscitation
algorithms, but the evidence for whether or not they are effective
has been questioned for nearly two decades (Lundin 2016; Nolan
2002; Perkins 2014). Adrenaline has been used over a range of
doses (0.5 mg to more than 10 mg) through intracardiac, intra-
venous, endobronchial and intraosseous routes.
Vasopressin was explored as an adjunct or alternative to adrenaline
in the late 1990s. Early experimental and animal studies sug-
gested that vasopressinwas superior to adrenaline, particularly dur-
ing prolonged resuscitation (Wenzel 2000). However, evaluation
in subsequent randomised controlled trials in humans produced
equivocal results (Layek 2014). Vasopressin was recommended
in American Heart Association guidelines from 2000 through to
2015, when its routine use was no longer recommended (Link
2015).
How the intervention might work
The proposed mechanism of action for adrenaline in cardiac ar-
rest has been described previously (Nolan 2013). Stimulation of
α-receptors located on vascular smooth muscle causes vasocon-
striction which increases aortic diastolic pressure and coronary
perfusion pressure, which optimises the chances of achieving re-
turn of spontaneous circulation (ROSC) (Paradis 1990). Poten-
tially harmful effects arise from deleterious changes in cerebral
microvascular blood flow leading to worsening of cerebral injury
(Burnett 2012; Ristagno 2009), increased cardiac instability af-
ter ROSC and adverse metabolic and immunomodulatory effects
(Nolan 2013; Wiedermann 2015). The potentially deleterious ef-
fects of adrenaline led to the search for alternative vasopressors.
Vasopressin is a naturally-occurring antidiuretic hormone. In high
doses it acts as a potent vasoconstrictor via V1a receptors located
on smooth muscle cells, resulting in increased systemic vascu-
lar resistance which raises coronary perfusion pressure (Lindner
1995). Previous laboratory data suggest that vasopressin is su-
perior to adrenaline in improving vital organ perfusion during
CPR, post-ROSC survival leading to better neurological outcome
(Mentzelopoulos 2012).
Why it is important to do this review
Observational studies allow large amounts of data to be collected
but are often limited by bias and confounding. Statistical tech-
niques can be used to adjust for differences inmeasured confound-
ing variables, but unknown confounders may still lead to biased
results.
An early evaluation of the effect of vasopressors for cardiac arrest
was presented by the Ontario Prehospital Advanced Life Support
(OPALS) group. This prospective, observational study tested the
incremental effect on the rate of survival after out-of-hospital car-
diac arrest of adding a programme of advanced life support (ALS,
endotracheal intubation and intravenous drugs) to a programme
of rapid defibrillation in the late 1990s. The ALS interventions
produced no increase in survival (odds ratio (OR) 1.1, 95% confi-
dence interval (CI) 0.8 to 1.5), raising uncertainty about the role
of drugs and advanced airway management in cardiac arrest. (Stiell
2004).
One of the first large prospective evaluations to raise concern about
adrenaline in cardiac arrest was a propensity-matched observa-
tional study from Japan (Hagihara 2012), which enrolled 417,188
participants with out-of-hospital cardiac arrest. The study found
that those who received adrenaline had improved rates of return of
spontaneous circulation (adjusted (Adj) OR 2.51, 95% CI 2.24 to
2.80), but fewer participants were alive at 30 days (Adj OR 0.54,
95% CI 0.43 to 0.68) and the neurological outcome was worse
(Adj OR 0.21, 95% CI 0.10 to 0.44) (Hagihara 2012). The effect
of unmeasured confounders and the challenges this presents in
interpreting observational studies is highlighted by a subsequent
analysis (Nakahara 2013). In this study researchers used a different
propensity-matched scoring algorithm to analyse data from the
same registry used by Hagihara 2012, which mitigated the signal
of harm shown byHagihara 2012 and suggested marginally better
outcomes in participants with non-shockable rhythms(Nakahara
2013). This may explain in part the high levels of heterogeneity
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noted in meta-analyses of observational studies of vasopressors in
cardiac arrest (Loomba 2015).
Vasoactive drugs have been an established treatment for cardiac
arrest throughout the world, even though there was no evidence
that they were beneficial for long-term outcomes (Nolan 2015b).
Recent evidence from observational studies shows a consistent
pattern of benefit on short-term outcomes (return of spontaneous
circulation and survival to hospital admission), but a reduction in
survival to hospital discharge and the proportion of participants
surviving with a favourable neurological outcome (Perkins 2014).
However, such studies are limited by unmeasured confounders,
not least the fact that those with the best prognosis (i.e. with a
rapid return of spontaneous circulation after defibrillation or other
resuscitation measures) are less likely to receive adrenaline.
In 2015 the International Liaison Committee on Resuscitation
(ILCOR) synthesised the available evidence and concluded that
there is insufficient evidence to know if adrenaline or other vasoac-
tive drugs had beneficial or harmful effects on survival to discharge
from hospital and on neurological outcome (Nolan 2015b). IL-
COR called for placebo-controlled trials to evaluate the use of
any vasopressor in adult and paediatric cardiac arrest (Kleinman
2018).
Against this background, we set out to complete a comprehensive
review of randomised controlled trials examining the effectiveness
of vasoactive drugs during the resuscitation of adults and children
in cardiac arrest. This review considers and pools evidence from
randomised controlled trials of the two most commonly used va-
soactive drugs (adrenaline and vasopressin) and considers the ef-
fect of drug dose and whether they work best singly or in com-
bination. It extends previous systematic reviews through rigorous
assessment of bias, by focusing only on randomised controlled tri-
als, including adult and paediatric studies and from both an out-
of-hospital and in-hospital settings (Larabee 2012; Soar 2015).
O B J E C T I V E S
To determine whether adrenaline or vasopressin or both, admin-
istered during a cardiac arrest, afford any survival benefit.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Any randomised controlled trial comparing (1) standard-dose (or
high-dose) adrenaline versus placebo; (2) standard-dose adrenaline
versus high-dose adrenaline; or (3) adrenaline versus vasopressin
(alone or in combination with adrenaline). We include non-En-
glish articles (Li 1999; Zhu 2000), conference abstracts (Sanchez-
Mendiola 1998) and letters to the editor of peer-reviewed journals
(Polglase 1994; Schmidbauer 2000) in this review. We exclude an-
imal studies. We include data from all papers for the same study
population as one study, e.g. Ong 2012.
Types of participants
We include all participants of any age suffering cardiac arrest
from any cause. Trials could enrol participants suffering cardiac
arrest either outside of hospital (OHCA) or during hospitalisation
(IHCA).
Types of interventions
We include trials that compared intravenous adrenaline versus
placebo, high-dose adrenaline or vasopressin. Optimal adminis-
tration of adrenaline is intravenous (IV), with a free-flowing saline
infusion, although flushing intravenous lines with 20 to 30 mls of
IV fluid is commonly practised. We also include the intra-osseous
route. We accepted adrenaline administered by an endotracheal
tube, although this demonstrates different pharmacodynamic and
pharmacokinetic properties. Intracardiac adrenaline administra-
tion has essentially been abandoned for more than a decade, and
we do not include it in this review. The comparisons of interest
were:
• Standard-dose adrenaline versus placebo
• Standard-dose adrenaline versus high-dose adrenaline
• Standard-dose adrenaline versus vasopressin
• Standard-dose adrenaline versus vasopressin plus adrenaline
The standard dosages of adrenaline and vasopressin that are com-
monly used in clinical studies are 1 mg and 40 IU, respectively.
Types of outcome measures
Primary outcomes
We initially proposed the following outcomes, but we have not
covered the last three in the results of this review because they were
rarely reported in the included studies.
• Survival to hospital discharge.
• Survival to hospital admission.
• Neurological outcome, assessed using either the Glasgow
Outcome Scale (Jennett 1975; Teasdale 1998) or Cerebral
Performance Category (Jennett 1975) or modified Rankin scale
(Quinn 2009).
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Secondary outcomes
• Return of spontaneous circulation (ROSC)
• All-cause mortality
• Return of non-perfusing cardiac rhythm
• Admission to intensive care unit (ICU) (not reported)
Search methods for identification of studies
Electronic searches
We searched the following electronic databases from their incep-
tion to 8 May 2018, using the MeSH and text terms shown in
Appendix 1:
• Cochrane Central Register of Controlled Trials
(CENTRAL), Issue 4 of 12, 2018 (Cochrane Library)
• Database of Abstracts of Reviews of Effects (DARE), Issue 2
of 4, 2015 (Cochrane Library) (No longer updated)
• Epub Ahead of Print, In-Process and Other Non-Indexed
Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 08
May 2018)
• Embase Classic and Embase (Ovid, 1947 to 2018 May 07)
The RCT filter for MEDLINE is the Cochrane sensitivity-max-
imising RCT filter. For Embase, we applied the terms as recom-
mended in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Lefebvre 2011).
Searching other resources
We checked the reference lists of all included studies and relevant
systematic reviews (e.g. Lin 2014), for additional references to
randomised trials.
We also searched the International Liaison Committee on Resus-
citation (ILCOR) 2015 Advanced Life Support Consensus on Sci-
ence and Treatment Recommendations (CoSTR) (Soar 2015).
We searched for ongoing trials on 5 September 2018, using var-
ious combinations of keywords such as ’adrenaline, epinephrine,
vasopressin, cardiac arrest, heart arrest, resuscitation’, on the fol-
lowing trials registers:
• ClinicalTrials.gov (www.clinicaltrials.gov).
• International standardised randomised controlled trials
number ( ISRCTN) registry ( www.isrctn.com/).
• World Health Organization ( WHO) International Clinical
Trials Registry Platform ( ICTRP) ( www.who.int/ictrp/en/).
• NHS Clinical Trials and Medical Research ( www.nhs.uk/
Conditions/Clinical-trials/Pages/clinical-trial-details.aspx?
TrialId= ).
Data collection and analysis
Selection of studies
Two review authors (JF and IJ initially; JF and TW in subsequent
searches) independently read the titles and abstracts of relevant
papers retrieved by the search strategy described above, to identify
potentially suitable studies. If in doubt about whether a title was
relevant, we read the full article. We retrieved full publications of
all potentially-relevant studies and stored them electronically in an
Endnote library. Two review authors (TWand JF) determined trial
eligibility independently, using a standardised inclusion form, and
excluding studies that did not meet the inclusion criteria. We did
not apply any language restrictions.We resolved any disagreements
by discussion with the other two review authors (GP and SG).We
detail the excluded studies and reasons for their exclusion in the
Characteristics of excluded studies table.
Data extraction and management
We recorded data initially on paper, and then on electronic data
extraction forms (which we had piloted) and entered them into
Review Manager 5. We recorded all clinically relevant outcomes,
including adverse events. We resolved differences through re-ex-
amination of the study report and further discussion, consulting
with a third review author (IJ/GP) if we could not achieve con-
sensus.
We sought the following data items from each study:
Study characteristics
• Location of study
• In-hospital cardiac arrest (IHCA) or out-of-hospital cardiac
arrest (OHCA), or both
• Type of emergency medical system (EMS) (OHCA)
• Study design: RCT or quasi-RCT
• Blinding
Participant characteristics in each arm of the study
• Age (mean, standard deviation (SD), range)
• Male %
• Ventricular fibrillation (VF)/ventricular tachycardia (VT) %
• Witnessed (OHCA) %
• Cardiac aetiology %
• EMS witnessed (OHCA) %
• Bystander cardiopulmonary resuscitation (CPR)
(OHCA)%
• Initial rhythm %
• Study inclusion/exclusion criteria
Number of participants in each study arm
• Number eligible
• Excluded pre-randomisation
• Numbers randomised
• Lost to follow-up
• Number analysed
Details of intervention/comparison groups
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• Study drug, control ‘drug’, dose, route, frequency,
maximum dose, time frames
• Other interventions, e.g. IV flushing agent
• Other specific protocols for resuscitation
Outcomes:
• Event numbers and denominator numbers for each study
arm
• Return of spontaneous circulation (ROSC)
• Survival to hospital admission (OHCA only)
• Admission to ICU
• Discharged from hospital alive (or in-hospital mortality)
• Neurological outcome on discharge from hospital (and tool
used to measure)
One of the included studieswas only available inChinese. The data
extraction for this paper was undertaken by a translator (native
Chinese speaker), and the data were double-checked against the
English abstract (TW and JF).
Assessment of risk of bias in included studies
Two review authors (TW, JF) independently assessed risks of bias,
using the Cochrane ’Risk of bias’ tool. This involves judgements
across a series of domains of bias, as described in Chapter 8 of the
Cochrane Handbook (Higgins 2017).
Three independent investigators (TW, GDP and SG) reviewed
papers co-authored by authors of this systematic review (e.g. Jacobs
2011), using the criteria recommended by the Cochrane Heart
Group. Similarly, TW (who was not a co-investigator on the study
or a co-author of the paper) assessed risks of bias for the Perkins
2018 study.
Measures of treatment effect
We used risk ratios (RRs) with 95% confidence intervals (CIs) to
compare dichotomous outcomes. We had planned to analyse con-
tinuous outcomes as mean differences (MDs), but none were re-
ported.We dichotomised neurological outcomes reported asCere-
bral Performance Category (Jennett 1975) scores (1 to 5) as fol-
lows: 1 - 2 ‘good’ neurological outcome and 3 - 5 ’poor’ neuro-
logical outcome. Similarly, we rated a score of 3 or less on the
modified Rankin scale, (Quinn 2009), which ranges from 0 (no
symptoms) to 6 (death), as a ’favourable’ neurologic outcome.
Unit of analysis issues
Whilst therewas a potential problemwith includingfivemulti-arm
studies (Callaham 1992; Ducros 2011; Li 1999; Polglase 1994;
Zhu 2000), we avoided an issue with unit of analysis by treating
each dose as a separate analysis, so that the same control group
was not used twice within the same analysis.
Dealing with missing data
We made no attempt to impute missing data values. We tried to
contact the authors of Lee 2000 but there was no reply. We did
not attempt to contact other trial authors to identify missing data
because many of the studies are quite old.
Assessment of heterogeneity
We examined groups of trials for clinical and statistical hetero-
geneity; the former involved assessment of whether we judged the
participants, interventions, comparisons and outcomes to be suf-
ficiently similar to ensure an answer that is clinically meaningful,
while the latter involved the use of the Chi2 and I2 statistics and
visual inspection of the forest plots. As in the Cochrane Handbook
(Chapter 9) (Higgins 2017), we consider an I2 statistic greater
than 50% to represent substantial heterogeneity.
Assessment of reporting biases
To establish the potential influence of small-trial effects and possi-
ble publication bias, we constructed funnel plots for each outcome
where we had included more than 10 studies in the meta-analysis.
Data synthesis
Where we deemed clinical and statistical heterogeneity to be ac-
ceptable, we conducted meta-analyses using Review Manager 5
to combine results for each outcome across studies. We used a
random-effects model to calculate a weighted average of Mantel-
Haenszel risk ratios across studies for all outcomes. We did not
assume that all studies measured the same underlying true effect
(i.e. fixed-effect across studies).
Subgroup analysis and investigation of heterogeneity
The a priori subgroup analyses were: (1) adult participants and
paediatric participants; (2) OHCA and IHCA events. Both are
considered potential effect modifiers, due to known differences in
cardiac arrest aetiology in the subgroups.
Sensitivity analysis
To determine whether the findings of the systematic review were
influenced by specific studies, we performed sensitivity analyses
restricting the analysis to a subset of the studies, by excluding those
at high risk of bias (as shown in red in Figure 2) in any domain.
We performed sensitivity analyses for the following comparisons:
(1) high-dose versus standard-dose adrenaline; (2) vasopressin ver-
sus vasopressin plus adrenaline.
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‘Summary of findings’ tables
We used the GRADE approach ( www.gradepro.org ) to con-
struct a ‘Summary of findings’ table for each outcome for the pri-
mary comparison, where possible. The five GRADE considera-
tions (study limitations, consistency of effect, imprecision, indi-
rectness and publication bias) are used to assess the quality of the
body of evidence for each outcome.
R E S U L T S
Description of studies
Results of the search
The search found 2056 papers, reduced to 1808 after de-duplica-
tion. We excluded 1730 of these on the basis of title and abstract
not meeting the study criteria. A recently published RCT (Perkins
2018) of SDE versus placebo was included. We also identified: a
potential study (Ghafourian 2015) from a recent systematic review
(Belletti 2018), which was subsequently excluded based on non-
randomisation of the ’controls’ and uncertainty about the random
allocation of treatment arms of the study. Two ongoing studies
(Andersen 2018; Raymond 2008) were also excluded, resulting
in 80 papers for full-text review. We excluded 48 papers at this
stage, because they did not meet the study inclusion criteria af-
ter review of the text; see Figure 1. We included 26 studies re-
ported in 32papers (Brown 1992;Callaham1992;Callaway 2006;
Choux 1995; Ducros 2011; Gueugniaud 1998; Gueugniaud
2008; Jacobs 2011; Li 1999; Lindner 1991a; Lindner 1997;
Lipman 1993; Mukoyama 2009; Ong 2012; Patterson 2005;
Perkins 2018; Perondi 2004; Polglase 1994; Sanchez-Mendiola
1998; Schmidbauer 2000; Sherman 1997; Stiell 1992; Stiell 2001;
Wenzel 2004; Woodhouse 1995; Zhu 2000), as shown in the
Characteristics of included studies table.
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Figure 1. Selection process
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The papers were published between 1992 and 2018, 13 of
them before 2000 (Brown 1992; Callaham 1992; Choux 1995;
Gueugniaud 1998; Li 1999; Lindner 1991a; Lindner 1997;
Lipman 1993; Polglase 1994; Sanchez-Mendiola 1998; Sherman
1997; Stiell 1992; Woodhouse 1995), five from 2000 up to 2005
(Perondi 2004; Schmidbauer 2000; Stiell 2001;Wenzel 2004;Zhu
2000), four from 2005 up to 2010 (Callaway 2006; Gueugniaud
2008; Mukoyama 2009; Patterson 2005), and four from 2010
onwards (Ducros 2011; Jacobs 2011; Ong 2012; Perkins 2018).
A total of 21,704 participants were included in the analyses. Two
Chinese papers (Li 1999; Zhu 2000) and one Japanese paper
(Nishizawa 1993) were translated into English. Three studies were
specifically from paediatric populations (Patterson 2005; Perondi
2004; Sanchez-Mendiola 1998).
There was substantial variation between studies in the number
of participants included. In the three RCTs of adrenaline versus
placebo the sample sizes varied from 194 (Woodhouse 1995) to
534 (Jacobs 2011) and 8104 (Perkins 2018). Considering stud-
ies of high-dose adrenaline versus standard-dose adrenaline, the
sample sizes ranged from 43 (Li 1999; Zhu 2000) to 3907 partic-
ipants (Gueugniaud 1998), and for vasopressin versus standard-
dose adrenaline the sample sizes ranged from 30 (Ducros 2011)
to 1186 participants (Wenzel 2004).
Included studies
Most of the studies (16/26) were of people who suffered OHCAs
(Brown 1992; Callaham 1992; Callaway 2006; Choux 1995;
Ducros 2011;Gueugniaud 1998;Gueugniaud 2008; Jacobs 2011;
Lindner 1997; Mukoyama 2009; Patterson 2005; Perkins 2018;
Polglase 1994; Schmidbauer 2000; Sherman 1997;Wenzel 2004),
including one paediatric study (Patterson 2005). In-hospital car-
diac arrests (IHCAs) included cardiac arrests in the Emergency
Department (ED) and intensive care unit (ICU). Four studies
(Lindner 1991a; Ong 2012; Stiell 1992; Woodhouse 1995) in-
cluded both out-of-hospital and in-hospital cardiac arrest, one
which was OHCA and ED (Ong 2012), and six in-hospital (Li
1999; Lipman 1993; Perondi 2004; Sanchez-Mendiola 1998;
Stiell 2001; Zhu 2000), two of which were paediatric studies
(Perondi 2004; Sanchez-Mendiola 1998).
Of the 26 studies included in this review, three studies compared
adrenaline to placebo (Jacobs 2011; Perkins 2018; Woodhouse
1995). Fifteen studies compared standard-dose adrenaline (SDA)
with high-dose adrenaline (HDA), ranging from 2 mg to 10 mg
doses (Brown 1992; Callaham 1992; Choux 1995; Gueugniaud
1998; Lindner 1991a; Li 1999; Lipman 1993; Patterson
2005; Perondi 2004; Polglase 1994; Sanchez-Mendiola 1998;
Schmidbauer 2000; Sherman 1997; Stiell 1992; Zhu 2000); six
studies compared SDA to vasopressin (Li 1999; Lindner 1997;
Mukoyama 2009; Ong 2012; Stiell 2001; Wenzel 2004); three
studies (Callaway 2006; Ducros 2011; Gueugniaud 2008) exam-
ined the effect of SDA and vasopressin combined with SDA. Note
that Li 1999 is included in the SDA versus HDA analysis and the
SDA versus vasopressin analysis.
Five studies had more than one intervention group. Li 1999 re-
ported results from the control group (SDA) compared to three
intervention groups: HDA, standard-dose vasopressin and high-
dose vasopressin. Zhu 2000 compared administration of SDA to 2
mg adrenaline every three minutes and also with increasing doses
of adrenaline (1 mg adrenaline initially and then progressively in-
creased dosage to 2 mg every three minutes). Polglase 1994 com-
pared two different doses of adrenaline (5 mg and 10 mg) to SDA.
Two studies compared SDA toHDAandnoradrenaline (Callaham
1992) or HDA administered with nitroglycerine (Ducros 2011).
We discarded the results from the noradrenaline arm and theHDA
with nitroglycerine arm, because they did not meet the selection
criteria.
Most studies reported intravenous administration of the study
drug.One study (Schmidbauer 2000) administered the study drug
through the endobronchial route and three used a combination
of routes: intravenous or by the endotracheal tube (Gueugniaud
1998; Stiell 1992); intravenous or intra-osseous (Perkins 2018);
and intravenous, endobronchial or intra-osseous (Patterson 2005).
Baseline characteristics
Baseline characteristics were similar between groups for most
of the studies, but the characteristics that were reported var-
ied between studies. One study did not report baseline char-
acteristics (Schmidbauer 2000). Differences in baseline charac-
teristics between groups were evident in seven studies (Choux
1995; Gueugniaud 1998; Jacobs 2011; Lipman 1993; Ong 2012;
Sherman 1997; Stiell 1992). Choux 1995 reported similar base-
line characteristics in standard-dose or placebo and high-dose
adrenaline groups, except for the time from Basic Life Support
to Advanced Cardiac Life Support (P = 0.04), which was longer
for the high-dose adrenaline group. There were fewer men in the
standard-dose adrenaline group compared to the adrenaline plus
vasopressin group in Gueugniaud 2008, at 72% versus 75% (P =
0.03). Lipman 1993 found no difference in age, sex or the number
of days in ICU, but the Acute Physiology Score 24 hours before
the cardiac arrest and the dose of dobutamine administered were
higher in the high-dose adrenaline group. A higher proportion of
participants with a medical history in the vasopressin group was
reported by Ong 2012, but the only significant history was higher
hyperlipidaemia in the standard-dose adrenaline group. Stiell 1992
reported that the prevalence of ischaemic heart disease was lower
in the low-dose adrenaline group. Jacobs 2011 reported a marginal
difference in the proportion of participants whose cardiac arrest
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waswitnessed by a bystander (53%placebo versus 44%adrenaline,
P = 0.05).
The mean age was 62 years for the control and intervention
groups in the adult studies that reported age (Brown 1992;
Callaway 2006; Choux 1995; Ducros 2011; Gueugniaud 1998;
Gueugniaud 2008; Jacobs 2011; Li 1999; Lindner 1991a; Lindner
1997; Lipman 1993;Mukoyama 2009; Ong 2012; Polglase 1994;
Sherman 1997; Stiell 1992; Stiell 2001;Wenzel 2004;Woodhouse
1995; Zhu 2000). Callaham 1992 reported a median age of 67
years for both groups andPerkins 2018 reported amean age in both
groups of 70 years. There were a similar proportion of adult men,
around 66% in both groups. Two paediatric studies (Patterson
2005; Perondi 2004) reported the mean age as 4.7 years in the
control group and 4.5 years in the intervention group, and a sim-
ilar proportion of boys in both group (56% versus 57%).
The initial cardiac arrest rhythmwas reported by all but four stud-
ies (Li 1999; Polglase 1994; Schmidbauer 2000; Zhu 2000); and
was generally categorised as a shockable rhythm, i.e. ventricular
fibrillation or (pulseless) ventricular tachycardia (VF/pVT) or a
non-shockable rhythm, i.e. asystole or pulseless electrical activity
(PEA). PEA is characterised by “presence of spontaneous orga-
nized cardiac electric activity in the absence of blood flow sufficient
to maintain consciousness” (Myerburg 2013). The proportion of
participants with an initial rhythm of ventricular fibrillation (VF),
asystole and pulseless electrical activity (PEA)were similar between
control and intervention groups, but variedwidely between studies
(Appendix 2). This included one study (Lindner 1997) that only
included people with ventricular fibrillation, two studies (Lipman
1993; Sanchez-Mendiola 1998) that only included people with
asystole and one study that only enrolled participants with asystole
or PEA (Lindner 1991a). Patterson 2005 reported that 95% of
the children overall had asystole.
The proportion of arrests witnessed by a bystander was reported
in 15 studies (Brown 1992; Callaham 1992; Callaway 2006;
Gueugniaud 1998; Gueugniaud 2008; Jacobs 2011; Lindner
1991a; Lindner 1997; Mukoyama 2009; Ong 2012; Patterson
2005; Perkins 2018; Sherman 1997; Stiell 1992; Stiell 2001), with
bystander-witnessed arrests ranging from 24% (Patterson 2005)
to close to 80% (Stiell 2001). Witnessed EMS (paramedic-wit-
nessed) cardiac arrests were reported in three studies (Callaway
2006; Jacobs 2011; Perkins 2018), in 12%or fewer of participants.
There were 14 studies that reported the proportion of partici-
pants that received bystander CPR (Brown 1992; Callaham 1992;
Callaway 2006; Gueugniaud 1998; Gueugniaud 2008; Jacobs
2011; Lindner 1997; Mukoyama 2009; Ong 2012; Patterson
2005; Perkins 2018; Stiell 1992;Wenzel 2004;Woodhouse 1995).
Whilst the percentage of bystander CPR was similar in the inter-
vention and control groups, there was considerable variation be-
tween studies, ranging from around 15% (Ong 2012) to almost
60% (Perkins 2018).
The number of doses of study drug administered to a participant
also varied between studies. A single dose of study drugwas admin-
istered in four studies (Brown 1992; Lindner 1997; Ong 2012;
Stiell 2001), up to two doses in two studies (Gueugniaud 2008;
Wenzel 2004), three doses in three studies (Callaway 2006;Ducros
2011; Lipman 1993), four doses in one study (Sherman 1997),
and five doses in three studies (Jacobs 2011, Stiell 1992; Perkins
2018). The protocol for both of the standard-dose adrenaline
versus placebo controlled trials allowed up to 10 doses (Jacobs
2011; Perkins 2018), and up to 15 doses in two studies (Choux
1995; Gueugniaud 1998). Studies were permitted to use open-
label adrenaline after the maximum doses of study drug.
Outcomes
Several survival endpoints were used. Return of spontaneous cir-
culation (ROSC) was the most common, although the actual def-
inition was often not specified. Survival time to hospital discharge
(STHD)was also often reported and survival to hospital admission
(STHA) reported less often. Other endpoints included survival
to one hour (Stiell 2001), to 12 hours (Lindner 1991a; Lipman
1993), to 24 hours (Gueugniaud 1998; Lindner 1997; Lipman
1993; Mukoyama 2009; Patterson 2005; Perondi 2004), to three,
eight, 15 and 21 days (Choux 1995), to 30 days (Callaway 2006;
Stiell 2001; Perkins 2018 ), to six months (Choux 1995), to one
year (Gueugniaud 2008) and, in an ICU study, ICU survival
(Lipman 1993). Neuological outcomes were measured using var-
ious tools, as described under ’Neurological outcomes’ below in
Effects of interventions.
We used the ’N’ randomised as the denominator for analyses as
far as possible. However, we used the available ’n’ where this was
not clear, or where there was a large discrepancy between ’n’ ran-
domised and ’n’ analysed, eg Gueugniaud 1998. Similarly, we
chose to use the amended denominator where loss to follow up
for different outcomes (e.g. neurological ones) was described (eg
Perkins 2018; Wenzel 2004). There is therefore some discrepancy
in the denominators across different outcomes within the same
study.
Differentmethods and time points were used to assess neurological
outcome. Cerebral Performance Category (CPC) scores were used
in 11 studies (Brown 1992; Callaham 1992; Gueugniaud 1998;
Gueugniaud 2008; Jacobs 2011; Mukoyama 2009; Ong 2012;
Perondi 2004; Stiell 1992; Stiell 2001; Wenzel 2004), making it
the most common measure of neurological outcome used. CPC
was recorded most often at hospital discharge, but others recorded
CPC at 96 hours (and at discharge) (Stiell 1992) or at six months
(Wenzel 2004). CPC scores were most often dichotomised into
scores of less than three (i.e. ’good’) and three to five (i.e. ’poor’).
However, Brown1992 dichotimised goodoutcomes asCPCone to
three and poor outcomes as four and five according to whether the
participant was conscious or unconscious, and Stiell 1992 reported
the ’best category of cerebral performance’, i.e. CPC = 1. Perkins
2018 measured neurological outcomes at hospital discharge and
at three months using the modified Rankin scale (Quinn 2009).
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Survival with a favourable neurological outcome was defined as a
score of three or less on the modified Rankin scale (which ranges
from 0 (no symptoms) to 6 (death)). One study (Patterson 2005)
used the Glasgow Outcome Scale (Jennett 1975), which has five
categories: death, persistent vegetative state, severe disability, mod-
erate disability, and good recovery.
The Glasgow Coma Scale (GCS) (Teasdale 1998) was also used
to assess neurological outcome (Choux 1995; Gueugniaud 1998;
Lindner 1997; Stiell 1992), albeit at different time points and us-
ing different summary measures. Stiell 1992 reported the highest
GCS at hospital discharge; Lindner 1997 reported the mean GCS
at hospital discharge; Gueugniaud 1998 reported the highest GCS
at the time of admission and at one week; and Choux 1995 re-
ported GCS at day 3 and day 21 after the OHCA. Sherman 1997
assessed GCS at different time points, but there were no survivors
for assessment at hospital discharge.
Two studies (Stiell 1992; Stiell 2001) reported the median Mini-
Mental State Examination (MMSE) scores (Teng 1987) of OHCA
survivors at hospital discharge.
The two Chinese studies described neurological outcome as “dis-
charged from hospital with ’normal’ status” (Li 1999; Zhu 2000).
However, it is unclear whether only survivors with ’normal’ status
were included in the assessment of STHD.
Hospital length of stay was only reported by two studies (Callaham
1992; Perkins 2018) and neither study found a difference between
the respective treatment groups.
Funding
The source of funding was not stated in 11 of the 26 studies. The
study drugs were provided or funded by the manufacturer in four
out of 26 studies, but neither drug represents a profitable com-
mercial option. The other 11 studies were funded by organisations
such as research foundations and government funding bodies.
Excluded studies
Studies were excluded because they were non-cardiac arrest pa-
pers (McCrirrick 1992; McCrirrick 1994, Quadrel 1995), re-
views (Aung 2005; Larabee 2012; Mentzelopoulos 2012; Meyer
2011; Sillberg 2008; Xiaoli 2010; Zwingmann 2012), narra-
tives (Pellegrino 2006; Berthier 1987; Cohen 1975), editorials
(McIntyre 2004) or critiques (Worster 2005), before-and-after
studies (Carvolth 1996), cohort studies (Dieckmann 1995), other
non-RCTs (Morris 1997; Niemann 2000; Ohshige 2005) or used
surrogate measures not included in our systematic review’s selec-
tion criteria (Paradis 1991; Quinton 1987; Woodhouse 1992).
Eight RCTswere excluded because theywere of drugs not included
in this systematic review’s selection criteria (Mentzelopoulos 2007;
Mentzelopoulos 2009; Olasveengen 2009; Olson 1989; Patrick
1995; Song 1997; Turner 1988; Weaver 1990). For example,
Mentzelopoulos (Mentzelopoulos 2007; Mentzelopoulos 2009)
included methylprednisolone with vasopressin and adrenaline to
compare the effect on outcomes with standard-dose adrenaline.
The study found increased ROSC and STHD in the combination
group, but it is unclear whether the results were related to methyl-
prednisolone or a combination of the drugs used (Mentzelopoulos
2009).We excludedOlasveengen 2009 because the study included
all intravenous drugs and was not limited to the drugs included in
our systematic review, i.e. adrenaline, vasopressin (or terlipressin).
Lee 2000 was excluded because it was a pilot study of 10 par-
ticipants from a larger RCT in progress, of which few details
were provided in the conference report, no record of the study
could be found, and we were unsuccessful in contacting the au-
thors. Ghafourian 2015), identified from a recent systematic re-
view (Belletti 2018), was excluded based on non-randomisation
of the ’controls’ and uncertainty about the random allocation of
treatment arms of the study. The two ongoing studies (Andersen
2018; Raymond 2008), the details of which can be found in
Characteristics of ongoing studies, are not included in the analysis
because of lack of data.
Risk of bias in included studies
The results of our assessment of risks of bias in the included studies
can be seen in the Description of studies table and are summarised
in Figure 2 and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Random sequence generation
All studies were randomised with the exception of one quasi-
randomised trial (Callaham 1992). Eleven studies reported a
computer-generated randomisation sequence (Callaway 2006;
Ducros 2011; Jacobs 2011; Lindner 1997; Lipman 1993; Ong
2012; Perkins 2018; Perondi 2004; Sherman 1997; Stiell 2001;
Wenzel 2004). Three studies used a central randomisation sched-
ule (Gueugniaud 1998; Gueugniaud 2008; Stiell 1992). We rated
these 14 studies at low risk of bias. Ten studies (Brown 1992;
Choux 1995; Li 1999; Lindner 1991a; Mukoyama 2009; Polglase
1994; Sanchez-Mendiola 1998; Schmidbauer 2000; Woodhouse
1995; Zhu 2000) stated that the study was “randomised” but did
not report the method used for randomisation. We rated these
10 studies as unclear riskWe judged two studies (Patterson 2005;
Callaham 1992) to be at high risk for bias. In a paediatric study of
OHCA, Patterson 2005 used computer-generated randomisation
for six centres, while the other centre assigned participants to the
study group if their medical record number ended in an odd num-
ber and to the standard-dose group if their medical record number
ended in an even number. Quasi-randomisation using alternation,
in which the study drug and dose were changed for the entire city
on Wednesdays, was used by Callaham 1992.
Allocation concealment
Nineteen studies described allocation concealment (Brown 1992;
Callaham 1992; Callaway 2006; Choux 1995; Ducros 2011;
Gueugniaud 1998; Gueugniaud 2008; Jacobs 2011; Lindner
1991a; Lindner 1997; Lipman 1993; Ong 2012; Perkins 2018;
Perondi 2004; Sherman 1997; Stiell 1992; Stiell 2001; Wenzel
2004; Woodhouse 1995) and were considered as low risk. In
Patterson 2005 it was uncertain whether the opaque envelopes
were tamper-proof, and we rated the study as being at unclear risk
of bias. Paramedics could have altered the dose given in Polglase
1994, and we considered the study to be at high risk; as we did so
for Li 1999; and Sanchez-Mendiola 1998. Three studies did not
report any information about allocation concealment (Mukoyama
2009; Schmidbauer 2000; Zhu 2000) and were rated at unclear
risk of bias.
Blinding
Blinding (performance bias and detection bias): survival
outcomes
Blinding was described in 18 studies (Brown 1992; Callaham
1992; Callaway 2006; Choux 1995; Ducros 2011; Gueugniaud
1998; Gueugniaud 2008; Jacobs 2011; Lindner 1991a; Lindner
1997; Ong 2012; Perkins 2018; Perondi 2004; Sherman 1997;
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Stiell 1992; Stiell 2001; Wenzel 2004; Woodhouse 1995). We
rated three studies (Patterson 2005; Polglase 1994; Sanchez-
Mendiola 1998) at high risk of bias. Blinding was only used in
two of the seven centres because of technical difficulty in Patterson
2005. The other two studies (Polglase 1994; Sanchez-Mendiola
1998) were unblinded to the drug dose administered. Blinding
was unknown in five studies (Li 1999; Lipman 1993; Mukoyama
2009; Schmidbauer 2000; Zhu 2000) and we rated them at un-
clear risk of bias.
Blinding (performance bias and detection bias):
neurological outcome
Four studies were blinded to group allocation for neurological out-
come (Jacobs 2011; Ong 2012; Stiell 1992; Perkins 2018) and
we rated them at low risk, but for most studies it was unclear
whether the assessor was aware of the allocation group (Brown
1992; Callaham 1992; Gueugniaud 1998; Gueugniaud 2008;
Lindner 1997; Mukoyama 2009; Patterson 2005; Perondi 2004;
Sherman 1997; Stiell 2001; Wenzel 2004) and we rated them at
unclear risk of bias. Blinding was not reported in Choux 1995, but
theGlasgowComaScore (GCS) and electroencephalogram (EEG)
are susceptible to bias because of the small sample size, with neu-
rological assessments not being performed systematically, but were
“made by different physicians” and “particular therapies given in
the different hospitals could not be controlled”. Sanchez-Mendiola
1998 did not blind caregivers to the drug dose administered which
we rated at a high risk of bias. No neurological outcomes were
reported in nine studies (Callaway 2006; Ducros 2011; Li 1999;
Lindner 1991a; Lipman 1993; Polglase 1994; Schmidbauer 2000;
Woodhouse 1995; Zhu 2000).
Incomplete outcome data
Most studies accounted for all their outcome data and we
rated them at low risk (Brown 1992; Callaway 2006; Choux
1995; Ducros 2011; Gueugniaud 2008; Li 1999; Lindner 1991a;
Lindner 1997; Lipman 1993; Ong 2012; Patterson 2005; Perkins
2018;; Sanchez-Mendiola 1998; Sherman 1997; Stiell 1992; Stiell
2001; Wenzel 2004; Zhu 2000).
Many studies (Ducros 2011; Gueugniaud 1998; Gueugniaud
2008; Jacobs 2011; Lindner 1997; Patterson 2005; Perkins 2018;
Perondi 2004; Stiell 2001; Wenzel 2004) claimed to perform in-
tention-to-treat analysis, i.e. including all randomised cases in the
analysis, but some were ’per protocol’ analyses because they did
not include those participants who were randomised but later ex-
cluded, e.g. because of not meeting selection criteria, missing data,
or unclear group allocation.
We assessed five studies as high risk of attrition bias. Jacobs 2011
planned to enrol 5000 participants. Enrolment issues, withdrawal
of participating centres, and lack of willingness of paramedics to
participate in a trial involving a placebo were responsible for en-
rolment being restricted to 601 participants (12% of the original
sample size), of whom 534 had their data analysed. We therefore
assessed this study at high risk for incomplete outcome reporting.
Mukoyama 2009 excluded 37% of cases after randomisation and
Polglase 1994 excluded 35% because of “irregularities in dosing or
incomplete documentation”. Woodhouse 1995 excluded 10 par-
ticipants for protocol violations, 7 for inadequate records and 145
participants received open-label 1mg adrenaline instead of study
drug. Gueugniaud 1998 exclude 580 participants (15% of the to-
tal) from the final analysis, for various reasons.
Lipman 1993 had more than 10% of the randomised cohort ex-
cluded from the study but was rated at low risk. Wenzel 2004 had
20% of participants who survived to hospital discharge but were
lost to follow-up for neurological outcome. Three studies were
rated as unclear risk of attrition bias (Callaham 1992; Perondi
2004; Schmidbauer 2000)
Selective reporting
We reviewed the published papers for details of the outcomes that
were assessed. All but four studies were assessed as unclear for this
domain. Choux 1995 listed STHD as an outcome measure but
it was not reported, so this study was assessed as being at high
risk of bias. Schmidbauer 2000 was assessed as being at high risk
of reporting bias because only ROSC was reported for VF and
Asystole patients. Perkins 2018 and Jacobs 2011 were assessed as
being at low risk of selective reporting.
Other potential sources of bias
All but four studies (Gueugniaud 1998; Sanchez-Mendiola 1998;
Sherman 1997; Woodhouse 1995) were assessed unclear risk of
other bias. No study compared post-resuscitation care in the study
groups. We considered Gueugniaud 1998 to be at high risk of
other bias due to presenting baseline characteristics and some out-
comes for the intervention group only. Sanchez-Mendiola 1998
was only available as a conference abstract so was also considered
to be at high risk of ’other’ bias. We rated Sherman 1997 at high
risk of bias in the ’Other bias’ section: enrolment was discontinued
before reaching the recruitment target because of “geographic relo-
cation of investigators, concerns re deferred consent, intercurrent
results of recent trials, similar trials”. In addition, intention-to-
treat was not stated and participants who received the study drug
but did not meet the entrance requirement were excluded from
data analysis.We also rated the Woodhouse 1995 study as being
at high risk of other bias as the supervising physician was stated to
treat patients differently depending on their allocated group.
Sanchez-Mendiola 1998 and Schmidbauer 2000 provided insuf-
ficient detail in several categories in the ’Risk of bias’ assessment,
and we rated them at high risk of potential bias overall.
Publication bias
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Funnel plots for high-dose adrenaline versus standard-dose
adrenaline are shown in Figure 4 for ROSC and Figure 5 for
STHD. We did not produce funnel plots for other outcomes or
comparisons, due to limited studies (fewer then 10). Visual anal-
ysis of the funnel plots revealed that they were roughly not sym-
metrical, suggesting the possibility of publication bias. The funnel
plot for ROSC (Figure 4) suggests a lack of small studies with an
RR of less than about 1.1 (the point estimate for the biggest stud-
ies), which could be due to publication bias. The funnel plot for
survival (Figure 5) looks less asymmetrical, but there is still only
one small study on the left side of the plot versus several on the
right.
Figure 4. Funnel plot of comparison: 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA),
outcome: 2.8 ROSC (adults vs children).
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Figure 5. Funnel plot of comparison: 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA),
outcome: 2.1 Survival to hospital discharge.
Effects of interventions
See: Summary of findings for the main comparison Standard-
dose adrenaline (SDA) compared to placebo for cardiac arrest;
Summary of findings 2 Standard-dose adrenaline (SDA)
compared to high-dose adrenaline (HDA) for cardiac arrest;
Summary of findings 3 Standard-dose adrenaline (SDA)
compared to vasopressin for cardiac arrest; Summary of findings
4 Standard-dose adrenaline (SDA) compared to SDA plus
vasopressin for cardiac arrest
Survival to hospital discharge (STHD)
STHD: Adrenaline versus placebo
Two studies compared standard-dose adrenaline (multiple doses)
versus placebo (Jacobs 2011; Perkins 2018), and one smaller study
(Woodhouse 1995) compared high-dose adrenaline (2 x 10 mg
doses) versus placebo before reverting back to standard (1 mg)
doses of adrenaline. In the Woodhouse 1995 study there were no
survivors to hospital discharge in either the high-dose adrenaline
or placebo groups, and hence the pooled RR for adrenaline ver-
sus placebo is calculated from the two studies with events (Jacobs
2011; Perkins 2018). Jacobs 2011 (standard-dose adrenaline ver-
sus placebo) reported limited evidence of a difference in STHD,
with the effect estimate suggesting a possible two-fold increase but
the confidence interval indicating great uncertainty that could in-
clude either a small decrease or a very large increase (risk ratio (RR)
2.12, 95%confidence interval (CI) 0.75 to 6.02; 534participants).
The larger Perkins 2018 study reported an increase in STHD for
participants in the intervention (adrenaline) group compared to
the placebo group (RR 1.40, 95% CI 1.08 to 1.83; 8004 partic-
ipants). The pooled estimate for standard-dose adrenaline versus
placebo showed an increase in STHD in favour of adrenaline: RR
1.44, 95% CI 1.11 to 1.86; 2 studies; 8538 participants; I2 = 0%;
moderate-quality evidence; Analysis 1.1.
STHD: Standard-dose adrenaline (SDA) versus high-dose
adrenaline (HDA)
Nine adult studies (Brown 1992; Callaham 1992; Gueugniaud
1998; Li 1999; Lindner 1991a; Polglase 1994; Sherman 1997;
Stiell 1992; Zhu 2000) and three paediatric studies (Patterson
19Adrenaline and vasopressin for cardiac arrest (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2005; Perondi 2004; Sanchez-Mendiola 1998) reported STHD
for the comparison of high-dose adrenaline (HDA) versus stan-
dard-dose adrenaline (SDA). There was considerable variation be-
tween studies in unadjusted STHD, ranging from 0% to 14% in
the HDA group and 0% to 5% in the SDA group for adults; 0%
to 20% in the HDA group to 0% to 12% in the SDA group for
paediatric studies. Two of the studies comparing SDA versusHDA
and reporting STHD had zero events in both arms of the study
(Polglase 1994; Sherman 1997), meaning that we did not include
these two studies in our calculation of the pooled RR for Analysis
2.1, nor in the subgroup analyses in Analysis 2.2 and Analysis 2.3.
There was no evidence of a statistically significant difference in the
pooled estimate for STHD in HDA versus SDA: RR 1.10, 95%
CI 0.75 to 1.62; participants = 6274; studies = 10; I2 = 24%; very
low-quality evidence; Analysis 2.1. Choux 1995 did not report
STHD, but did report 21-day survival. Including Choux 1995
in the pooled analysis (i.e. equating 21-day survival with STHD)
only slightly affected the effect estimate and the 95% confidence
intervals, but not the conclusion of no effect.(RR 1.17, 95% CI
0.80 to 1.71; participants = 6810; studies = 11; I2 = 25%) The
very low-quality of the evidence for these two analyses means that
we are uncertain of the effect of SDA compared with HDA on
survival to hospital discharge.
We conducted two predefined subgroup analyses: (1) adults and
children; and (2) IHCA and OHCA events.
(1) Three paediatric studies, one of OHCA (Patterson 2005),
and two of IHCA (Perondi 2004; Sanchez-Mendiola 1998) com-
pared high-dose to standard-dose adrenaline. Whilst there was
no evidence of a statistically significant difference in STHD (RR
1.54, 95% CI 0.17, 13.66 ; 3 studies; 317 participants), there was
high clinical and statistical heterogeneity (I2 = 61%; Analysis 2.2).
There was no evidence of subgroup difference in STHD for adults
versus children: Test for subgroup differences: Chi2 = 0.17, df = 1
(P = 0.68), I2 = 0.0%.
(2) Six of the studies were OHCA (Brown 1992; Callaham 1992;
Gueugniaud 1998; Patterson 2005; Polglase 1994 (not included
in the meta-analysis) ; and Sherman 1997 (not included in the
meta-analysis); four were IHCA (Li 1999; Perondi 2004; Sanchez-
Mendiola 1998; Zhu 2000). Two studies (Lindner 1991a; Stiell
1992) included both IHCA and OHCA (adult) participants. The
Lindner 1991a was excluded from the IHCA/OHCA subgroup
analysis, as it was not possible to distinguish results for the IHCA/
OHCA groups. There was no evidence of subgroup difference
in STHD for SDA compared to HDA in OHCA studies versus
IHCA studies: Test for subgroup differences: Chi2 = 0.30, df = 1
(P = 0.58), I2 = 0%; Analysis 2.3.
STHD: Standard-dose adrenaline versus vasopressin
The pooled estimate for the six studies (Li 1999; Lindner 1997;
Mukoyama 2009; Ong 2012; Stiell 2001;Wenzel 2004) that com-
pared SDA to vasopressin showed no evidence of a statistically sig-
nificant difference in STHD among 2511 participants: RR 1.25,
95%CI0.84 to 1.85; I2 =29%; very low-quality evidence; Analysis
3.1. The very low quality of evidence means that we are uncer-
tain of the effect of SDA versus vasopressin on STHD. Consid-
ering STHD for the three OHCA studies only (Lindner 1997;
Mukoyama 2009;Wenzel 2004), there was no evidence of a statis-
tically significant difference in the pooled results: RR 1.26, 95%
CI 0.76 to 2.07; 1542 participants, I2 = 29%,; Analysis 3.2). Sim-
ilarly, there was no evidence of a statistically significant difference
in STHD between SDA versus vasopressin for IHCA participants
(Li 1999; Stiell 2001): RR 2.21, 95% CI 0.29 to 17.06; 242 par-
ticipants, but heterogeneity was very high (I2 = 77%; P = 0.04).
There was no evidence of OHCA/IHCA subgroup difference in
STHD: Test for subgroup differences: Chi2 = 0.28, df = 1 (P =
0.60), I2 = 0%; Analysis 3.2.
STHD: Standard-dose adrenaline versus vasopressin plus
adrenaline
Three studies (Callaway 2006; Ducros 2011; Gueugniaud 2008)
compared SDA to SDA plus vasopressin. Gueugniaud 2008 found
no evidence of a statistically significant difference between the
SDA-plus-vasopressin group compared to the SDA (and placebo)
group for STHD after OHCA: RR 0.73, 95% CI 0.43 to
1.23; 2887 participants. Callaway 2006 compared vasopressin to
placebo after both groups had received a dose of SDA and reported
30-day survival, not STHD. There was no evidence of a statisti-
cally significant difference in 30-day survival between the groups:
RR 1.18, 95% CI 0.32 to 4.32; 325 participants. In a small study
(N = 30), Ducros 2011 compared up to three successive doses of
SDA versus SDA plus vasopressin and found no evidence of a sta-
tistically significant difference in STHD: RR 0.23, 95% CI 0.01
to 4.36. In a pooled analysis there was no evidence of a statistically
significant difference in STHD/30-day survival, but the very low
quality of the evidence means that we are uncertain of the effect
on this outcome: RR 0.76, 95% CI 0.47 to 1.22; 3 studies; 3242
participants; I2 = 0%; very low-quality evidence; Analysis 4.1.
Survival to hospital admission (STHA)
STHA: Adrenaline versus placebo
Both Jacobs 2011 and Perkins 2018 found a two to three-fold
increase in STHA for adult participants who received SDA com-
pared toplacebo.The pooled estimate of the two studies showed an
increase in STHA for participants in the intervention (adrenaline)
group compared to placebo group: RR 2.51, 95%CI 1.67 to 3.76;
8489 participants; I2 = 77%; moderate-quality evidence; Analysis
1.2. Woodhouse 1995 did not report STHA.
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STHA: Standard-dose adrenaline (SDA) versus high-dose
adrenaline (HDA)
Five studies in adults (Brown 1992; Callaham 1992; Choux 1995;
Gueugniaud 1998; Polglase 1994) reported the proportion of peo-
ple surviving to hospital admission among those who received
HDA compared to SDA. The pooled estimate showed a 13% in-
crease in STHA for the HDA group: RR 1.13, 95% CI 1.03 to
1.24; 5 studies; 5764 participants; I2 = 0%; Analysis 2.4. However,
the very low quality of evidence suggests uncertainty in the effect
for this outcome. No paediatric study reported STHA.
Survival to 24 hours was reported by five studies (Choux 1995;
Gueugniaud 1998; Lipman 1993; Patterson 2005; Perondi 2004)
that compared HDA to SDA. In the individual studies, there was
no evidence of a difference in 24-hour survival between HDA
and SDA in the three adult studies (Choux 1995; Gueugniaud
1998; Lipman 1993), nor the two paediatric studies (Patterson
2005; Perondi 2004). . The pooled estimate found no evidence
of a statistically significant difference in 24-hour survival between
HDA and SDA: (RR 1.04, 95% CI 0.76 to 1.43; participants =
4179; studies = 5; I2 = 39%); Analysis 2.5.
STHA: Standard-dose adrenaline versus vasopressin
Administration of vasopressinwas associatedwith increased STHA
compared to SDA when we combined the results from the three
studies (Ong 2012; Lindner 1997; Wenzel 2004) reporting this
endpoint: RR 1.27, 95% CI 1.04 to 1.54; 3 studies; 1953 partic-
ipants; I2 = 27%; low-quality evidence; Analysis 3.3.
STHA: Standard-dose adrenaline versus vasopressin plus
adrenaline
A pooled estimate of the effect of vasopressin and adrenaline com-
pared to SDA from three studies (Callaway 2006; Ducros 2011;
Gueugniaud 2008) showed no effect on STHA: RR 0.95, 95%CI
0.83 to 1.08; 3 studies; 3249 participants; I2 = 0%; low-quality
evidence; Analysis 4.2.
Neurological outcome
Neurological outcome: Adrenaline versus placebo
In the Jacobs 2011 study, nine of the 11 survivors (3.1% overall)
in the SDA group had a favourable neurological outcome (CPC <
3) at hospital discharge, whilst all five of the surviving participants
in the placebo group (1.9% overall) had a favourable neurological
outcome: RR 1.73, 95% CI 0.59 to 5.11; 534 participants. In the
Perkins 2018 study, there was no difference in the percentage of
participants who had a favourable neurological outcome at hos-
pital discharge (mRs ≤ 3) (or at three months after the OHCA)
between the SDA (2.2%) and placebo (1.9%) groups: RR 1.17,
95% CI 0.86 to 1.59; 8001 participants. The pooled estimate
of SDA versus placebo showed no statistically significant differ-
ence in favourable neurological outcome between the SDA and
placebo groups: RR 1.21, 95% CI 0.90 to 1.62; 2 studies; 8535
participants; I2 = 0%; low-quality evidence; Analysis 1.3. How-
ever, Perkins 2018 also showed that severe neurologic impairment
at hospital discharge (a mRs of 4 or 5) was more frequent in the
SDA group than in the placebo group (39 of 126 participants
(31.0%) versus 16 of 90 participants (17.8%)).
Neurological outcome: Standard-dose adrenaline versus
high-dose adrenaline
Two studies (Callaham 1992; Gueugniaud 1998) reported CPC
scores < 3 for participants receiving SDA or HDA, with neither
finding evidence of a difference in neurological outcome between
the SDA and HDA groups. Stiell 1992 reported CPC scores cate-
gory ’1’ and found no evidence of difference between the SDA and
HDA groups (RR 0.63, 95% CI 0.28 to 1.42; 650 participants).
Brown 1992 recorded CPC score categories < 4, i.e. “conscious
at time of hospital discharge” and reported 92% of participants
in the SDA group who survived to hospital discharge and 94%
in the HDA group had CPC < 4. Including this study with the
others reporting CPC scores (i.e. Brown 1992; Callaham 1992;
Gueugniaud 1998; Stiell 2001), there was no evidence of a statis-
tically significant difference in the effect of SDA versus HDA on
’good’ neurological outcomes: (RR 0.91, 95% CI 0.65 to 1.26;
participants = 5803; studies = 4; I2 = 0%); Analysis 2.6. The very
low quality of evidence means that we are uncertain of the effect
of SDA versus HDA on this outcome. Neurological outcome in
the Li 1999 study was described as “discharged from hospital with
pre-arrest conscious state, heart rate and respiratory rate status” -
and was not included in the meta-analysis. The GCS neurolog-
ical assessments in Choux 1995 at day 3 and day 21 were made
by different physicians and (according to the authors) “were not
systematically performed”; so we have not included these results
in the meta-analysis. However, the authors reported that there was
no evidence of difference in GCS between the intervention SDA
and HDA groups (Choux 1995).
Three paediatric studies comparing SDA to HDA assessed neu-
rological outcome (Perondi 2004; Patterson 2005; Sanchez-
Mendiola 1998). Given the small number of survivors in each
study and the different assessment tools used, we provide a nar-
rative summary. Perondi 2004 reported no survivors in the HDA
group; in the SDA group, two children had a paediatric CPC score
of ’1’ and the other two children (who were impaired before the
hospital cardiac arrest) had the same neurological outcome after
the IHCA. Patterson 2005 used an adapted Glasgow Outcome
Scale (Jennett 1975) to assess neurological outcome at hospital
discharge. In the HDA group two children had good, one had
moderate and six children had a severe neurological outcome. Both
surviving children in the SDA group had severe neurological out-
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come (P = 0.51). Sanchez-Mendiola 1998 reported no survivors
in the SDA group, and of the two survivors in the HDA group
both had “neurologic damage” at hospital discharge.
Neurological outcome: Standard-dose adrenaline versus
vasopressin
For the four studies (Mukoyama 2009; Ong 2012; Stiell 2001;
Wenzel 2004) that reported neurological outcome as CPCs for
the vasopressin versus SDA comparison, there was no evidence of
a statistically significant difference in the pooled result: RR 0.82,
95% CI 0.54 to 1.25; participants = 2406; studies = 4; I2 = 0%;
Analysis 3.4. The very low quality of the evidence indicates uncer-
tainty around this outcome. Ong 2012 followed up participants
to one year and reported no evidence for a difference between the
SDA and vasopressin groups at that time. Lindner 1997 reported
no evidence of a difference in the mean(sd) Glasgow Coma Scale
scores for the three STHD participants in the SDA group com-
pared to the eight STHD participants in the vasopressin group
(10.7 (3.8) versus 11.7 (1.6), P = 0.78), but this was not included
in the meta-analysis due to the use of a different neurologic assess-
ment scale.
Neurological outcome: Standard-dose adrenaline versus
vasopressin plus adrenaline
Gueugniaud 2008 compared CPC scores < 3 between the SDA
plus vasopressin group and the SDA with placebo group, and
found no evidence of difference in CPC scores: RR 0.65, 95%
CI 0.33 to 1.31; participants = 887; studies = 1; very low-quality
evidence; Analysis 4.3.
Return of spontaneous circulation (ROSC)
ROSC: Adrenaline versus placebo
Jacobs 2011 reported that pre-hospital ROSC in OHCA was sig-
nificantly higher in the SDA groupwhen compared to placebo: RR
2.80, 95% CI 1.78 to 4.41; participants = 534. Similarly, Perkins
2018 reported more than a tripling of the proportion of partici-
pants achieving pre-hospital ROSC in the SDA group (36.3% ver-
sus 11.7%; RR 3.10, 95% CI 2.82 to 3.41; participants = 7935).
In theWoodhouse 1995 study, immediate survival, defined as “sta-
ble cardiac rhythm with palpable pulse at time cardiac arrest team
left”, was higher, but not significantly different in OHCA in the
HDA group compared to placebo (RR 1.37, 95%CI 0.53 to 3.53;
participants = 194).
The pooled estimate for the three studies (Jacobs 2011; Perkins
2018; Woodhouse 1995) that compared the effect of adrenaline
versus placebo on the proportion of participants who achieved
ROSC was: RR 2.86, 95% CI 2.21 to 3.71; participants = 8663;
studies = 3; I2 = 33% ; Analysis 1.4. Removal of the Woodhouse
1995 study, which had a high risk of bias (see Figure 2) and a
different experimental intervention (HDA compared to placebo),
hadminimal effect on the pooled estimate (RR 3.09, 95%CI 2.82
to 3.39; participants = 8469; studies = 3; I2 = 0%).
ROSC: Standard-dose adrenaline versus high-dose
adrenaline
Of the 7014 participants (adults and children) in the 13 studies
(Brown 1992; Callaham 1992; Choux 1995; Gueugniaud 1998;
Li 1999; Patterson 2005; Perondi 2004; Polglase 1994; Sanchez-
Mendiola 1998; Schmidbauer 2000; Sherman 1997; Stiell 1992;
Zhu 2000;) that compared ROSC in participants receiving HDA
or SDA, there was a small increase in ROSC of 15% in the HDA
group: RR 1.15, 95%CI 1.02 to 1.29; I2 = 34%; Analysis 2.8. The
very low quality of evidencemeans there is uncertainty around this
outcome. There was no substantial change in the estimate with
the removal of Schmidbauer 2000 (excluded because of a high risk
of bias).
Two studies also compared graded doses of adrenaline (Zhu
2000) or 5 mg adrenaline (Polglase 1994) to SDA and found
similar results to participants receiving HDA, as shown in the
Characteristics of included studies table. The pooled estimate for
the four studies (Li 1999; Perondi 2004; Sanchez-Mendiola 1998;
Zhu 2000) that were conducted in-hospital showed a slight in-
crease in the relative risk of ROSC but the confidence interval
also includes the possibility of no effect or even a small decrease:
RR 1.78, 95% CI 0.82 to 3.88; participants = 190; Analysis 2.7.
However there was a high level of heterogeneity (I2 = 68%; P =
0.02). There was no evidence of subgroup difference in ROSC for
OHCA versus IHCA (test for subgroup differences: Chi2 = 1.29,
df = 1, P = 0.26, I2 = 22%; Analysis 2.7).
Three paediatric studies (Patterson 2005; Perondi 2004; Sanchez-
Mendiola 1998) compared ROSC in SDA versus HDA in 258
children and found no evidence of a difference in ROSC, but
with substantial heterogeneity: RR 1.31 95% CI 0.67 to 2.56; I
2 = 63%; Analysis 2.8. Excluding one study (Sanchez-Mendiola
1998) because of a high risk of bias, there was no evidence of
a difference in the effect estimate for ROSC (RR 1.13, 95% CI
0.73 to 1.73; participants = 222; studies = 2; I2 = 41%). There
was no evidence of subgroup difference in ROSC for adults versus
children; test for subgroup differences: Chi2 = 0.15, df = 1 (P =
0.70), I2 = 0.0%; Analysis 2.8.
ROSC: Standard-dose adrenaline versus vasopressin
The pooled estimate for the six studies ( Li 1999; Lindner 1997;
Mukoyama 2009; Ong 2012; Stiell 2001;Wenzel 2004) that com-
pared SDA to vasopressin showed no evidence of a statistically sig-
nificant difference in ROSC: RR 1.10, 95%CI 0.90 to 1.33; stud-
ies = 6; participants = 2531; I2 = 61%; very low-quality evidence;
Analysis 3.5. There was no difference for participants who had an
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IHCA (RR 1.76, 95% CI 0.40 to 7.71; participants = 242, studies
= 2; I2 = 84%) or an OHCA (RR 1.05, 95% CI 0.80 to 1.39; par-
ticipants = 1562; studies = 3; I2 = 56%; Analysis 3.6). However,
there was substantial statistical heterogeneity for the IHCA sub-
group. There was no evidence of subgroup difference in ROSC in
OHCA versus IHCA; test for subgroup differences: Chi2 = 0.45,
df = 1 (P = 0.50), I2 = 0%; Analysis 3.6.
ROSC: Standard-dose adrenaline versus vasopressin plus
adrenaline
The pooled estimate of three studies (Callaway 2006; Ducros
2011; Gueugniaud 2008) that compared SDA versus vasopressin
plus adrenaline showed no difference in ROSC: RR 0.97, 95%
CI 0.87 to 1.08; participants = 3249; studies = 3; I2 = 0%; low-
quality evidence; Analysis 4.4.
Other outcomes
We prespecified three other outcomes in our protocol (Jacobs
2003), namely: all-cause mortality, return of non-perfusing
rhythm, and admission to ICU, but we have not included them
in the review for the following reasons.
Firstly, all-cause mortality is not reported in resuscitation research,
since survival at specific time points (e.g. ’STHD’) is the recom-
mendedoutcome (Perkins 2015). Return of non-perfusing rhythm
was not reported by any studies. Admission to ICUwas reported as
an outcome by several studies (Gueugniaud 1998; Lindner 1997;
Ong 2012; Patterson 2005; Stiell 1992), but tended to be a sur-
rogate for admission to hospital in OHCA. This outcome is not
recommended in the Utstein guidelines (Perkins 2015), and we
therefore have not analysed it separately.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Standard-dose adrenaline (SDA) compared to high-dose adrenaline (HDA) for cardiac arrest
Patient or population: people suf fering cardiac arrest
Setting: either outside of hospital (OHCA) or during hospitalisat ion (IHCA)
Intervention: High-dose adrenaline (HDA)
Comparison: Standard-dose adrenaline (SDA)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with standard-
dose adrenaline (SDA)
Risk with high-dose
adrenaline (HDA)
Survival to hospital dis-
charge
Study populat ion RR 1.10
(0.75 to 1.62)
6274
(10 RCTs)
⊕©©©
VERY LOWa,b,c,d
Two more studies (N =
245) reported no sur-
vivors in either arm, but
could not be added to
the meta-analysis due
to zero events
OHCA and IHCA
33 per 1000 36 per 1000
(24 to 53)
Survival to hospital ad-
mission
Study populat ion RR 1.13
(1.03 to 1.24)
5764
(5 RCTs)
⊕©©©
VERY LOWc,e
OHCA only
213 per 1000 241 per 1000
(220 to 264)
Favourable neurologi-
cal outcomes
Study populat ion RR 0.91
(0.65 to 1.26)
5803
(4 RCTs)
⊕©©©
VERY LOWc,d,f,g
Favourable neurologi-
cal outcomes were de-
f ined as a CPC score of
< 3 in two studies;CPC <
2 in one study and CPC
< 4 in one study
OHCA and IHCA
26 per 1000 23 per 1000
(17 to 32)
Return of spontaneous
circulat ion
Study populat ion RR 1.15
(1.02 to 1.29)
7014
(13 RCTs)
⊕©©©
VERY LOWa,b,c,g
OHCA and IHCA
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303 per 1000 349 per 1000
(309 to 391)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; CPC: cerebral performance category
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aThe funnel plots were slight ly asymmetrical, so downgraded one level for possible publicat ion bias.
bDowngraded one level as f ive studies at high risk of bias.
cDowngraded one level for inconsistency. Sett ing (in, out of hospital, emergency department) varies between studies. Variat ion
in route of administrat ion, doses and t im ing of dose administrat ion between studies.
dDowngraded one level for imprecision. Conf idence interval includes possibility of clinically important harm or benef it .
eDowngraded one level as three studies at high risk of bias.
fDowngraded one level as two studies at high risk of bias.
gDowngraded one level for inconsistency, due to substant ial stat ist ical heterogeneity.
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Standard-dose adrenaline (SDA) compared to vasopressin for cardiac arrest
Patient or population: people suf fering cardiac arrest
Setting: either outside of hospital (OHCA) or during hospitalisat ion (IHCA)
Intervention: Vasopressin
Comparison: Standard-dose adrenaline (SDA)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with standard-
dose adrenaline
Risk with vasopressin
Survival to hospital dis-
charge
Study populat ion RR 1.25 (0.84 to 1.85 2511
(6 RCTs)
⊕©©©
VERY LOWa,b,c
OHCA and IHCA
72 per 1000 90 per 1000
(60 to 133)
Survival to hospital ad-
mission
Study populat ion RR 1.27
(1.04 to 1.54)
1953
(3 RCTs)
⊕⊕©©
LOWb
OHCA and IHCA (ED)
260 per 1000 330 per 1000
(270 to 400)
Favourable neurologi-
cal outcomes
Study populat ion RR 0.82
(0.54 to 1.25)
2406
(4 RCTs)
⊕©©©
VERY LOWb,c
Favourable neurologi-
cal outcomes were de-
f ined as a CPC score of
< 3
OHCA and IHCA
39 per 1000 32 per 1000
(21 to 49)
Return of spontaneous
circulat ion
Study populat ion RR 1.10
(0.90 to 1.33)
2531
(6 RCTs)
⊕©©©
VERY LOWa,b,d
OHCA and IHCA
311 per 1000 342 per 1000
(280 to 413)
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; CPC: cerebral performance category
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level as two studies at high risk of bias.
bDowngraded two levels for inconsistency. Studies included in- and out-of -hospital cardiac arrest and cardiac arrests in the
emergency department. Inclusion criteria varied between studies, with inconsistencies in intervent ions given.
cDowngraded two levels for imprecision. Events less than 300, upper and lower CI lim its include both meaningful benef it and
harm.
dDowngraded one level for imprecision. Upper and lower CI lim its include both meaningful benef it and harm.
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Standard-dose adrenaline (SDA) compared to SDA plus vasopressin for cardiac arrest
Patient or population: people suf fering cardiac arrest
Setting: either outside of hospital (OHCA) or during hospitalisat ion (IHCA)
Intervention: SDA plus vasopressin
Comparison: Standard-dose adrenaline (SDA)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with standard-
dose adrenaline (SDA)
Risk with SDA plus va-
sopressin
Survival to hospital dis-
charge
Study populat ion RR 0.76
(0.47 to 1.22)
3242
(3 RCTs)a
⊕©©©
VERY LOWa,b
OHCA only
24 per 1000 18 per 1000
(11 to 29)
Survival to hospital ad-
mission
Study populat ion RR 0.95
(0.83 to 1.08)
3249
(3 RCTs)
⊕⊕©©
LOWa,c
-OHCA only
218 per 1000 207 per 1000
(181 to 236)
Favourable neurologi-
cal outcomes
Study populat ion RR 0.65
(0.33 to 1.31)
2887
(1 RCT)
⊕©©©
VERY LOWa,b
Favourable neurologi-
cal outcomes was de-
f ined as a CPC score of
< 3
OHCA only
14 per 1000 9per 1000
(5 to 18)
Return of spontaneous
circulat ion
Study populat ion RR 0.97
(0.87 to 1.08)
3249
(3 RCTs)
⊕⊕©©
LOWa,c
OHCA only
299 per 1000 290 per 1000
(260 to 323)
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; CPC: cerebral performance category
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded two levels for imprecision. Event rate less than 300 and conf idence interval includes possibility of clinically
important harm or benef it .
bDowngraded one level for inconsistency. Sett ing (in, out of hospital, emergency department) varies between studies. Variat ion
in route of administrat ion, doses and t im ing of dose administrat ion between studies.
cDowngraded one level for imprecision. Conf idence interval includes possibility of clinically important harm or benef it .
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D I S C U S S I O N
Summary of main results
This systematic review and meta-analysis combines the results
from 26 studies that reported the effect of administration of
adrenaline or vasopressin or both on patient outcomes after cardiac
arrest.We imposed no language or age limits, and the cardiac arrest
could occur out of hospital (OHCA) or in the hospital (including
ED or ICU) (IHCA). Because different aetiology is often involved
in paediatric cardiac arrests (Reis 2002), we performed separate
analyses for adults and children, and for IHCA andOHCA events.
A primary outcome was survival to hospital discharge (STHD).
Timely restoration of cardiac rhythm and circulation (i.e. ROSC)
is essential for short-term survival but STHD and the quality of
survival are most important for patients, their families and care-
givers (Haywood 2018).We foundhigh-quality evidence from two
randomised controlled trials (Jacobs 2011; Perkins 2018; 8538
participants in total) that showed that standard-dose adrenaline
(1 mg repeated doses), compared to placebo, increased STHD.
By contrast, we are uncertain about STHD in studies that com-
pare high-dose adrenaline (HDA) and standard-dose adrenaline
(SDA), vasopressin versus SDA or vasopressin/adrenaline versus
SDA, due to very low-quality evidence. The information provided
by subgroup analyses (adults versus children and IHCA versus
OHCA) were limited by the small number of children and in-
hospital cardiac arrests reported. Although the analyses performed
showed no evidence of a difference in STHD (primary outcome),
the confidence intervals were wide.
Survival to hospital admission (STHA)was reported less often than
STHD. SDA compared to placebo more than doubled STHA. Al-
though the analysis suggests that HDA increased STHA by 13%
compared to SDA, we are uncertain about this effect, due to very
low-quality evidence. Vasopressin increased STHA by 27% com-
pared to SDA; but the pooled effect of SDA compared to vaso-
pressin plus SDA found no evidence for a difference between the
two groups.
Survival with a favourable neurological outcome is important for
patients and their families (Haywood 2018), but several studies
did not report neurological outcomes (Callaway 2006; Ducros
2011; Lindner 1991a; Lipman 1993; Polglase 1994; Schmidbauer
2000;Woodhouse 1995). Those that did used a range of methods:
cerebral performance category (CPC) scores, Glasgow coma score
(GCS), Glasgow outcome score, mini-mental state examination
(MMSE) and electroencephalogram (EEG) (see Primaryoutcomes
in the Included studies section for more details). In the compari-
son of SDA to placebo, the pooled estimate did not show evidence
of a difference in survival with a favourable neurological outcome
(Jacobs 2011; Perkins 2018); however, both studies reported more
participants surviving with impaired neurological outcome in the
adrenaline arm. Of the four studies that compared SDA to HDA
(Brown 1992; Callaham 1992; Gueugniaud 1998; Stiell 1992)
and reported CPC scores, the pooled analysis did not show any
difference in neurologic outcome, but there is uncertainty around
this result due to the very low quality of evidence. However. there
was substantial heterogeneity (I2 = 62%), with small sample sizes
and wide confidence intervals, and variation in the definition of
’good’ CPC scores. The five studies (Mukoyama 2009; Ong 2012;
Stiell 2001; Wenzel 2004;Gueugniaud 2008) that included vaso-
pressin in the comparison found no evidence of improved neuro-
logical outcome, but again very low-quality evidence makes this
uncertain. Hospital discharge was the most commonly collection
time point for assessing neurological outcome, but longer follow-
up is needed to assess the effects of the treatments received.
Whilst not a patient-centred outcome (Perkins 2015), return of
spontaneous circulation (ROSC) is commonly reported as an ini-
tial survival outcomemeasure in resuscitation research.Despite the
different operational definitions (as shown in the Characteristics
of included studies table), we include ROSC as a secondary out-
come. As has been widely reported elsewhere (Larabee 2012; Lin
2014), SDA increased ROSC compared to placebo. ROSC pro-
vides time to initiate therapies that may enable recovery, but the
use of vasopressors could have negative effects on vital organs that
may worsen neurological outcome (Ristagno 2009; Soar 2011).
ROSC without good-quality survival is a poor outcome for pa-
tients.
Overall completeness and applicability of
evidence
We conducted comprehensive searches using bibliographic
databases, with no limits on language or date of publication. Two
Chinese papers (Li 1999; Zhu 2000) and one Japanese paper
(Nishizawa 1993) were translated into English. We also checked
several systematic reviews (Aung 2005; Larabee 2012; Lin 2014;
Mentzelopoulos 2012; Meyer 2011; Sillberg 2008; Wyer 2006),
and included in our review all studies included in these reviews
that met our selection criteria. While we included 26 studies with
28 comparisons in our review, there were several groups such as
IHCA and cardiac arrests in children that had too few participants
or had levels of heterogeneity across studies that precluded confi-
dence in interpretation of the pooled results.
Furthermore, all studies in our review were conducted in relatively
resource-rich countries, with well-established emergency medical
responses, and as such may not be applicable to resource-lim-
ited settings. Out of the 26 studies only four used a placebo (
Gueugniaud 2008; Jacobs 2011; Perkins 2018;Woodhouse 1995),
and one of these (Gueugniaud 2008) administered adrenaline to
both groups, i.e. placebo and adrenaline were administered in the
control group and 1 mg of adrenaline and 40 IU of vasopressin
in the experimental group. Two of the trials of placebo versus
adrenaline were challenged by the “unwillingness of providers to
randomise subjects to the placebo arm“ (Jacobs 2011;Woodhouse
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1995), and Perkins 2018 was subject to adverse media reporting
during the conduct of the trial.
Quality of the evidence
We rated eight studies (Callaway 2006;Ducros 2011; Jacobs 2011;
Lindner 1991a; Lindner 1997; Ong 2012; Perkins 2018; Stiell
1992) at low risk of bias for most categories. These include Ducros
2011, that was excluded in the Mentzelopoulos 2012 systematic
review for high risk of bias, and Jacobs 2011, that was rated as
”fair“ by Larabee 2012 because of the problems with recruitment
to the study. In a sensitivity analysis, we excluded two studies
(Sanchez-Mendiola 1998; Schmidbauer 2000) for high risk of bias
overall; the exclusion from pooled analyses reduced statistical het-
erogeneity but did not change the overall pooled result. Valid in-
terpretation of the pooled estimate for the three paediatric studies
(Patterson 2005; Perondi 2004; Sanchez-Mendiola 1998) was not
possible, because of the substantial heterogeneity.
We sought to compare low- and high-dose adrenaline and
adrenaline versus vasopressin, but study protocols varied. Some
studies (Callaway 2006; Perondi 2004; Sherman 1997) required
both groups to have an initial dose of SDA before administra-
tion of the study drug. The number of doses of study drug varied
from one (Brown 1992; Lindner 1997; Ong 2012; Stiell 2001) to
15 (Choux 1995; Gueugniaud 1998). After the number of pre-
defined study drug doses had been administered participants of-
ten received subsequent doses of SDA as required. Patterson 2005
permitted the administration of double doses of adrenaline for
the second and subsequent doses, at the physician’s discretion.
Sanchez-Mendiola 1998 allowed HDA to be administered after
the initial dose of study drug. In Callaway 2006, which compared
vasopressin to SDA, physicians were allowed to administer open-
label vasopressin according to medical judgement. Adrenaline was
used in all other studies that allowed vasopressors after the pre-
scribed number of study drug doses had been administered, which
varied considerably between studies.
Whilst many study protocols specified administration of the study
drug as soon as practicable, in reality the time from onset of car-
diac arrest to drug delivery varied widely. For example, in the large
OHCA RCT of adrenaline vs placebo (Perkins 2018), with an
average response time from emergency call to scene of around six
minutes (comparable to many ambulance services worldwide), the
median time from call to administration of the study agent was
21 minutes (interquartile range (IQR) 16 to 27 minutes). One
OHCA study (Mukoyama 2009) did not allow vasopressor ad-
ministration at all in the field, requiring instead that patients be
randomly assigned to either vasopressin or SDA immediately after
admission to the emergency room. This resulted in an interval of
30 minutes or more from call to drug administration. It is likely
that the time interval from the arrest until drug administration is
reduced in IHCA, since the response team is ’on site’. Stiell 2001
reported a mean time interval of 6.1 minutes to administration
of study drug in their IHCA study. Similarly, Perondi 2004, the
paediatric IHCA study where most participants were in intensive
care unit or the emergency department, with 78% being moni-
tored electrocardiographically, reported a mean time interval from
call to drug administration of less than three minutes.
The differences in vasopressor administration timing and drug
administration protocol can make interpretation of the specific
effects of a therapy difficult when comparing outcomes between
groups (Soar 2011). Similarly, differences in medical treatment
and emergencymedical services structure may affect outcomes in a
RCT, e.g. the French OHCA studies (Choux 1995; Ducros 2011;
Gueugniaud 1998; Gueugniaud 2008) used physician-staffedmo-
bile ICUs. There was therefore heterogeneity in the settings, in-
terventions and participant populations reported in this review.
This in part explains why, despite the fact that we only included
randomised controlled trials, the levels of evidence quality were
very low and low, increasing to high only in the adrenaline-placebo
trials.
This review was limited to reporting randomised controlled trials.
Assessment of quality of the evidence for each outcome using
GRADE identified at best moderate-quality evidence but mostly
low or very low. For SDA compared to placebo, the quality of
evidence was moderate for STHD, ROSC, and STHA, and low
for favourable neurological outcomes (see Summary of findings
for the main comparison). We rated the level of evidence for SDA
compared to HDA as very low for all outcomes (see Summary of
findings 2), with the quality of evidence downgraded for serious
risk of bias, serious imprecision and serious inconsistency.We rated
SDA versus vasopressin as very low quality of evidence for STHD,
neurological outcome and ROSC, and low quality for STHA (see
Summary of findings 3), with the quality of evidence downgraded
for risk of bias, very serious inconsistency and imprecision. Finally,
for SDA compared to vasopressin plus adrenaline, we judged the
level of evidence to be low or very low (see Summary of findings
4), with the quality of evidence downgraded for serious risk of
inconsistency and very serious risk of imprecision.
Potential biases in the review process
Although we performed an extensive search of the literature, we
may have missed some papers reporting relevant studies. We in-
cluded both OHCA and IHCA, and stratified some analyses to
account for differences in outcomes because of the location of
the cardiac arrest. Often only the sicker patients were included in
studies, e.g. those in ventricular fibrillation (VF)/pulseless ventric-
ular tachycardia (VT) were randomised after initial defibrillation
shockswere unsuccessful (Gueugniaud 2008; Jacobs 2011; Perkins
2018). Patients with a brief duration of VF and therefore a high
likelihood of survival and subsequent good neurological recovery
were not included inmost studies. The selection of endpoints may
not be the most suitable for people who suffer a cardiac arrest.
Merely having ROSC and not surviving beyond a few hours may
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provide the opportunity to apply post-resuscitation care that can
affect survival, but it is not a good outcome for patients if survival
is of poor quality.
Neurologic outcomesweremost commonly assessed using the five-
point Cerebral Performance Category. However, the ’cut point’ to
define a favourable neurologic outcome varied across studies.
Studies were published between 1991 (Lindner 1991a) and 2018
(Perkins 2018). It is difficult to account for variations in prac-
tice over time, as well as differences between hospitals and EMS
providers, which could impact on patient outcomes.
We also cannot rule out the possibility that non-significant trials
might be less likely to be published.
The source of funding was not stated in 11 of the 26 studies,
The study drugs were provided and funded by the manufacturer
in four of the 26 studies, but neither drug represents a profitable
commercial option, given that they are ’off patent’.
Agreements and disagreements with other
studies or reviews
Several systematic reviews (with and without meta-analyses) have
been published in the last 15 years. Some were similar to ours in
that they considered a range of interventions involving adrenaline,
i.e. SDAversus placebo,HDAversus SDA, or vasopressin (alone or
in combination with adrenaline) versus SDA (Larabee 2012; Lin
2014). Others restricted their reviews to comparisons of SDA ver-
sus vasopressin (alone or in combination with adrenaline) (Aung
2005; Mentzelopoulos 2012; Sillberg 2008; Wyer 2006; Xiao-li
2010). Our systematic review and meta-analysis provides a com-
prehensive report of the current literature of RCTs of OHCA
and IHCA, adults and paediatric studies, and comparisons of
adrenaline versus placebo, standard-dose adrenaline versus high-
dose adrenaline, and adrenaline versus vasopressin (alone and in
combinationwith adrenaline). The followingprovides an overview
of the differences between our systematic review and those listed
above.
Aung 2005 included five RCTs (Lee 2000; Li 1999; Lindner
1997; Stiell 2001; Wenzel 2004) that compared vasopressin to
adrenaline. Our review excluded Lee 2000 because the conference
abstract was a pilot study of 10 participants from a larger RCT
in progress, for which few details were provided. We could find
no record of the study, and were unsuccessful in contacting the
authors. The methodological quality of three studies (Lindner
1997; Stiell 2001;Wenzel 2004) was rated as low risk, but Li 1999
was rated at high risk of bias, which differed from our assessment
in which we did not rate the study as having a high risk overall.
Aung 2005 concluded that there was no evidence of a difference
in any of the outcomes (ROSC, STHA, STHD or neurological
outcome) between the vasopressin and adrenaline groups.
Wyer 2006 compared vasopressin and adrenaline in cardiac arrest,
but only included three RCTs (Lindner 1997; Stiell 2001; Wenzel
2004), which they regarded as ”well-reported“, and referred to the
Aung 2005 systematic review. Wyer 2006 excluded two studies
(Lee 2000; Li 1999), which were rated by Aung 2005 as “low
quality”. They stated that these two papers provided insufficient
information about the study populations, treatment protocols, or
the susceptibility to bias. We have also excluded Lee 2000, as ex-
plained above. We agree with Wyer’s assessment that the inclu-
sion of Lee 2000 in a pooled analysis ”might distort the estimates
in ways that the parsimoniously reported data does not allow an
investigator to anticipate or assess”. However, we did not exclude
any study based on risk of bias, and we have therefore included
Li 1999. Based on the three RCTs included in Wyer 2006, the
authors concluded that “the evidence did not show a consistent
benefit of vasopressin compared to adrenaline in increasing STHD
or improving neurologic outcome”.
Sillberg 2008 reported the results from three RCTs that compared
the effect of vasopressin plus adrenaline versus repeated doses of
SDA alone in OHCA (Callaway 2006; Wenzel 2004) and IHCA
(Stiell 2001). Three excluded studies were not identified in the
report. The authors did not conduct a meta-analysis because they
believed that “the three studies were too dissimilar to allow pooling
of results”. However, they noted that only Wenzel 2004 showed
improved outcomes (ROSC, admission tohospital andSTHD) for
the combination of vasopressin and epinephrine (adrenaline). Our
review assigns these three studies to different comparison groups,
i.e. Stiell 2001 and Wenzel 2004 to the ’SDA versus vasopressin’
comparison, and Callaway 2006 to the ’SDA versus adrenaline
and vasopressin’ comparison.
Xiao-li 2010 compared the effect of vasopressin and adrenaline
used together versus adrenaline alone in adults in cardiac ar-
rest. They included six studies (Callaway 2006; Grmec 2006;
Gueugniaud 2008; Lindner 1997; Stiell 2001;Wenzel 2004).One
of the included studies (Grmec 2006) was an observational cohort
study (not an RCT) and was therefore excluded from our review.
The two studies that were excluded from the Xiao-li 2010 review
due to methodological concerns were not identified. Outcomes
assessed were ROSC, STHA, survival at 24 hours, STHD and
neurological outcome. Xiao-li 2010 reported increased 24-hour
survival for the vasopressin-plus-adrenaline group but no evidence
of a difference for the other outcomes. As explained above, we
separated the adrenaline-versus-vasopressin studies into two dis-
tinct comparisons based on whether or not the two drugs were co-
administered.
Mentzelopoulos 2012 examined the effect of any vasopressin
regimen versus adrenaline on outcomes from cardiac arrest.
Eight studies (Callaway 2006; Ducros 2011; Gueugniaud 2008;
Lindner 1997; Mentzelopoulos 2009; Mukoyama 2009; Stiell
2001; Wenzel 2004) were initially selected but two were excluded
(Ducros 2011; Mukoyama 2009) because of a high risk of bias.
Ducros 2011 was excluded because the risk of bias for blinding of
long-term outcomes was unclear, i.e. there was a lack of explicit
reporting of blinding for data collectors, outcome assessors and
data analysts, the estimated sample size was not reached, and the
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frequency of bystander CPR differed between groups. Mukoyama
2009 was excluded because there was no blinding for short-term
or long-term outcomes and there was no power calculation. We
excluded neither of these studies from our review. Mentzelopoulos
2012 also included Mentzelopoulos 2009, which we excluded
from our review because it did not allow the direct contribution
of vasopressin on outcomes to be assessed. The conclusion drawn
by Mentzelopoulos 2012 was that “Vasopressin use in the resusci-
tation of cardiac arrest patients is not associated with any overall
benefit or harm”.
Larabee 2012 examined the effect of vasopressors on outcomes
in participants who suffered cardiac arrest. Unlike our review,
Larabee 2012 included controlled trials, meta-analyses and case
series, and is therefore not directly comparable with our review,
which only includes RCTs. The only RCT included in Larabee
2012 that was not included in our review was Olasveengen 2009.
This study compared the provision of advanced cardiac life support
with and without intravenous drug administration, rather than
comparing specific drugs. For this reason we excluded it from our
review. Larabee 2012 concluded that “Epinephrine is associated
with improvement in short term survival outcomes as compared
to placebo, but no long-term survival benefit has been demon-
strated”.
In 2015 the International Liaison Committee for Resuscitation
(ILCOR) conducted a number of systematic reviews of advanced
life support interventions, including Epinephrine (adrenaline)
versus placebo; Standard-dose epinephrine (SDE) versus high-dose
epinephrine (HDE); and Epinephrine versus vasopressin in combina-
tion with epinephrine (Soar 2015). These systematic reviews and
meta-analyses were incorporated into a single publication (Lin
2014). The search strategy for Lin 2014 was undertaken up un-
til July 2013, and hence does not include the recently-published
Perkins 2018 study. The inclusion criteria of the Lin 2014 review
also differ from ours by restricting analyses to adult participants,
thus excluding the three paediatric studies in our review (Perondi
2004; Patterson 2005; Sanchez-Mendiola 1998). Studies were also
excluded if it was not possible to separate outcomes amongst those
sustaining in- and out-of-hospital cardiac arrests, thereby exclud-
ing Lindner 1991a; Lipman 1993 andWoodhouse 1992.We iden-
tified and translated two Chinese studies (Li 1999; Zhu 2000)
which were not included in the Lin 2014 review and also included
Polglase 1994 (Research letter), Stiell 2001 (IHCA) and the recent
Perkins 2018 study. The Lin 2014 review included 14 studies for
the four comparisons as follows: (1) one study for adrenaline versus
placebo (Jacobs 2011); (2) six studies for SDA versusHDA (Brown
1992; Callaham 1992; Choux 1995; Gueugniaud 1998; Sherman
1997; Stiell 1992); (3) six studies for SDA versus adrenaline plus
vasopressin (Callaway 2006; Ducros 2011; Gueugniaud 2008;
Lindner 1997; Ong 2012; Wenzel 2004); and (4) one study for
SDA versus vasopressin alone (Mukoyama 2009). Our classifica-
tion of studies that fell within the ’SDA vs vasopressin alone’ and
the ’SDA versus adrenaline plus vasopressin’ comparisons differed
from those in Lin 2014. In the ’SDA versus adrenaline plus vaso-
pressin’ comparison,we only included studieswhere the adrenaline
and vasopressin were co-administered (Callaway 2006; Ducros
2011; Gueugniaud 2008), whereas Lin 2014 defined their com-
parison of ’Adrenaline and vasopressin combination’ as “the use of
both drugs concomitantly during resuscitation, regardless of the
order of drug administration or specific trial intervention” (Lin
2014).
With respect to the pooled analyses for each of the four compar-
isons: (1) Lin 2014 only included one study (Jacobs 2011) for the
’SDA versus placebo’ comparison and is therefore not comparable
with our review, which now includes the substantial recent Perkins
2018 study; (2) As in our review, Lin 2014 reported a reduced risk
of ROSC for SDA compared to HDA (RR 0.85, 95% CI 0.75 to
0.97; 6 studies; 6174 participants; I2= 48%), and a small reduction
in STHA for SDA compared to HDA (RR 0.87, 95% CI 0.76
to 1.00; 4 studies; 5699 participants; I2 = 34%), but no differ-
ence in STHD or neurological outcomes; (3) Lin 2014 reported
no difference between SDA versus adrenaline plus vasopressin for
any of the outcomes (ROSC, STHA, STHD, neurological out-
come); and (4) only one study (Mukoyama 2009) was included
in the Lin 2014 ’SDA versus vasopressin alone’ comparison. In
contrast, (and possibly due to the difference in inclusion criteria
and allocation of studies to specific comparisons) we found a small
increase in STHA in favour of vasopressin compared to SDA in
the pooled estimate (RR 1.27, 95% CI 1.04 to 1.54; 3 studies;
1953 participants; I2 = 27%; Analysis 3.3). Lin 2014 concluded
that there was “no clear advantage of SDA over placebo, HDA,
adrenaline and vasopressin combination, or vasopressin alone, in
STHD or neurological outcome in adults after OHCA.”
Zhang 2017 is the most recently published review prior to our
own. It was conducted to evaluate the efficacy of vasopressin and
adrenaline combined, compared to adrenaline alone in people who
suffered anOHCA,with a search current to Februrary 2017. They
included nine studies in the review, five of which we also include
in our review (Callaway 2006; Ducros 2011; Gueugniaud 2008;
Ong 2012; Wenzel 2004), plus four Chinese studies that we did
not identify in our searches (He 2010; Hu 2008; Xiao 2007; Yang
2012). We contacted the senior author of the Zhang 2017 review
to clarify the citations for the four Chinese studies, who confirmed
that reference 19 in this paper is incorrect, and should be He
2010. ROSC was the only outcome reported in Zhang 2017, with
a pooled analysis that showed that vasopressin-epinephrine was
associated with a higher rate of ROSC (OR 1.67, 95% CI 1.13
to 2.49; 9 studies; 5047 participants). In contrast, in our review
we did not find that the ROSC rate was increased in either of the
analyses that involved vasopressin (see Analysis 3.5; Analysis 4.4).
However, unlike Zhang 2017, we distinguished between studies
that compared vasopressin versus adrenaline (see Analysis 3.5) and
those that compared vasopressin plus adrenaline versus adrenaline
(see Analysis 4.4). It is therefore not surprising that there was very
high heterogeneity (I2 = 83%) in the pooled estimate in the Zhang
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2017 meta-analysis for ROSC.
As described in the Results (Outcomes) section above, we chose to
use the amended denominator where loss to follow up for differ-
ent outcomes (e.g. neurological status) was described (e.g. Perkins
2018; Wenzel 2004). There is therefore some discrepancy in the
denominators used in analyses described in other systematic re-
views. For example, similar to our review, the Mentzelopoulos
2012 review used ’adjusted’ denominators, but this was not done
in the Lin 2014 review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our review adds to the body of knowledge about the effect of
vasopressors on survival and neurological outcomes from cardiac
arrest. We included both adults and children, and we compared
patient outcomes of in- and out-of-hospital cardiac arrests. How-
ever, most studies enrolled adult participants with out-of-hospital
cardiac arrest, and this therefore limits the generalisability of our
findings to in-hospital cardiac arrest and to paediatric cardiac ar-
rest.
Compared to placebo, moderate-quality evidence showed that
standard-dose adrenaline improved the return of spontaneous cir-
culation, admission to hospital and survival to hospital discharge
in people with out-of-hospital cardiac arrest. The effect on survival
with a favourable neurological outcome at discharge is uncertain,
as the evidence includes the possibility of benefit or harm.
The evidence for high-dose adrenaline compared to standard-dose
adrenaline was of very low quality, so we are uncertain of the effect
on the return of spontaneous circulation, admission to hospital,
survival to hospital discharge or survival with favourable neuro-
logical outcome.
Low-quality evidence showed that vasopressin compared to stan-
dard-dose adrenaline improved only survival to hospital admis-
sion, with uncertainty about the effect on other outcomes, due to
very low-quality of evidence.
Vasopressin and adrenaline compared to standard-dose adrenaline
alone (very low- and low-quality evidence) showed no significant
effects for any of the prespecified outcomes.
Recommendations for the use of adrenaline should be informed by
the findings of this review, taking into account the characteristics of
the healthcare system (EMS and hospital facilities) and the values,
preferences and priorities of the communities they serve.
Implications for research
• We defined only limited subgroup analyses in our protocol,
as we anticipated (and experienced) difficulty in extracting
relevant subgroup data from the index studies. Future studies
should seek to report sufficiently granular information on
subgroups of participants, to enable a better understanding of
treatment effects in different groups of participants.
• There is a paucity of research relating to in-hospital cardiac
arrest, and to in- and out-of-hospital cardiac arrest in children.
• Further research is required to better understand patients’
prioritisation of outcomes following cardiac arrest, particularly
their preferences about ‘trade-offs’ between survival and
neurological outcome
• Further research is required to identify interventions that
can sustain the large increase in return of spontaneous circulation
and survival to hospital admission through to survival to hospital
discharge with favourable neurological outcomes.
• Further research on time to drug administration is required,
since this may influence outcomes.
• The cost effectiveness of vasopressors as a treatment for
cardiac arrest needs to be considered, especially in relation to the
survivor’s long-term quality of life.
• Investigation is needed about dosing and mode of
administration of adrenaline, e.g. the use of lower doses of
adrenaline or as a continuous effusion, targeting physiological
measurements of organ perfusion.
• The implications of vasopressor use for cardiac arrest on the
rates of organ donation need to be considered.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Brown 1992
Methods Prospective, multicentre, double-blind RCT
Multiple EMS USA
1 October 1989 to 1 December 1990
Participants Included: OHCA patients > 18 years; in VF after 3 DC shocks or rhythm changed to
asystole/PEA, or patients in asystole or PEA after BLS, ETT and IV access, at time when
first drug to be administered
Excluded: “Pregnancy, cardiac arrest associated with trauma, hypothermia, drowning,
confirmed drug overdose or primary respiratory arrest, e.g. hanging, airway obstruction,
patients with clear signs of irreversible cardiac arrest, e.g. rigor mortis, or patients where
ETT and IV access could not be gained.”
Participants: 1280 (632 standard-dose adrenaline group and 648 high-dose adrenaline
group)
Interventions High-dose group: 0.2 mg per kilogram IV (1:1000)
Standard-dose group: 0.02 mg of adrenaline per kilogram of body weight IV (1:10,000)
, with 20 ml normal saline flush
Single dose of study drug only, then “All other care as per American Heart Association
guidelines.”
Outcomes Survival to hospital discharge, survival to hospital admission, neurological outcome,
ROSC, successful resuscitation
Neuro outcomes measured using CPC at hospital discharge: ’conscious at discharge’ was
CPC1-3; ’unconscious at discharge’ was CPC 3 or4
No hospital length of stay reported
Notes Various USA Emergency Medical Services. Emergency Medical Service: EMT-D and
paramedics
Ethics not stated, not registered, no consort diagram, no sample size calculation, inten-
tion-to-treat analysis
Funding: Abbott Laboratories manufactured and supplied the syringes and epinephrine
used in this study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Number and coded syringes
placed in random order in packaged groups
and randomly distributed to each centre by
manufacturer”
Randomisation method not stated but
done by manufacturer
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Brown 1992 (Continued)
Allocation concealment (selection bias) Low risk Numbered and coded syringes of equal vol-
ume and appearance
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk EMS staff and study investigators blinded
to study treatment. Participant uncon-
scious at the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participant unconscious at the time of
event and blinding for hard outcome
(death/survival) unlikely to be associated
with risk of bias. Uncertain as to whether
the assessor was aware of the allocation
group for neurological outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for. Intention to
treat analysis
Cases with missing data excluded for the
variable of interest
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported, but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias Unclear risk Role of industry funder in manuscript
preparation unclear
No postresuscitation care reported
Callaham 1992
Methods Double-blind RCT
OHCA, San Francisco, California USA
15 August 1990 to 15 January 1992
Participants Included: “All patients≥ 18 years, in nontraumatic, normothermic cardiac arrest, treated
by paramedics, who would receive adrenaline according to American Heart Association
advanced cardiac life support guidelines”
Excluded: hospital outcome unknown (1 patient), medication unknown (21 patients),
did not receive study drug and were erroneous entries (5 patients)
Participants: 2694 patients with cardiac arrests during the study period, resuscitation
attempted on 1062 patients, 843 met entry criteria, 27 excluded (1 hospital outcome
unknown, 21 drug uncertain, 5 did not receive study drug) - 816 enrolled (not clear if
after randomisation)
Excluding 270 patients in high-dose noradrenaline (NA) group, 546 patients: high-dose
adrenaline = 286, standard-dose adrenaline = 260
Interventions High-dose adrenaline (15 mg) versus standard-dose adrenaline (1 mg), diluted in 10
mls of unknown substance, blindly substituted for advanced cardiac life support doses
of adrenaline. Paramedics could give up to 3 doses (vials) of drug. Drug administered
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Callaham 1992 (Continued)
intravenously
Outcomes Survival to hospital discharge, survival to hospital admission (i.e. Critical Care Unit for
at least one hour), neurological outcomes, pre-hospital ROSC (“presence of ameasurable
BP or palpable pulse that persisted for at least 5minutes”), hospital LOS, critical care unit
LOS, significant complications, neurological outcomes measured using CPC at hospital
discharge, hospital length of stay
Notes EMS - paramedics
Also compared noradrenaline versus adrenaline.
Ethics approval. not registered, sample size calculation performed, ITT not stated, 843
patients randomised but 816 analysed (27 were lost to follow-up), plus unknown study
group in 3 survivors and the data not analysed
The number of patients in 2 of the 3 study groups vary between Table 2 and Table 3.
This appears to be a transposition typographical error i.e. Tabe 2: HDA = 286, SDA =
260, NA = 270 versus Table 3:HDA = 286, SDA = 270, NA = 260. By checking the
calculations within the Tables, we concluded that the group numbers in Table 2 were
correct, i.e. HDA = 286, SDA = 260, NA= 270
Funding: this study was funded by a grant from the State of California Emergency
Medical Services Authority, Sacramento
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi randomisation using alternation, i.e.
study drug and dose changed for entire city
on Wednesdays, i.e. non-concurrent con-
trols
Allocation concealment (selection bias) Low risk Colour coded identical vials of low dose
adrenaline, high dose adrenaline or nora-
drenaline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk EMS staff and study investigators blinded
to study treatment. Patient unconscious at
the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient unconscious at the time of event
and blinding for hard outcome (death/sur-
vival) unlikely to be associated with risk of
bias. Uncertain as to whether the assessor
was aware of the allocation group for neu-
rological outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data on witnessed and bystander CPR sta-
tus missing in some
Study drug could not be identified with
complete certainty in 3/18 survivors, ex-
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Callaham 1992 (Continued)
cluded
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias Unclear risk Not an intention to treat analysis, 832 en-
rolled, analysed 816 and unable to assess
impact
No postresuscitation care reported
Callaway 2006
Methods Double blind RCT
Pittsburgh, Pennsylvania
May 2003 to April 2005
Participants Included: patients aged≥ 18 years who received > or = 1 dose of intravenous adrenaline
during cardiopulmonary resuscitation for non-traumatic, out-of-hospital cardiac arrest
Excluded: if cardiac arrest resulted from trauma, if prisoner, if efforts were discontinued
because of advanced directives or family wishes before study drug administration, if
ROSC occurred before study drug administration, if no intravenous access was obtained,
or open-label vasopressin used before study drug administration
Participants: 701 patients, 376 not eligible = 325 patients randomised (167 patients
received vasopressin and 158 received placebo). One survivor in placebo group lost to
follow-up after hospital discharge
Interventions After first dose of adrenaline patient administered 40 IU of vasopressin or placebo as
soon as possible . Endotracheal or intraosseous routes not allowed. “Physicians allowed
to administer open-label vasopressin according to medical judgment”
Control: placebo
Outcomes Survival at 30 days, discharge disposition, ROSC at any time during resuscitation (“pal-
pable pulses at any site for any duration, unambiguously indicated in the record when
team decided that chest compressions no longer necessary for treatment”), presence of
pulses at ED, adverse events
No neurological outcome reported. No hospital length of stay reported
Notes Treated by paramedics from “City of Pittsburgh Bureau of EmergencyMedical Services”
Ethics obtained, trial not registered, sample size calculation performed. Intention to treat
analysis used. Consort flow diagram used
Funding: this study was supported by a grant from the Pittsburgh Emergency Medicine
Foundation, Pittsburgh, Pennsylvania
Risk of bias
Bias Authors’ judgement Support for judgement
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Callaway 2006 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated list of random num-
bers in blocks of 50
Allocation concealment (selection bias) Low risk Identical vials
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Investigators, paramedics, and subjects
were blinded as towhether drug or placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient unconscious at the time of event
and blinding for hard outcome (death/sur-
vival) unlikely to be associated with risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk One patient lost to follow-up after hospital
discharge. 46 patients received open label
vasopressin - accounted for in the results
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias Unclear risk Sensitivity analysis of including versus ex-
cluding patients who received open-label
vasopressin by physician after study drug
administered
No postresuscitation care reported
Choux 1995
Methods Double blind prospective randomised, single centre study
Lyon, France
January 1991 to July 1992 (18 months)
Participants Included: OHCA, over 18 years of age, initial ECG indicated asystole or PEA; initial
ECG indicated VF, and either ECG rhythm remained in VF despite three successive
counter-shocks or it changed to asystole or PEA
Excluded: patients under 18 years of age, clear signs of irreversible cardiac arrest (such
as rigor mortis, decomposition, or dependent lividity), and if received adrenaline before
the mobile ICU care
Participants: 536 OHCA patients enrolled (265 standard-dose adrenaline group and 271
high-dose adrenaline group). All appear to have been analysed
Interventions Repeated standard-dose adrenaline (1 mg) vs repeated high-dose adrenaline (5 mg) at 5
min intervals, to a maximum of fifteen doses, according to standard protocols for ACLS.
Except for the adrenaline dosage, no other changes made to protocols. Drugs generally
given intravenously through peripheral antecubital short catheter or through CVC
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Choux 1995 (Continued)
Outcomes Survival to hospital admission, survival day 21, neurological outcome, ROSC (return
of a palpable pulse and blood pressure [palpable, auditory, or both]), 6-month survival,
adverse effects
Neuro outcomes measured using GCS and EEG at 3 days and 21 days. No hospital
length of stay reported
Notes SAMU (Fench Emergency Medical Service) “first-aid men initiated basic life support
(BLS)”. Mobile intensive care unit with doctor and nurse sent to scene immediately,
advanced cardiac life support initiated
Ethics approval not stated, not registered.No sample size calculation, no consort diagram,
intention to treat analysis not specified, missing data not reported.65 not 63 patients
admitted in HDA group as written in text
Funding:not stated. The drugs for the study were prepared by the Edouard Herriot
Hospital’s pharmacy (where the SAMU of Lyon is located)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned to receive either stan-
dard-dose (1 mg) epinephrine or high-dose
(5 mg). Randomisation process not de-
scribed but used treatment packs with 15
ampoules
Allocation concealment (selection bias) Low risk Study drugs prepared by hospital’s phar-
macy and delivered in packages of 10 ran-
domised treatments; each treatment con-
tained 15 x 5 ml ampoules with the same
dosage (1 or 5 mg) aimed at one cardiac
arrest, 5 ml ampoules identical in appear-
ance. Investigators had no control; physi-
cians used treatments sequentially
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk EMS staff and study investigators blinded
to study treatment. Patient unconscious at
the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient unconscious at the time of event
and blinding for hard outcome (death/sur-
vival) unlikely to be associated with risk of
bias. Neurological outcome not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Hospital Dischare Alive % not reported -
although it is reported as an outcome mea-
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Choux 1995 (Continued)
sure on p4 of the manuscript
Other bias Unclear risk Intention to treat analysis not specified,
number of exclusions described; funding
source unclear
No postresuscitation care reported
Ducros 2011
Methods Prospective, randomised, double-blinded controlled trial
Single, French pre-hospital setting in Paris
August 2001 to August 2004
Participants Included: adults with witnessed OHCA who presented with VF, PEA, or asystole and
requiring ACLS, and for whom BLS with active compression-decompression CPR (al-
ready started by firefighters before arrival of medical team)
Excluded: unwitnessed cardiac arrest, spontaneous palpable carotid or femoral pulse re-
stored before administration of vasopressor, lack of intravenous access, pregnancy, trau-
matic injuries and anatomic abnormalities that prevented safe femoral artery cannula-
tion, presumed irreversible death or known terminal illness at beginning of ACLS
Participants: 48 patients screened, 4 patients excluded for ethical consideration, 44
patients witnessed cardiac arrest enrolled: standard-dose adrenaline group N = 16,
adrenaline and vasopressin groupN=14 adrenaline,vasopressin and nitroglycerine group
N = 14 plus 20ml normal saline flush. All 44 patients included in analysis
Interventions “Patients received either adrenaline alone (A alone) or adrenaline plus vasopressin (A+V)
or adrenaline plus vasopressin plus nitroglycerin (A+V+N)”. Three successive adminis-
trations of study drugs every 5minutes, all administered intravenously. “After 15minutes
study period, patients in cardiac arrest (regardless of group) received 1 mg of adrenaline
every 3 minutes until ROSC achieved or ACLS discontinued. Other interventions used
at discretion of physician managing the CPR”. Femoral arterial line inserted after first
dose
Outcomes Survival to hospital admission, Survival to hospital discharge, ROSC (not defined). No
neurological outcome reported. No hospital length of stay reported
Notes Prehospital emergency response two-tiered - “combines basic life support (BLS) with
firefighters and advanced cardiac life support (ACLS) with out-of-hospital emergency
medical services”
Ethics approval, not registered. Sample size calculation performed, intention to treat
analysis, missing data not reported
Funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
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Ducros 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Randomly assigned to receive either stan-
dard-dose (1 mg) epinephrine or high-dose
(5mg). Randomly generated by a computer
Allocation concealment (selection bias) Low risk Study drugs prepared by hospital’s phar-
macy and delivered in packages of 10 ran-
domised treatments; each treatment con-
tained 15 x 5 ml ampoules with the same
dosage (1 or 5 mg) aimed at one cardiac
arrest, 5 ml ampoules identical in appear-
ance, placed in sealed numbered envelopes
Investigators had no control; physicians
used treatments sequentially
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk EMS staff and study investigators blinded
to study treatment. Patient unconscious at
the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient unconscious at the time of event
and blinding for hard outcome (death/sur-
vival) unlikely to be associated with risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias Unclear risk Funding source not stated. No postresusci-
tation care reported
Gueugniaud 1998
Methods Prospective, multicenter, randomised controlled trial
12 centres in France and Belgium
1 September 1994 to 1 September 1996
Participants Included: Patients aged 18+ who had out-of-hospital cardiac arrest if the cardiac rhythm
continued to be VF despite administration of external electrical shocks, asystole or PEA
at the time epinephrine was administered
Excluded: traumatic cardiac arrest; obvious signs of irreversible cardiac arrest; or if
epinephrine had been injected before study resuscitation
Participants: 3,946 patients, “39 packages not used properly” = 3907; 1938 standard-
dose adrenaline group and 1969 high-dose adrenaline group (intention to treat analysis)
580 (15%) further exclusions (45 not eligible or received study drug inappropriately,
190 missing data or lost to follow-up, 345 traumatic cardiac arrests) = 3,327 patients
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Gueugniaud 1998 (Continued)
enrolled: 1,650 standard-dose adrenaline group and 1,677 high-dose adrenaline group
= final analysis
Interventions Patients received up to 15 high doses (5 mg) or standard doses (1 mg) of adrenaline
“according to the current protocol for ACLS” (IV or occasionally endobronchial)
Outcomes Survival to hospital discharge, survival to hospital admission, i.e. ICU admission (pulse
andBPpresent), survival to 24hours, neurologic outcome,ROSC (return of spontaneous
palpable pulse and blood pressure for at least one minute)
Neuro outcomes were assessed at the time of admission and at one week according to
the highest score on the Glasgow Coma Scale (from 3, worst, to 15, best) and at hospital
discharge according to CPC: CPC 1-2 considered ’good’. No hospital length of stay
reported
Notes EMS two-tiered (SAMU) - first tier has emergency medical ambulances staffed by tech-
nicians to provide basic life support. Second tier mobile intensive care unit, with doctor
and nurse, sent to scene immediately, advanced cardiac life support initiated
Ethics approval, not registered, no consort diagram.No sample size calculation, intention
to treat analysis initially, missing data not reported
Funding: supported in part in France by the Research Delegation of the Hospices Civils
de Lyon and the Economic Services of the Edouard Herriot Hospital, and in Belgium
by Les Amis du Service d’Aide Médicale Urgente
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation schedule
Allocation concealment (selection bias) Low risk “Two regimens of adrenaline provided in
packages of 15 coded 5-ml ampoules with
the same dosage of adrenaline. Each pack-
age was used for one person with cardiac
arrest. Study packages were available in spe-
cial sets of 10 randomised packages in all
the medical ambulances of the 12 centres.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All investigators and personnel provid-
ing care outside the hospital blinded as to
which dose was administered and had no
control over the order in which the sets
used.” Patient unconscious at the time of
event
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient unconscious at the time of event
and blinding for hard outcome (death/sur-
vival) unlikely to be associated with risk of
bias. Uncertain as to whether the assessor
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Gueugniaud 1998 (Continued)
was aware of the allocation group for neu-
rological outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk “39 packages not used properly for cardiac
arrests, 580 patients (15%) subsequently
excluded from the final analysis (by two
investigators unaware of treatment assign-
ment): 45 patients who did not meet the
eligibility criteria or who received the study
medication inappropriately, 190 patients
for whom essential data were not available
or who were lost to follow-up, and 345 pa-
tients who had traumatic cardiac arrest.”
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias High risk Table 1 shows results of intention to treat
analysis but Table 3 showed results after
15% exclusions after randomisation. Base-
line characteristics and some outcomes for
treated group analysis only
No difference shown in outcomes
No postresuscitation care reported
Gueugniaud 2008
Methods Multicenter study, randomly assigned adults with out-of-hospital cardiac arrest
31 SAMU and SMUR units, France
1 May 2004 to 30 April 2006
Participants Included: adult patients (18+ yrs) with OHCA presenting with VF, PEA, or asystole
requiring vasopressor therapy during CPR
Excluded: successful defibrillation without administration of a vasopressor, traumatic
cardiac arrest, pregnancy, documented terminal illness, presence of a do-not resuscitate
order, and obvious signs of irreversible cardiac arrest
Participants: 2956 randomised and 62 (2%) excluded from analysis, including 26 in the
combination therapy group and 36 in the epinephrine-only group (P = 0.22). Twenty-six
of the excluded patients did not consent to participation in the study, 29 had traumatic
cardiac arrest, and 7 were treated but did not meet the inclusion criteria. Data from the
remaining 2894 patients - 1442 combination of adrenaline and vasopressin and 1452
standard-dose adrenaline alone were analysed
Interventions Successive injections of 1 mg of adrenaline and saline placebo OR 1 mg of adrenaline
and 40 IU of vasopressin. Up to two study drug doses and then additional adrenaline if
needed. All drugs administered intravenously
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Gueugniaud 2008 (Continued)
Outcomes Survival to hospital discharge, survival to hospital admission, neurologic recovery, ROSC
(spontaneous return of a palpable pulse and measurable BP for at least 1 minute), one-
year survival
Neuro outcomes were assessed using CPC at hospital discharge: <3 (ie 1 or 2) considered
’good’. No hospital length of stay reported
Notes EMS two-tiered service (Service d’AideMédicaleUrgente [SAMU]) - first tier emergency
medical ambulances staffed by technicians to provide basic life support. Second tier
mobile ICU, with doctor and nurse, sent to scene immediately, advanced cardiac life
support initiated
France - several units rural and metro
Ethics approval, trial registered [NCT00127907], no consort diagram, sample size cal-
culation. Intention-to-treat analysis. No interim analysis performed during the study
period
Funding: supported by the Programme Hospitalier de Recherche Clinique 2003 of the
French Ministry of Health Research and the French Health Product Safety Agency and
by the Research Delegation of the Hospices Civils de Lyon. The Research Delegation of
the Hospices Civils de Lyon has received grant support from Aguettant Laboratories
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation schedule
Allocation concealment (selection bias) Low risk Sets of 40 drug boxes, with stratification
according to centre
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All investigators and emergency medical
service personnel unaware of which study
drugs used and had no control over the
order in which the study-drug sets used
through out trial.” “Possibility of making
the physician aware of the identity of the
study drugs was available in the case of ad-
verse events, but never used.” Patient un-
conscious at the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient unconscious at the time of event
and not blinding for hard outcome (death/
survival) unlikely to be associated with risk
of bias. Not explicitly stated if those assess-
ing neurological status on discharge were
blinded to the group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2,956 randomised: 62 patients (2.1%) ex-
cluded from analysis (26 in combination
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Gueugniaud 2008 (Continued)
therapy group and 36 in epinephrine-only
group, P = 0.22). 26 excluded patients did
not consent to participation, 29 traumatic
cardiac arrest, and 7 treated but did not
meet inclusion criteria = 2894 patient data
analysed
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias Unclear risk Survival data from 7 patients missing Table
2, not reported in text or Table legend. No
postresuscitation care reported
Jacobs 2011
Methods Double blind randomised placebo-controlled trial of adrenaline in out-of-hospital cardiac
arrest
Perth, Western Australia
11 August 2006 to 30 November 2009
Participants Included: cardiac arrest from any cause, aged 18+ years, with resuscitation commenced
by paramedics
Excluded: patients who responded early to defibrillation not randomised
Participants: 4103 OHCA patients screened, 3502 excluded - 2513 because resuscitation
efforts were not commenced by paramedics as death had clearly been established. 601
randomised. Documentation available for 534 patients: 262 in placebo group and 272
in adrenaline group
Interventions 1 mg adrenaline or 1 ml normal saline (placebo) administered intravenously as clinically
indicated with maximum dose of 10 ml (10 mg adrenaline or 10 ml normal saline).
No other resuscitation drugs administered pre-hospital during trial and endobronchial
administration of drugs not permitted
Outcomes Survival to hospital discharge, survival to hospital admission, neurologic outcome, pre-
hospital ROSC (period of sustained ROSC in the field for greater 30 seconds). Neuro
outcomes were assessed using CPC at hospital discharge: <3 (ie 1 or 2) considered ’good’.
No hospital length of stay reported
Notes EMS ALS paramedics
Ethics approval, registered with the Australian and New Zealand Clinical Trials Register
(ACTRN12605000062628), sample size calculation, intention to treat analysis. No loss
to follow-up
Funding: this study was funded by the National Health and Medical Research Council
(Grant No. 254537). The funding body had no involvement in any aspect of study
design, conduct or analysis
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Jacobs 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation sched-
ule.
Allocation concealment (selection bias) Low risk “Study drugs commercially prepared, inde-
pendent of investigators, in identical 10 ml
vials containing either adrenaline 1:1000 or
placebo (sodium chloride 0.9%) with tam-
perproof seals distinguishable only by a spe-
cific randomisation number.” Study drugs
centrally issued to paramedic crews using
the same distribution process as for other
drugs used within the ambulance service
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk EMS staff and study investigators blinded
to study treatment. Patient unconscious at
the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient unconscious at the time of event
and not blinding for hard outcome (death/
survival) unlikely to be associated with risk
of bias. “CPC scores derived from medi-
cal chart review for patients surviving to
hospital discharge, with the chart reviewer
blinded to the study group allocation”
Incomplete outcome data (attrition bias)
All outcomes
High risk 67 (11%) unable to be analysed due to ran-
domisation number not being recorded
These are missing for all outcomes. Not
sure how many lost form each group but
numbers remaining look fairly balanced.
Small number of survivors means that it is
possible that bias has been introduced by
losing a few survivors from one group
Selective reporting (reporting bias) Low risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias Unclear risk Intention to treat analysis;
Planned sample size not achieved.
Some baseline imbalances but adjusted
analysis performed (adjusting for age, gen-
der, bystander witnessed, initial rhythm
shockable, and response interval. This
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Jacobs 2011 (Continued)
showed little difference but not certain how
well this controlled for imbalances
No postresuscitation care reported
Li 1999
Methods “Randomised study” of in-hospital and ED cardiac arrest, cardiac arrest confirmed by
ECG or monitor
Participants 83 patients with in-hospital (including ED) cardiac arrest “randomly divided” into 4
groups: (1) standard-dose adrenaline 22 patients, (2) high-dose adrenaline 21 patients,
(3) low dose vasopressin 20 patients, (4) high dose vasopressin 20 patients
Interventions (1) Standard dose 1 mg adrenaline vs high dose adrenaline 5mg
(2) Standard dose 1 mg adrenaline vs 0.5 U/kg vasopressin
(3) Standard dose 1 mg adrenaline vs 1.0 U /kg vasopressin.
Adrenaline was administered IV every 5 minutes and vasopressin every 10 minutes PRN
Outcomes Survival to hospital discharge, ROSC (longer 30 minutes), neurological outcome (de-
scribed as discharged from hospital with pre-arrest conscious state, heart rate and respi-
ratory rate status)
Notes EMS not described.
Chinese paper, translated by independent researcher.
Ethics approval not stated. Trial not registered. Data collection started February 1996,
conclusion date unknown. Did not compare VF with asystole/PEA. Discrepancy in
survival data high dose vasopressin (33.5% in the abstract vs 35% in the main text).
No description of initial rhythm. ITT not stated. No missing data reported. No consort
diagram
Funding: not known
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation method not reported - pos-
sible risk that it is not a RCT
Allocation concealment (selection bias) High risk Not reported - high risk of non-random al-
location e.g. “84 patients with cardiac ar-
rest were divided into 4 groups”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Patient unconscious at the time of event.
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Li 1999 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Patient unconscious at the time of event
and blinding for hard outcome (death/sur-
vival) unlikely to be associated with risk of
bias. Uncertain as to whether the assessor
was aware of the allocation group for neu-
rological outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analysis on all 83 patients
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias Unclear risk Intention to treat analysis not reported
but all patients accounted for, but funding
source unclear. No postresuscitation care
reported
Lindner 1991a
Methods Prospective randomised double blind controlled trial
Ulm University Hospital, Germany
Participants Included: in-hospital or out of hospital cardiac arrest, asystole or PEA
Excluded: < 18 years, obvious non-cardiac cause, e.g. trauma, patients given DC shock
before adrenaline administered
Participants: 68 patients - 40 standard-dose adrenaline group, 28 high-dose adrenaline
group - included in analysis
Interventions Single dose of study drug, either standard-dose adrenaline (1mg) or high-dose adrenaline
(5 mg). If the first dose of adrenaline (1 or 5 mg) failed, standardized advanced life-
support was applied in all cases (up to 10 mg adrenaline). Study drugs administered
intravenously, peripheral or external jugular vein
Outcomes Survival to hospital discharge, 12-hour survival (Initial resuscitation success - haemody-
namic status stable, with or without dopamine, for at least 12 hours)
No neurological outcome reported. No hospital length of stay reported
Notes “Cardiopulmonary resuscitation by emergency physicians of the Emergency Care Unit”
Ethics approval, trial not registered, recruitment period not stated, ITT not stated,
no missing data reported. No consort diagram - unclear if N = 68 was the number
randomised i.e. whether or not there was any loss to follow-up
Funding: not stated
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly allocated,method not described
Allocation concealment (selection bias) Low risk Study drug prepared in identical ampoules
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double blind”. Investigators, paramedics,
blinded to study treatment. Patient uncon-
scious at the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient unconscious at the time of event
and not blinding for hard outcome (death/
survival) unlikely to be associated with risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analysis on all 68 patients
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias Unclear risk Intention to treat analysis not stated; un-
equal numbers in each group (40:28); but
funding source not stated. No postresusci-
tation care reported
Lindner 1997
Methods Prospective, randomised controlled trial comparing vasopressin with adrenaline in pa-
tients with VF in out-of-hospital cardiac arrest
Greater metropolitan area of Ulm, Germany
July 1994 to December 1995
Participants Included: OHCA VF resistant to electrical defibrillation.
Excluded: age < 18 years, OHCA due to trauma or terminal illness, pregnancy or
bronchial epinephrine administration
Participants: 40 patients randomised - 20 standard-dose adrenaline group, 20 vasopressin
group - 40 included in analysis
Interventions Adrenaline (1 mg intravenously; N = 20) or vasopressin (40 U intravenously; N = 20) in
10 ml syringes via peripheral or external jugular vein then flushed with Ringers Lactate.
One dose of study drug and then usual care
Outcomes Survival to hospital discharge, survival to hospital admission (successful resuscitation to
ICU admission), survival for 24 hours, neurological outcome, ROSC (return of sponta-
neous, palpable carotid pulse for undefined period at any time after drug administration)
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Lindner 1997 (Continued)
. Neuro outcomes were assessed using GCS with mean (sd) GCS compared between
treatment groups. No hospital length of stay reported
Notes First response team mobile intensive care unit staffed “by paramedics and a physician
specialising in emergency care”
Ethics approval, trial not registered, sample size calculation reported, ITT performed.
No missing data reported. Consort diagram
Funding: supported by a grant from the Laerdal Foundation, Norway
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation
Allocation concealment (selection bias) Low risk Numbered and pre-coded, pre-filled sy-
ringes identical in appearance
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind study.
Investigators, paramedics, blinded to study
treatment. Patient unconscious at the time
of event
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient unconscious at the time of event
and not blinding for hard outcome (death/
survival) unlikely to be associated with risk
of bias. Uncertain as to whether the asses-
sor was aware of the allocation group for
neurological outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients accounted for. Nomissing data
reported
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias Unclear risk Intention to treat analysis stated in abstract.
No post resuscitation care reported
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Lipman 1993
Methods Randomised double-blind controlled trial of in-ICU cardiac arrests
Multidisciplinary adult ICU South Africa
July 1990 to June 1991
Participants Included: adult patients requiring CPR, witnessed asystolic cardiac arrest in ICU. 80%
’“overwhelming sepsis”
Participants: 40patients randomised, 5 excluded (3missingdata, 2 did notmeet inclusion
criteria). 16 standard-dose adrenaline group, 19 high-dose adrenaline group
Interventions Patients received standard dose of adrenaline (1 mg every five minutes) or high-dose
adrenaline (10 mg every five minutes), up to 3 doses then standard adrenaline
Outcomes Survival to 12 hours, survival to 24 hours, ICU survivors, days in ICU, “successfully
resuscitated” (not defined). No neurological outcome reported. No hospital length of
stay reported
Notes Ethics approval, no sample size calculation, ITT not reported. Nomissing data reported.
No consort diagram
Funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation code
Allocation concealment (selection bias) Low risk Ampoules sealed by smelting and labelled
drug A or drug B. Ampoules identical and
code broken after trial
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated but ampoules identical. Patient
unconscious at the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Patient unconscious at the time of event
and not blinding for hard outcome (death/
survival) unlikely to be associated with risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5 patients excluded after being entered into
the study, 3 with missing data
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
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Lipman 1993 (Continued)
Other bias Unclear risk 80% of patients had “overwhelming sep-
sis”; funding source unclear. No post resus-
citation care reported
Mukoyama 2009
Methods Prospective, single centre, randomised controlled clinical trial
June 2001 to May 2006
Participants Included: out-of-hospital cardiac arrest (presumed cardiac etiology) after the arrival of
the EMTs, or if they were transported to ED under CPR on arrival at ED
Excluded: age < 18 years (N = 6), lack of intravenous access, injection of vasopressors in
the pre-hospital
setting, indications of emergency cardiopulmonary bypass (N = 61), documented ter-
minal illness (N = 18), do-not-resuscitate order, non-cardiac etiology according to the
Utstein criteria, e.g. asphyxia, pneumonia (N = 17) excluded after randomisation
Patients (N = 17) found to have cardiac arrest from non-cardiac cause also excluded after
randomisation
Participants: 534 patients randomised, 198 (37%) excluded - 96 had traumatic cardiac
arrest and 102 treated but did not meet inclusion criteria. 336 patients analysed: vaso-
pressin group N = 178; adrenaline group N = 158
Interventions Receive maximum of four injections of either 1mg of adrenaline (control group) or 40 IU
of vasopressin (study group) immediately after ED admission, repeated every 5 to 10min
until the cumulative dose reached. No combined injections of vasopressors administered
in either group. All drugs injected intravenously with 20 ml normal saline flush after
each dose
Outcomes Survival to hospital discharge, neurological outcome, ROSC (defined as “return of spon-
taneous circulation by the time patient moved from ED to ICU and intensive care
commenced”), 24-hour survival. Neuro outcomes were assessed using CPC at hospital
discharge: < 3 (i.e. 1 or 2) considered ’good’. No hospital length of stay reported
Notes Nearest available ambulance dispatched to scene, manned by three emergency medical
technicians (EMTs) providing basic life support and airway maintenance. “EMTs strictly
prohibited from intravenously injecting vasopressors or any other drugs in the pre-
hospital setting”
Ethics approval, no trial registration, no sample size calculation, nomissing data reported.
Consort diagram
Abstract states that there were N = 137 in Vaspressin group and 118 in the Adreanaline
group - but from Table 1 it can be seen that these numbers only relate to the non-VF
sub-group. Analysis included both the VF and non-VF patients
Funding: not stated.
All of the authors declared that they had no conflicts of interest to disclose
Risk of bias
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Mukoyama 2009 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of EMS staff not reported. It is
likely that there was no blinding of the
drugs administered. Patient unconscious at
the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported. Patient unconscious at the
time of event andnot blinding for hard out-
come (death/survival) unlikely to be asso-
ciated with risk of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Patients (37%) excluded after randomisa-
tion
CPC scores clarified with authors
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry. ROSC definition not “Ut-
stein”
Other bias Unclear risk Funding source unclear. No post resuscita-
tion care reported.
Ong 2012
Methods Randomised, double-blind, multi-centre, parallel design trial, four adult public hospital
ED’s
Singapore
9 March 2006 to 19 January 2009
Participants Included: All cardiac arrest patients in ED, including pre-hospital and ED arrests aged
> 16 (age >=21 for one hospital)
Excluded: traumatic cardiac arrest or when CPR contraindicated (e.g., for those ‘ob-
viously dead’ as defined by the presence of decomposition, rigor mortis, or dependent
lividity)
Participants: 790 patients screened: 63 excluded, 727 randomised: low dose adrenaline=
353; vasopressin= 374 - and analysed.3 patients lost to follow-up (1 standard-dose
adrenaline group, 2 vasopressin group) after discharge
Interventions Eligible patients randomly assigned to receive intravenous adrenaline (1 mg) or vaso-
pressin (40 IU) in ED. One dose only then open-label adrenaline
61Adrenaline and vasopressin for cardiac arrest (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ong 2012 (Continued)
Outcomes Survival to hospital discharge or 30 days post arrest, survival to hospital admission (pa-
tients successfully resuscitated admitted to ICU), neurological outcome, ROSC (“pres-
ence of any palpable pulse detected by manual palpation of a major artery”). Neurologi-
cal outcomes were assessed using CPC at hospital discharge: < 3 (i.e. 1 or 2) considered
’good’
Notes Paramedics with basic life support skills who can defibrillate with automated external
defibrillators and insert laryngeal mask airways
Ethics approval, not registered. Sample size calculation. ITT not stated but evident from
consort diagram. Planned, blinded, safety monitoring interim conducted when 300
participants enrolled. Safety monitoring committee (SMC) - two independent clinicians
and one statistician
Funding: the study was funded by National Medical Research Council, Ministry of
Health, Singapore (NMRC/0673/2002); Singapore Health Services Pivotal Trials Grant,
Singapore (PTC01/2006/006); and Singapore General Hospital Research Fund, Singa-
pore (SRF#145/08). The funding sources had no involvement in the study design, col-
lection, analysis, and interpretation of data, writing of manuscript, and in the decision
to submit the manuscript for publication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation stratified by site, with vary-
ing block sizes of four and six, via the use of
a randomisation envelope. Randomisation
list generated by trial statistician. Trial drug
administered in sequential order according
to the randomisation list
Allocation concealment (selection bias) Low risk Study drugs pre-prepared, in coded 10 ml
syringes with identical appearance, by trial
pharmacist, according to randomised list.
Study drugs placed in the randomisation
envelopes and kept in ED
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All participants, assessors, and other per-
sonnel blinded except the pharmacist and
trial statistician. Patient unconscious at the
time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Unblinding was performed at the end of
the trial when all participants completed
follow-up.” Patient unconscious at the time
of event and not blinding for hard outcome
(death/survival) unlikely to be associated
with risk of bias
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Ong 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Three patients lost to follow-up after dis-
charge -> 1 year follow-up data missing
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias Unclear risk Cohort chart shows intention to treat anal-
ysis not stated, all patients accounted for.
No post resuscitation care reported
Patterson 2005
Methods Multicentre, randomised study of out-of-hospital cardiopulmonary arrest
7 tertiary paediatric centre ED’s, USA
May 1991 to October 1996
Participants Included:OHCA refractory to pre-hospital resuscitation efforts. Cardiopulmonary arrest
classified as “medical” or “traumatic.” Ages ranged from newborn to 22 years
Excluded: - respiratory arrest alone (0 patients), responding to pre-hospital interventions
before ED arrival (2 patients), “do not resuscitate” orders (0 patients), evidence of pro-
longed cessation of circulation, i.e. rigor mortis, dependent lividity, and core temperature
less than 33C (not suffering from exposure or near drowning, 8 patients), arrested ED
(7 patients)
Participants: 230 patients randomised, excluded 17 from analysis (8 patients were found
to have rigor/dependent lividity, 2 patients presented to the emergency department with
a perfusing rhythm, and 7 patients arrested in the emergency department) = 213 patients
included in analysis: (171 medical and 59 trauma)
86 patients received standard dose (59 medical and 27 trauma patients) and 127 patients
received high dose (95 medical and 32 trauma patients)
Interventions “Standard-dose (0.01 mg/kg) adrenaline vs high-dose (0.1 mg/kg for the initial dose and
0.2 mg/kg for subsequent doses) adrenaline administered every 5 minutes until ROSC”.
Standard dose group eligible to have doses doubled for second and subsequent doses at
physician’s discretion. Adrenaline administered via an intravenous (IV) line, intraosseous
(IO) line, or endotracheal (ET) tube (ET doses doubled)
Outcomes Survived to hospital discharge, survived at least 24 hours, neurological outcome (Glasgow
Outcome Scale), ROSC - (“return of a cardiac rhythm with a palpable pulse for greater
than 20 minutes and admission” to ICU). Neurological outcomes were assessed using
the Glasgow Outcome Scale at hospital discharge; scores not dichotomised into good/
poor. No hospital length of stay reported
Notes “All the hospitals participating in this study were served by emergency medical systems
with advanced life support capabilities”
Ethics approval, not registered. Intention to treat analysis, sample size calculation. No
missing data reported. Consort chart. Study stopped early because of changes in ethics
requirement
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Patterson 2005 (Continued)
Funding: this study was supported in part by a grant from the Nation’s Capital Affiliate
of the American Heart Association
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “Randomization method varied by institu-
tion and by whether enrolment occurred at
the time of pre-hospital contact (2 centres)
or arrival to ED (5 centres). Six centres ran-
domised patients by using individual en-
velopes designatinghigh or standard dosage
that hadbeen generated using a table of ran-
domdigits.One centre used an “acutemed-
ical record system” - patients whose med-
ical record number ended in an odd digit
were assigned to the study group, whereas
patients with evenmedical record numbers
were assigned to the standard-dose group.”
Allocation concealment (selection bias) Unclear risk opaque tamper proof envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Only blinded in 2/7 centres secondary to
the technical difficulty in doing so. Patients
unconscious at the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unknown
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients accounted for, excluded 17
from analysis.
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias Unclear risk Study stopped early secondary to imple-
mentation of new regulations on waiver
of informed consent. No post resuscitation
care reported
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Perkins 2018
Methods Multicenter, randomised, double-blind, placebo-controlled PARAMEDIC2 trial con-
ducted by five National Health Service ambulance services in the United Kingdom
Participants Included: 8,014 adult patients with out-of-hospital cardiac arrest in theUnited Kingdom
for which advanced life support was provided by trial-trained paramedics
Excluded: known or apparent pregnancy, age of less than16 years, cardiac arrest from
anaphylaxis or asthma, or the administration of epinephrine before the arrival of the
trial-trained paramedic. Traumatic cardiac arrests were excluded in accordance with local
protocols In one ambulance service
Participants: parenteral epinephrine 4015, saline placebo 3999
Interventions Paramedics at five National Health Service ambulance services administered either
parenteral epinephrine or saline placebo, along with standard care. Single doses of
epinephrine or saline administered by an intravenous or intraosseous route every 3 to 5
minutes
Outcomes 30 day survival to hospital discharge, rate of survival until hospital discharge with a
favourable neurologic outcome, lengths of stay in the hospital (LoS) and in the intensive
care unit (ICU), the rates of survival at hospital discharge and at 3 months, and the
neurologic outcomes at hospital discharge and at 3months, serious adverse events (death,
hospitalisation, and disability), other adverse events
Notes Funding: funded by the U.K.National Institute for Health Research and others; Current
Controlled Trials number, ISRCTN73485024
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The programming team at the Warwick
Clinical Trials Unit provided randomisa-
tion with concealed assignment
Allocation concealment (selection bias) Low risk A randomisation sequence was computer-
generated by the minimization method
with an overall assignment ratio of 1:1
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Concealed assignment: uniquely num-
bered but otherwise identical-appearing
trial packs contained 10 prefilled syringes,
with each syringe containing either 1 mg
of epinephrine or 0.9% saline. Concealed
assignment of study drug and placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed by research paramedics,
who were unaware of treatment assign-
ments
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Perkins 2018 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between the opening of the trial packs and
administration of epinephrine or placebo,
87 patients (1.1%) were ineligible to par-
ticipate in the trial. Another 2 patients had
unknown trial-group assignments because
of missing trial-pack numbers. Data for the
primary outcome were available for 4012
patients (99.9%) in the epinephrine group
and 3995 patients (99.9%) in the placebo
group.
Selective reporting (reporting bias) Low risk Characteristics of patients well balanced
at baseline, concurrent treatments were
similar.as were key intervals in providing
service (e.g., between the emergency call
and ambulance arrival) between the two
groups.The proportionof patientswhohad
a return of spontaneous circulation dur-
ing the prehospital resuscitation phase was
higher in the epinephrine group than in the
placebo group (36.3% vs. 11.7%), as was
the proportionwhowere transported to the
hospital (50.8% vs. 30.7%)
Other bias Unclear risk Prespecified subgroup analyses included
the patient’s age, cause of cardiac arrest, ini-
tial cardiac rhythm, whether the cardiac ar-
rest was witnessed, whether CPR was per-
formed by a bystander, interval between the
emergency call and ambulance arrival at the
scene, interval between ambulance arrival
and the trial-agent administration,and the
interval between the emergency call and
trial-agent administration. A P value for in-
teraction was reported in each analysis
Post hoc sensitivity analyses (which incor-
porated best-case and worst-case scenarios
and multiple imputation) were conducted
for survival at 30 days, survival at hospital
discharge, and survival with a good neuro-
logic outcome at discharge. No post resus-
citation care reported
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Perondi 2004
Methods Prospective, randomised, double-blind trial of in-hospital cardiac arrest
Childrens Institute Sao Paulo Brazil
31 October 1999 to 30 September 2001
Participants Included: children who remained in cardiac arrest despite CPR and an initial, standard
dose of adrenaline (0.01 mg per kilogram)
Excluded: neonates, children with sustained trauma, those whose cardiac arrest had
commenced outside the hospital, and those with do-not-resuscitate orders.Only initial
cardiac arrest evaluated
Participants: of 185 cardiac arrests that occurred during the study period, 117 children
met the exclusion criteria (excluded 67 cases because of orders not to attempt resuscita-
tion). Remaining 68 children were included in the study - 34 children high dose and 34
children low dose adrenaline
Interventions ”High-dose adrenaline (0.1 mg per kilogram of body weight) compared with standard-
dose adrenaline (0.01 mg per kilogram) as rescue therapy for in-hospital cardiac arrest in
children after failure of initial, standard dose of adrenaline“. Administered intravenously.
Outcomes Survived to hospital discharge, survived at least 24 hours, neurological outcome , ROSC
(Any and sustained > 20 min). Neurological outcomes were assessed a 6 months after
the discharge using the ”paediatric cerebral performance category’. No hospital length
of stay reported
Notes Ethics approval, trial not registered, Utstein-style reporting guidelines used, sample size
calculation, intention to treat analysis, no missing data supported, a priori sensitivity
analyses. Consort chart. Protocol violations occurred in 18 cases. Not clear if the N =
117 cases were excluded before or after randomisation
Apriori defined sub-group analysis of asphyxia-precipitated cardiac arrests
Low number of survivors. No post-arrest hypothermia or extracorporeal membrane
oxygenation to any patients
Funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization performed by single phar-
macist using random-number generator.
Treatment packages labelled with consecu-
tive numbers provided by random-number
generator
Allocation concealment (selection bias) Low risk Pharmacist prepared treatment pack-
ages, each containing 10 1-ml vials of
epinephrine in a solution of 1:1000 or 1:
10,000, labelled with consecutive numbers
provided by random-number generator
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Perondi 2004 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind, only pharmacist aware of
concentrations. Patient unconscious at the
time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient unconscious at the time of event
and not blinding for hard outcome (death/
survival) unlikely to be associated with risk
of bias. Uncertain as to whether the asses-
sor was aware of the allocation group for
neurological outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Protocol violations occurred in 18 cases.
Sensitivity analysis showed no difference
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias Unclear risk Intention-to-treat analysis; but funding
source unclear. No post resuscitation care
reported
Polglase 1994
Methods Randomised, unblinded study OHCA
Georgia, USA
October 1990 to January 1992
Participants Included: adult OHCA patients
Excluded: 161 OHCA patients ’reviewed’ (randomised) - 56 patients with “irregularities
in dosing or incomplete documentation”. Most exclusions given 1 mg adrenaline
Participants: 105 (41 on 1 mg dose, 30 on 5 mg dose, 34 on 10 mg dose)
Interventions 1 mg adrenaline compared to 5 mg and 10 mg doses. 1 mg prefilled syringe; “5 and 10
mg doses drawn from 30 ml syringe”. First and successive doses dictated by dose on card
otherwise ACLS algorithm followed
Outcomes Survival to hospital admission, survival to hospital discharge, ROSC (palpable return of
pulse and/or BP). No neurological outcome reported. No hospital length of stay reported
Notes Suburban and rural Emergency Medical Service. Study stopped for futility (no survivors
to hospital discharge)
Research ’Letter to Editor’. Ethics approval, trial not registered, no sample size calcu-
lation, intention to treat analysis not reported. No missing data reported. No consort
diagram. No survivors among excluded cases
Funding: not stated
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Polglase 1994 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Index cards containing assigned doses of
1mg, 5mg and 10mg doses adrenaline ran-
domised (method not stated) and placed in
paramedic drug boxes”
Allocation concealment (selection bias) High risk Probably not - since paramedics could have
altered the dose given
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded study - EMS staff knew which
study drug they were using. Patient uncon-
scious at the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unblinded study - but patient unconscious
at the time of event and not blinding for
hard outcome (death/survival) unlikely to
be associated with risk of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk 56 patients (35%) with “irregularities in
dosing or incomplete documentation”.
Most exclusions given 1mg adrenaline, no
survivors
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias Unclear risk Intention to treat analysis not reported. Ex-
clusions based on “irregularities in dosing”
suggests a ’per-protocol’ analysis; funding
source unclear. No post resuscitation care
reported
Sanchez-Mendiola 1998
Methods Randomized, unblinded, controlled trial
Mexico
Participants Included: paediatric patients hospitalised in the Paediatric Intensive Care Unit that
developed asystole during their hospital stay
Participants: 36 patients randomised and included in the analysis (16 received standard-
dose adrenaline and 20 high-dose adrenaline)
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Sanchez-Mendiola 1998 (Continued)
Interventions Randomized to receive first adrenaline high-dose (0.1mg/kg) or standard-dose adrenaline
(0.01 mg/kg), with subsequent doses using the high dose, “as per the American Heart
Association (AHA) and American Academy of Pediatrics (AAP) guidelines” (at the time)
Outcomes ROSC, survival to hospital discharge, neurologic outcome (method for assessing not
stated- just ’neurologic damage’). No hospital length of stay reported
Notes Conference abstract. Ethics not reported, not registered, no dates when study conducted,
no duration of study, no sample size calculation, ITT not stated. No consort chart. No
missing data reported. Used high dose adrenaline for subsequent doses for both groups
Funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation process not described but
“randomised” stated
Allocation concealment (selection bias) High risk Not reported - likely to be high risk
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Caregivers not blinded to drug dose admin-
istered.
Patient unconscious at the time of event.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported - unclear risk but patient un-
conscious at the time of event and not
blinding for hard outcome (death/survival)
unlikely to be associated with risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention to treat analysis not stated but all
cases accounted for
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias High risk Funding source unclear; Insufficient details
(conference abstract) to assess other poten-
tial sources of bias
Overall high risk of bias. No post resusci-
tation care reported
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Schmidbauer 2000
Methods RCT OHCA
Three years
Munich, Germany
Participants Selection criteria not reported but “out of hospital cardiac arrest” stated in title
Participants: 57 patients analysed (32 standard dose adrenaline and 25 high-dose
adrenaline)
Interventions Initial dose of 2.5 mg adrenaline vs initial 5 mg high-dose adrenaline both via endo-
bronchial route (unclear if other doses administered)
Outcomes ROSC. No neurological outcome reported. No hospital length of stay reported
Notes Research letter. Ethics not reported, trial not registered, no dates when study conducted,
no sample size calculation, intention to treat analysis not stated, no consort diagram, no
missing data reported - no details re the number randomised
Funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details of randomisation process -
simply states “controlled prospective ran-
domised study”
Allocation concealment (selection bias) Unclear risk No description
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of blinding. Patient uncon-
scious at the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of blinding. Patient uncon-
scious at the time of event and not blinding
for hard outcome (death/survival) unlikely
to be associated with risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Only results for 57 patients reported - over
three years
Selective reporting (reporting bias) High risk Only ROSC reported for VF and Asystole
patients
Other bias Unclear risk Funding source unclear; Insufficient details
to assess other potential sources of bias. No
post resuscitation care reported
Overall high risk of bias
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Sherman 1997
Methods Prospective, multicenter, blinded, controlled trial
8 USA academic centre emergency departments
1 year
Participants Included: atraumatic, non-hypothermic out of hospital cardiac arrest, who experienced
VF or asystole. and received at least one standard dose of adrenaline 0.5 to 1.0 mg
Excluded: less than 18 years of age, solid organ transplant recipients, not considered
candidates for full cardiopulmonary resuscitation, suspected of being pregnant, did not
have venous access, or had already received high-dose adrenaline or intravenous a-agonist
therapy during resuscitation
Particpants: patients who received study drug but who did not meet entrance criteria, as
determined by the blinded investigator, were excluded from data analysis. Two patients
were excluded due to inadequate data collection. 140 patients in analysis: 78 received
high-dose adrenaline and 62 received standard-dose adrenaline
Interventions Standard-dose adrenaline 0.01 mg/kg vs high-dose adrenaline group 0.1 mg/kg after
initial standard-dose adrenaline failed to resuscitate patients inwith asystole or VF. “Study
drug administered through peripheral, antecubital, or central venous route by high flow-
rate infusion every 5minutes but not endotracheal administration”. “Up to 4 doses of the
drug allowed”. “If the resuscitation attempt continued, further adrenaline administered
at discretion of primary physician”. Potency of drugs tested every 6 months
Outcomes Discharged from hospital, neurologic outcome, ROSC (“presence of organised cardiac
rhythm and palpable pulse at any time during resuscitation”), improvement in cardiac
rhythm. It was planned to evaluate neurologic outcomes using the Glasgow Coma Scale
however, there were no survivors to hospital discharge.Hospital length of sty was reported
- but there were no patients who survived to hospital discharge
Notes “Cardiopulmonary resuscitation provided by paramedics and emergency medical tech-
nicians, guided by standard ACLS protocol”
Ethics approval, not registered, sample size calculation performed. ITT not stated -
patients who received study drug but did not meet entrance requirement excluded from
data analysis
Enrollment discontinued before reaching target goal of 354 patients - geographic relo-
cation of investigators, concerns re deferred consent, intercurrent results of recent trials,
similar trials. No consort diagram. No missing data reported
Funding: supported in part byWyeth-Ayerst, Inc., the Laerdal Foundation, and theHaas
Fund of Mt. Sinai Hospital, Cleveland, Ohio
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation
Allocation concealment (selection bias) Low risk Adrenaline “prepackaged in dilutions of
either 0.1 mg/ml (1:10,000) or 1 mg/
ml (1:l000) in 12-ml, otherwise identical,
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Sherman 1997 (Continued)
blinded vials”. Numbered sequentially
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Blinded” but who not stated.Patient un-
conscious at the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient unconscious at the time of event
and not blinding for hard outcome (death/
survival) unlikely to be associated with risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Two patients (1.4%) were excluded due to
inadequate data collection
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias High risk Intention to treat analysis not stated. “En-
rollment discontinued before reaching tar-
get goal secondary to geographic move-
ment of investigators, concerns regarding
use of deferred consent, and intercurrent
results of other recent, similar trials”; Role
of industry funder unclear. No post resus-
citation care reported
Stiell 1992
Methods Triple blinded RCT in or out of hospital cardiac arrest
2 tertiary hospitals Ottawa Canada
18 December 1989 to 8 January 1992
Participants Included: “Patients treated for cardiac arrest (in or out of hospital) , required epinephrine,
if collapsed outside the hospital and no advanced-life-support measures other than de-
fibrillation before reaching the hospital”
Excluded: “<16 years of age, had a terminal illness, had not been given CPR for more
than 15 minutes, trauma, second cardiac arrest during same hospital admission or were
in operating theatre or recovery room”
Participants: 788 patients of whom 138 excluded (72 ineligible and not randomised,
66 patients after randomisation = 650 patients: 317 patients high-dose group and 333
patients standard-dose group analysed - no further loss to follow-up
33 patients (14 standard-dose adrenaline and 19 high-dose adrenaline) given medication
but ineligible for study (16 trauma patients, 9 terminal illness, 3 second arrest during
hospitalisation, 2 more than 15 minutes without CPR, 2 respiratory arrest, 1 < 16 years
Interventions Administered up to five doses of high-dose (7 mg) or standard-dose (1 mg) adrenaline at
five-minute intervals according to standard protocols for advanced cardiac life support.
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Stiell 1992 (Continued)
If physicians wanted to administer more than 5 doses adrenaline 1mg given. Drugs
administered IV (peripheral or central venous catheter) or occasionally endobronchial
but not in the pre-hospital setting
Outcomes Survived until hospital discharge, neurological outcome, successful resuscitation (return
of pulse and blood pressure for at least 1 hour), any ROSC. Neurological outcomes
were assessed using CPC at hospital discharge: (’1’ considered ’good’); and mini-mental
examination scores. No hospital length of stay reported
Notes Emergency medical service used EMT who provided BLS but did not intubate patients
or administer IV drugs
Ethics approval, trial not registered, independent data-monitoring committee. Interim
analysis performed, 125 patients in each arm. Sample size calculation not done, ITT
analysis not stated. No consort diagram. Missing data reported
Funding: supported by a grant (03089R) from the Emergency Health Services Branch
of the Ontario Ministry of Health. Dr. Stiell is a Career Scientist of the Health Research
Personnel Development Program of the Ontario Ministry of Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Each hospital provided central randomisa-
tion schedule but order of use of the pack-
ages which depended by chance on the lo-
cation of each cardiac arrest
Allocation concealment (selection bias) Low risk Study drugs prepared by pharmacy, pack-
ages of 5 coded and pre-loaded syringes, lo-
cated at 61 sites in the two hospitals. “The
order of use of packages depended on loca-
tion of each cardiac arrest”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Pre-loaded syringes - assume EMS staff
blinded to treatment allocation. Patient un-
conscious at the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All assessments were made in a double
blind manner”. Patient unconscious at the
time of event andnot blinding for hard out-
come (death/survival) unlikely to be asso-
ciated with risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk 66 patients (9%) excluded post randomisa-
tion (21 eligible but did not receive study
drug, 33 received study drug but not eli-
gible,12 patients received study drug inap-
propriately). No patients lost to follow-up
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Stiell 1992 (Continued)
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias Unclear risk Sensitivity analysis undertaken including
the 33 patients (14 standard dose group
and 19 high dose group) who received the
study drug but were declared ineligible, no
difference in results. No post resuscitation
care reported
Stiell 2001
Methods Multicentre triple-blind RCT of in-hospital cardiac arrest - EDs, critical care units, and
wards
3 Canadian teaching hospitals, Ottawa Canada
3 July 1997 to 30 November 1998
Participants Included: ”Adults admitted to hospital, had a cardiac arrest, and required adrenaline
according to AHA ACLS protocols for asystole, PEA, or refractory VF“
Excluded: ”< 16 years; documented terminal illness (life expectancy < 6 weeks, N = 4),
do not resuscitate status, admitted to hospital less than 24 hours after traumatic injury
(n=4); cardiac arrest secondary to obvious exsanguination (N = 8) such as ruptured aortic
aneurysm and massive gastrointestinal bleeding; cardiac arrest before arrival at hospital
(N = 50); cardiac arrest in the operating, recovery, or delivery rooms, previously entered
into study“ (N = 2).”
Participants: 324 patients assessed, “50 eligible patients not entered into study by attend-
ing clinicians because of urgency and stress of treating an immediately life-threatening
condition”
274 randomised, of these “74 ineligible patients received study drug and were excluded
afterwards for predefined exclusion criteria”
200 patients = 104 patients in vasopressin group and 96 in adrenaline group analysed
Interventions Received one dose of vasopressin 40 U or adrenaline 1 mg IV, as initial vasopressor
given at the outset of resuscitation. “All patients who failed to respond to initial drug
administration received, as rescue therapy, standard doses of adrenaline every 3-5 min”,
intravenously
Outcomes Survival to hospital discharge, 30-day survival, neurological outcome, ROSC (“any pe-
riod of time with patient generated pulse and BP”), survival to 1 hour after resuscitation
discontinued, other survivalmeasures, adverse events.Neurologic outcomeswere assessed
at hospital discharge using the modified mini-mental state examination (MMSE) and a
five-point cerebral performance scale. Percentages in each CPC category were provided
- so able to categorise CPC < 3 as ’good’ for this review
Notes Ethics approval, not registered, sample size calculationbut not powered todetect clinically
meaningful differences, adjudication committee, Intention to treat analysis. No loss to
follow-up. Potency of study drugs tested at two months storage
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Stiell 2001 (Continued)
Funding: the work was funded by a peer-reviewed grant from the Heart and Stroke
Foundation of Canada. Ferring, Canada, provided the vasopressin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomi-
sation. “Study drugs randomly distributed
to all cardiac arrest carts in all designated
study areas. Distribution of study drugs
on the cardiac arrest carts done by con-
secutive allocation from a computer-gener-
ated random listing stratified by centre and
prepared by the data coordinating centre.
Once opened, entire cardiac arrest box re-
turned to hospital pharmacy and another
study box released in appropriate sequence
according to randomisation schedule”
Allocation concealment (selection bias) Low risk “All drugs prepared by Ottawa Hospital
pharmacy in identical preloaded 10 mL sy-
ringes. Study syringes packaged in special
cardiac-arrest trays and boxes at multiple
sites throughout study hospitals”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Paper states “Triple blind”. Patient uncon-
scious at the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors blinded for primary outcome
(ROSC at 1 hour). Unclear for discharge
from hospital and other secondary out-
comes. Patient unconscious at the time of
event and not blinding for hard outcome
(death/survival) unlikely to be associated
with risk of bias. Uncertain as to whether
the assessor was aware of the allocation
group for neurological outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All excluded cases accounted for, no loss to
follow-up
Selective reporting (reporting bias) Unclear risk Primary and secondary outcomes defined
a priori reported. Relevant outcomes re-
ported - but not compared against a trial
protocol/clinical trial registry entry
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Stiell 2001 (Continued)
Other bias Unclear risk Intention to treat analysis not stated. “74
ineligible patients received study drug and
were excluded afterwards for predefined ex-
clusion criteria”. No post resuscitation care
reported
Wenzel 2004
Methods Double-blind, prospective, multicenter, randomised, controlled clinical trial
33 communities and involved 44 physician-staffed emergency medical service units in
Austria, Germany, and Switzerland
June 1999 to March 2002
Participants Included: Adult patients who had an out-of-hospital cardiac arrest and presented with
ventricular fibrillation, PEA or asystole requiring CPR with vasopressor therapy. Patients
who presented with pulseless electrical activity or asystole underwent randomisation
immediately; patients with VF underwent randomisation after first three attempts at
defibrillation had failed
Excluded: successful defibrillation without administration of a vasopressor, documented
terminal illness, lack of IV access, hemorrhagic shock, pregnancy, cardiac arrest after
trauma, age less than 18 years, and presence of a do-not-resuscitate order
Participants: 5967 screened, 4748 ineligible, 1219 patients underwent randomisation;
33 were excluded because of missing study-drug codes. Among remaining 1186 patients,
589 vasopressin and 597 adrenaline were analysed
Interventions Box containing the study drugs - either two ampoules of 1 mg of adrenaline or two
ampoules of 40 IU of vasopressin opened and either 1 mg of adrenaline or 40 IU of
vasopressin injected intravenously. If spontaneous circulation not restored within three
minutes after first injection of study drug, same drug at same dose injected again. If
spontaneous circulation not restored, patient given additional injection of adrenaline at
discretion of treating emergency physician. All drugs followed by 20 mls normal saline
Outcomes Survival to hospital discharge, survival to hospital admission, neurological outcome,
ROSC (not defined). Neurological outcomes were assessed using CPC at hospital dis-
charge. Percentages in each CPC category were provided - so able to categorise CPC <
3 as ’good’ for this review. No hospital length of stay reported
Notes Emergency Medical Service - “44 physician-staffed emergency medical service units”
Ethics approval, trial not registered, data and safety monitoring committee, sample size
calculation, intention-to-treat analysis. Consort flow diagram provided. Missing data
reported. Internal, blinded administrative interim analysis performed. Funding ended
December 2001, therefore enrolment stopped in March 2002
Funding: supported in part by a Founders Grant for Training in Clinical Critical Care
Research, Society of Critical CareMedicine, Des Plaines, Ill.; by Science Funds No. 7280
of the Austrian National Bank, Vienna, Austria; by the Dean’s Office of the Leopold-
Franzens University College of Medicine, Innsbruck, Austria; by the Laerdal Foundation
for Acute Medicine, Stavanger, Norway; by an Austrian Science Foundation grant (P-
14169-MED), Vienna, Austria; by Pfizer, Karlsruhe, Germany; by the Science Foun-
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Wenzel 2004 (Continued)
dation of the Tyrolean State Hospitals, Innsbruck, Austria; and by the Department of
Anesthesiology and Critical Care Medicine, Leopold-Franzens University, Innsbruck,
Austria
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly generated (? how) blocks of 10
stratified by Centre
Allocation concealment (selection bias) Low risk Not explicitly stated whether each ambu-
lance has more than one box of study drugs
to select from - albeit study ampoules iden-
tical in appearance
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk EMS staff and study investigators blinded
to study treatment. Patient unconscious at
the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient unconscious at the time of event
and not blinding for hard outcome (death/
survival) unlikely to be associated with risk
of bias. Uncertain as to whether the asses-
sor was aware of the allocation group for
neurological outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk 11 patients in the vasopressin group (1.9%)
and 9 in the epinephrine group (1.5%) lost
to follow-up before hospital discharge
11 patients (19.3%) in the vasopressin
group and 12 patients (20.7%) in
adrenaline group who survived to hospital
discharge lost to follow-up for neurological
outcome
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias Unclear risk Intention-to-treat analysis; but role of in-
dustry funder unclear. No post resuscita-
tion care reported
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Woodhouse 1995
Methods Placebo controlled, randomised trial
Brisbane Australia
July 1989 to December 1992
Participants Included: In-hospital and out-of-hospital arrests (45%), primary cardiac arrest only
Excluded: “Secondary causes were suspected as per the Utstein style”
Participants: 406 patients treated - 53 excluded; “10 for protocol violations, 7 had inad-
equate records and 36 terminated prematurely (cancers, severe multiple organ disease,
extreme old age)”
353 eligible patients, 14 patients (16 episodes) did not receive study drug and were
excluded
339 patients but 145 received open-label 1mg adrenaline instead of placebo (analysed
separately)
194patients recruited to study, 94high-dose adrenaline and100 placebo (saline) analysed
Interventions High dose (10mg) adrenaline vs. placebo (saline), two doses only. Two defibrillations
(not three) before randomisation for VF patients. “Once patient given both ampoules,
open label 1mg adrenaline could be administered”
Outcomes Survival at hospital discharge, immediate survival (stable cardiac rhythm with palpable
pulse at time cardiac arrest team left). No neurological outcome reported. No hospital
length of stay reported
Notes Ethics approval, trial not registered, sample size calculation, ITT analysis not described,
no Consort chart. “Study undertaken in a general hospital with cardiac arrests supervised
by numerous middle-level medical staff unhappy to use the placebo”. Missing data not
reported
Funding: Astra Pharmaceuticals (Sydney) was responsible for the manufacture and pack-
aging of the trial material
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation method not described but
it is stated “randomised into the trial”
Allocation concealment (selection bias) Low risk Blinded, randomised box containing two
10 ml ampoules, either 10mg adrenaline or
saline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Clinical staff blinded to study treatment.
Patient unconscious at the time of event
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Yes - data sheet sent to central area
where“where the data was validated, in a
blinded fashion”. Patient unconscious at
the time of event and not blinding for hard
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Woodhouse 1995 (Continued)
outcome (death/survival) unlikely to be as-
sociated with risk of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Excluded 10 patients for protocol viola-
tions, 7 for inadequate records
145 patients received open-label 1mg
adrenaline instead of study drug
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias High risk “Supervising physicians gave significant
preference for males, patients with no pre-
vious cardiac history and without multi-
ple organ disease to be given open 1 mg
adrenaline.” Patients in asystole “preferen-
tially placed in the trial group” (114 (69%)
vs. 170 (88%)) and patients in ventricular
fibrillation “preferentially given open 1 mg
adrenaline” (31 (21%) vs. 24 (12%) P < 0.
03); Role of industry funder unclear
Zhu 2000
Methods Randomised trial, single centre
Chinese university hospital
Participants 66 patients with cardiac arrest recruited in ED
Interventions Control (group A) 1 mg adrenaline 5 minutely; experimental (group B) 2 mg adrenaline
3minutely; graded dosage (group C) initial dose 1mg adrenaline, progressively increased
dosage 2 mg adrenaline 3 minutely
Outcomes ROSC (“spontaneous circulation restoration”), survival to hospital discharge, neurolog-
ical outcome (method of assessment unclear). No hospital length of stay reported
Notes Chinese paper translated into English by independent researcher.No description of EMS
or when study conducted
No ethics approval stated, registration of study not stated, no consort diagram, intention
to treat analysis not stated
Funding: not known
Risk of bias
Bias Authors’ judgement Support for judgement
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Zhu 2000 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomisation not described but it is
stated “randomised into the trial”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported. Patient unconscious at the
time of event.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported. Patient unconscious at the
time of event and not blinding for hard
outcome (death/survival) unlikely to be as-
sociated with risk of bias. Uncertain as to
whether the assessor was aware of the allo-
cation group for neurological outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete, 66 patients
Selective reporting (reporting bias) Unclear risk Relevant outcomes reported - but not com-
pared against a trial protocol/clinical trial
registry entry
Other bias Unclear risk Reported that there were no difference in
baseline characteristics of groups (age, gen-
der, aetiology cardiac arrest time), data not
shown.Nodescriptionof rhythmof cardiac
arrest. No intention to treat analysis stated
but all 66 patients included in the analysis.
Funding source not stated. No post resus-
citation care reported
ACLS - advanced cardiac life support
AHA - American Heart Association
BLS - basic life support
BP - blood pressure
CPC - Cerebral Performance Category
CVC - central venous catheter
DC - direct current
ECG - electorcardiogram
ED - emergency department
EMS - emergency medical service
EMT-D - emergency medical technician-defibrillator (a member of an emergency medical services crew withspecial training in the use
of cardiac defibrillating equipment)
ETT - endotrachel tube
GCS - Glasgow Coma Score
HDA high dose adrenaline
ITT - intention-to-treat
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IU - international unit
IV - intravenous
LOS - length of stay (usually means in hospital)
mg - milligram
ml - millilitre
OHCA - out-of-hospital cardiac arrest
PEA - pulseless electrical activity
RCT - randomised controlled trial
ROSC - return of spontaneous circulation
SAMU - Service d’Aide Médicale Urgente (Emergency Medical Service in France)
SDA - standard dose adrenaline
VF - ventricular fibrillation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aggarwal 1993 Not RCT - critique
Berthier 1987 Not RCT - review paper
Betleri 1966 Not RCT - case study
Callaham 1989 Not RCT - editorial
Callaham 1991a Not RCT - cohort study
Callaham 1991b Not RCT - letter
Carroll 2012 Not RCT - feasibility study
Carvolth 1996 Not RCT - before-and-after study
Cohen 1975 Not RCT - review paper
David 2007 Not RCT - cohort study
Di Stilio 2005 Not RCT - critique
Dieckmann 1995 Not RCT - cohort study
Ghafourian 2015 Not RCT - ’controls’ not randomised
Grmec 2006 Not RCT - cohort study
Hagihara 2012 Not RCT - cohort study
Herlitz 1995 Not RCT - cohort study
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Lee 2000 Conference abstract, preliminary report of 10 cases, no information of trial could be found, data sought but
no response from author
Lee 2001 Not RCT - case series
Lindner 1991b Not study drugs - comparison of noradrenaline
McCrirrick 1992 Not cardiac arrest - anaesthetised patients
McCrirrick 1994 Not cardiac arrest - bypass surgery patients
McIntyre 2004 Not RCT - editorial
Mentzelopoulos 2007 Not study drugs - comparison of vasopressin+epinephrine+methylprednisolone versus
placebo+epinephrine+placebo
Mentzelopoulos 2009 Not study drugs - comparison of vasopressin+epinephrine+methylprednisolone versus
placebo+epinephrine+placebo
Meyer 2011 Not RCT - review
Morris 1997 Not RCT - convenience sample pilot study
Niemann 2000 Not RCT - retrospective cohort study
Nishizawa 1993 Not RCT - cohort study
Ohshige 2005 Not RCT - cohort study
Olasveengen 2009 Not study drugs - RCT of intravenous drugs, not specifically adrenaline or vasopressin
Olasveengen 2010 Not RCT - post-hoc analysis
Olson 1989 Not study drugs - comparison of methoxamine versus epinephrine
Papastylianou 2010 Not RCT - cohort
Paradis 1991 Surrogate outcomes - coronary perfusion pressures and plasma catecholamines
Patrick 1995 Not study drugs - comparison of methoxamine versus epinephrine
Pellegrino 2006 Not RCT - review paper
Quadrel 1995 Not cardiac arrest - asthma patients
Quintana 2005 Not RCT - critique
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Quinton 1987 Surrogate outcomes - comparison of endotracheal versus intravenous adrenaline; surrogate outcomes of
plasma concentration of adrenaline and noradrenaline
Salam 2005 Not RCT - critique
Silfvast 1985 Not study drugs - comparison of adrenaline and phenylephrine
Song 1997 Not study drugs - comparison of methoxamine versus epinephrine
Turner 1988 Not study drugs - comparison of methoxamine versus epinephrine
Weaver 1990 Not study drugs - comparison of epinephrine and lidocaine
Woodhouse 1992 Surrogate outcomes - plasma catecholamines
Worster 2005 Not RCT - review of Wenzel 2004 paper
Youngquist 2012 Not RCT - letter
Zwingmann 2012 Not RCT - systematic review of mortality after out-of-hospital resuscitation of patients suffering a trauma
Characteristics of ongoing studies [ordered by study ID]
Andersen 2018
Trial name or title Vasopressin and methylprednisolone for in-hospital cardiac arrest (VAM-IHCA)
Methods Investigator-initiated, multicentre, randomised, placebo-controlled, parallel group, double-blind, superiority
trial of vasopressin and methylprednisolone during adult in-hospital cardiac arrest
5 enrolling sites in Denmark
Participants Adult in-hospital cardiac arrest: (n = 492) receiving at least 1 dose of adrenaline will be enrolled
Inclusion criteria:
1. In-hospital cardiac arrest
2. Age ≥ 18 years
3. Received at least 1 dose of adrenaline during cardiopulmonary resuscitation
Exclusion criteria:
1. Clearly-documented “do-not-resuscitate” order prior to the cardiac arrest
2. Prior enrolment in the trial
3. Mechanical circulatory support at the time of the cardiac arrest
4. Known or suspected pregnancy at the time of the cardiac arrest
Interventions “The study drugs will consist of 40 mg methylprednisolone (Solu-medrol®, Pfizer) and 20 IU of vasopressin
(Empressin®, Amomed PharmaGmbH) given as soon as possible after the first dose of adrenaline. Additional
doses of vasopressin (20 IU) will be administered after each adrenaline dose for a maximum of four doses
(80 IU). The placebo for vasopressin will consist of 1 mL of 9 mg/mL NaCl (”normal saline“) from 2 mL
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Andersen 2018 (Continued)
ampoules identical to the vasopressin ampoules. The placebo for methylprednisolone will also consist of 1
mL of 9 mg/mL NaCl”
Outcomes “The primary outcome is return of spontaneous circulation and key secondary outcomes include survival at
30 days and survival at 30 days with a favourable neurological outcome”
Starting date September 2018
Contact information Contact: Lars W Andersen, MD, MPH, PhD Associate Professor, Aarhus University Hospital
lwandersen@clin.au.dk
Notes clinicaltrials.gov/ct2/show/NCT03640949
Raymond 2008
Trial name or title A prospective, randomised, controlled trial of combination vasopressin and epinephrine to epinephrine only
for in-intensive care unit paediatric cardiopulmonary resuscitation
Methods Prospective, randomized, controlled trial
Participants up to 18 years (child, adult)
Interventions Experimental: 1
Paediatric patients that experience in-hospital CPA who remain in cardiac arrest despite CPR and an initial,
standard dose of epinephrine (0.01 mg/kg), will be randomly assigned to receive vasopressin (0.8 units/kg)
rescue as the second vasopressor medication
Active Comparator: 2
Paediatric patients that experience in-hospital CPA who remain in cardiac arrest despite CPR and an initial,
standard dose of epinephrine (0.01 mg/kg), will be randomly assigned to receive standard-dose epinephrine
(0.01 mg/kg)rescue as the second vasopressor medication
Outcomes Primary outcome measures:
Combination vasopressin and epinephrine (CPA refractory to cardiopulmonary resuscitation and initial
epinephrine dosing) will increase the proportion of patients surviving to hospital discharge by 25% compared
to epinephrine alone. Time frame: Immediate
Secondary Outcome Measures:
Combination vasopressin and epinephrine will decrease the time to ROSC. Time frame: Immediate
Vasopressin and epinephrine will improve the proportion of CPA survivors with favourable neurologic out-
come (short-term Pediatric Overall Performance Category) (POPC) score discharge of 1 - 3 or unchanged
from hospital admission at the time of hospital. Time frame: Period of hospitalisation
Vasopressin and epinephrine will improve the proportion of CPA survivors with favourable neurologic out-
come (short-term Paediatric Cerebral Performance Category) (PCPC) score of 1 - 3 or unchanged from
hospital admission at time of hospital discharge. Time frame: Period of hospitalisation
Combination vasopressin and epinephrine will improve 24-hour survival. Time frame: 24 hours
Combination vasopressin and epinephrine will decrease the proportion of patients who require prolonged
CPR (CPR > 20 minutes) to achieve sustained ROSC. Time frame: Immediate
Combination vasopressin and epinephrine will increase organ recovery in those people who meet brain death
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criteria following the CPA event. Time frame: Period of hospitalisation
Combination epinephrine and vasopressin will improve rates of return of spontaneous circulation (ROSC).
Time frame: Immediate
Starting date April 2008
Contact information clinicaltrials.gov/ct2/show/NCT00628550; Tia.Tortoriello@Childrens.com
Notes Study completion date was listed as December 2011. Researchers attempted to be contacted in February 2018
for an update, but no response
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D A T A A N D A N A L Y S E S
Comparison 1. Standard dose adrenaline (SDA) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Survival to hospital discharge 2 8538 Risk Ratio (M-H, Random, 95% CI) 1.44 [1.11, 1.86]
2 Survival to hospital admission 2 8489 Risk Ratio (M-H, Random, 95% CI) 2.51 [1.67, 3.76]
3 Neurological outcome 2 8535 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.90, 1.62]
4 ROSC 3 8663 Risk Ratio (M-H, Random, 95% CI) 2.86 [2.21, 3.71]
Comparison 2. Standard dose adrenaline (SDA) versus high dose adrenaline (HDA)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Survival to hospital discharge 10 6274 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.75, 1.62]
2 Survival to hospital discharge
(adult vs child)
10 6274 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.75, 1.62]
2.1 Adults 7 5957 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.73, 1.29]
2.2 Children 3 317 Risk Ratio (M-H, Random, 95% CI) 1.54 [0.17, 13.66]
3 Survival to hospital discharge
(OHCA vs IHCA)
9 6206 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.74, 1.34]
3.1 OHCA 5 5701 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.72, 1.32]
3.2 IHCA 5 505 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.42, 3.59]
4 Survival to hospital admission 5 5764 Risk Ratio (M-H, Random, 95% CI) 1.13 [1.03, 1.24]
5 24-hour survival 5 4179 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.76, 1.43]
6 Neurological outcome 4 5803 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.65, 1.26]
7 ROSC (OHCA vs IHCA) 12 6364 Risk Ratio (M-H, Random, 95% CI) 1.16 [1.06, 1.28]
7.1 OHCA 8 6174 Risk Ratio (M-H, Random, 95% CI) 1.13 [1.06, 1.22]
7.2 IHCA 4 190 Risk Ratio (M-H, Random, 95% CI) 1.78 [0.82, 3.88]
8 ROSC (adults vs children) 13 7014 Risk Ratio (M-H, Random, 95% CI) 1.15 [1.02, 1.29]
8.1 ROSC-adults 10 6697 Risk Ratio (M-H, Random, 95% CI) 1.14 [1.01, 1.29]
8.2 ROSC-children 3 317 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.67, 2.56]
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Comparison 3. Standard dose adrenaline (SDA) versus vasopressin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Survival to hospital discharge 6 2511 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.84, 1.85]
2 Survival to hospital discharge
(OHCA vs IHCA)
5 1784 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.84, 1.68]
2.1 OHCA 3 1542 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.76, 2.07]
2.2 IHCA 2 242 Risk Ratio (M-H, Random, 95% CI) 2.21 [0.29, 17.06]
3 Survival to hospital admission 3 1953 Risk Ratio (M-H, Random, 95% CI) 1.27 [1.04, 1.54]
4 Neurological Outcome 4 2406 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.54, 1.25]
5 ROSC 6 2531 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.90, 1.33]
6 ROSC (OHCA vs IHCA) 5 1804 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.84, 1.68]
6.1 OHCA 3 1562 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.80, 1.39]
6.2 IHCA 2 242 Risk Ratio (M-H, Random, 95% CI) 1.76 [0.40, 7.71]
Comparison 4. Standard dose adrenaline (SDA) versus [adrenaline and vasopressin]
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Survival to hospital discharge 3 3242 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.47, 1.22]
2 Survival to hospital admission 3 3249 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.08]
3 Neurological Outcome 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 ROSC 3 3249 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.87, 1.08]
88Adrenaline and vasopressin for cardiac arrest (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 Standard dose adrenaline (SDA) versus placebo, Outcome 1 Survival to hospital
discharge.
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 1 Standard dose adrenaline (SDA) versus placebo
Outcome: 1 Survival to hospital discharge
Study or subgroup Adrenaline Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Perkins 2018 128/4009 91/3995 93.9 % 1.40 [ 1.08, 1.83 ]
Jacobs 2011 11/272 5/262 6.1 % 2.12 [ 0.75, 6.02 ]
Total (95% CI) 4281 4257 100.0 % 1.44 [ 1.11, 1.86 ]
Total events: 139 (Adrenaline), 96 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.77 (P = 0.0057)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours adrenaline
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Analysis 1.2. Comparison 1 Standard dose adrenaline (SDA) versus placebo, Outcome 2 Survival to hospital
admission.
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 1 Standard dose adrenaline (SDA) versus placebo
Outcome: 2 Survival to hospital admission
Study or subgroup Intervention Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jacobs 2011 69/272 34/262 40.7 % 1.95 [ 1.34, 2.84 ]
Perkins 2018 947/3973 319/3982 59.3 % 2.98 [ 2.64, 3.35 ]
Total (95% CI) 4245 4244 100.0 % 2.51 [ 1.67, 3.76 ]
Total events: 1016 (Intervention), 353 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 4.41, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 4.45 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours adrenaline
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Analysis 1.3. Comparison 1 Standard dose adrenaline (SDA) versus placebo, Outcome 3 Neurological
outcome.
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 1 Standard dose adrenaline (SDA) versus placebo
Outcome: 3 Neurological outcome
Study or subgroup Intervention Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jacobs 2011 9/272 5/262 7.5 % 1.73 [ 0.59, 5.11 ]
Perkins 2018 87/4007 74/3994 92.5 % 1.17 [ 0.86, 1.59 ]
Total (95% CI) 4279 4256 100.0 % 1.21 [ 0.90, 1.62 ]
Total events: 96 (Intervention), 79 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours adrenaline
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Analysis 1.4. Comparison 1 Standard dose adrenaline (SDA) versus placebo, Outcome 4 ROSC.
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 1 Standard dose adrenaline (SDA) versus placebo
Outcome: 4 ROSC
Study or subgroup Intervention Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jacobs 2011 64/272 22/262 23.0 % 2.80 [ 1.78, 4.41 ]
Perkins 2018 1457/3975 468/3960 70.1 % 3.10 [ 2.82, 3.41 ]
Woodhouse 1995 9/94 7/100 6.9 % 1.37 [ 0.53, 3.53 ]
Total (95% CI) 4341 4322 100.0 % 2.86 [ 2.21, 3.71 ]
Total events: 1530 (Intervention), 497 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 3.00, df = 2 (P = 0.22); I2 =33%
Test for overall effect: Z = 7.93 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA), Outcome
1 Survival to hospital discharge.
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA)
Outcome: 1 Survival to hospital discharge
Study or subgroup High dose adrenaline
Standard
dose
adrenaline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brown 1992 31/648 26/632 26.5 % 1.16 [ 0.70, 1.94 ]
Callaham 1992 5/286 3/260 6.4 % 1.52 [ 0.37, 6.28 ]
Gueugniaud 1998 38/1677 46/1650 30.9 % 0.81 [ 0.53, 1.24 ]
Li 1999 3/21 1/22 2.9 % 3.14 [ 0.35, 27.88 ]
Lindner 1991a 4/28 2/40 5.0 % 2.86 [ 0.56, 14.54 ]
Patterson 2005 9/127 2/86 5.8 % 3.05 [ 0.67, 13.76 ]
Perondi 2004 0/34 4/34 1.7 % 0.11 [ 0.01, 1.99 ]
Sanchez-Mendiola 1998 4/20 0/16 1.8 % 7.29 [ 0.42, 126.07 ]
Stiell 1992 10/317 16/333 16.5 % 0.66 [ 0.30, 1.43 ]
Zhu 2000 2/23 1/20 2.6 % 1.74 [ 0.17, 17.78 ]
Total (95% CI) 3181 3093 100.0 % 1.10 [ 0.75, 1.62 ]
Total events: 106 (High dose adrenaline), 101 (Standard dose adrenaline)
Heterogeneity: Tau2 = 0.08; Chi2 = 11.78, df = 9 (P = 0.23); I2 =24%
Test for overall effect: Z = 0.49 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA), Outcome
2 Survival to hospital discharge (adult vs child).
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA)
Outcome: 2 Survival to hospital discharge (adult vs child)
Study or subgroup High dose adrenaline
Standard
dose
adrenaline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Adults
Brown 1992 31/648 26/632 26.5 % 1.16 [ 0.70, 1.94 ]
Callaham 1992 5/286 3/260 6.4 % 1.52 [ 0.37, 6.28 ]
Gueugniaud 1998 38/1677 46/1650 30.9 % 0.81 [ 0.53, 1.24 ]
Li 1999 3/21 1/22 2.9 % 3.14 [ 0.35, 27.88 ]
Lindner 1991a 4/28 2/40 5.0 % 2.86 [ 0.56, 14.54 ]
Stiell 1992 10/317 16/333 16.5 % 0.66 [ 0.30, 1.43 ]
Zhu 2000 2/23 1/20 2.6 % 1.74 [ 0.17, 17.78 ]
Subtotal (95% CI) 3000 2957 90.8 % 0.97 [ 0.73, 1.29 ]
Total events: 93 (High dose adrenaline), 95 (Standard dose adrenaline)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.56, df = 6 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
2 Children
Patterson 2005 9/127 2/86 5.8 % 3.05 [ 0.67, 13.76 ]
Perondi 2004 0/34 4/34 1.7 % 0.11 [ 0.01, 1.99 ]
Sanchez-Mendiola 1998 4/20 0/16 1.8 % 7.29 [ 0.42, 126.07 ]
Subtotal (95% CI) 181 136 9.2 % 1.54 [ 0.17, 13.66 ]
Total events: 13 (High dose adrenaline), 6 (Standard dose adrenaline)
Heterogeneity: Tau2 = 2.25; Chi2 = 5.08, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 3181 3093 100.0 % 1.10 [ 0.75, 1.62 ]
Total events: 106 (High dose adrenaline), 101 (Standard dose adrenaline)
Heterogeneity: Tau2 = 0.08; Chi2 = 11.78, df = 9 (P = 0.23); I2 =24%
Test for overall effect: Z = 0.49 (P = 0.63)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
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Analysis 2.3. Comparison 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA), Outcome
3 Survival to hospital discharge (OHCA vs IHCA).
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA)
Outcome: 3 Survival to hospital discharge (OHCA vs IHCA)
Study or subgroup High-dose adrenaline
Standard-
dose
adrenaline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 OHCA
Brown 1992 31/648 26/632 32.0 % 1.16 [ 0.70, 1.94 ]
Callaham 1992 3/260 5/286 4.4 % 0.66 [ 0.16, 2.73 ]
Gueugniaud 1998 38/1677 46/1650 44.6 % 0.81 [ 0.53, 1.24 ]
Patterson 2005 9/127 2/86 3.9 % 3.05 [ 0.67, 13.76 ]
Stiell 1992 2/170 2/165 2.4 % 0.97 [ 0.14, 6.81 ]
Subtotal (95% CI) 2882 2819 87.3 % 0.97 [ 0.72, 1.32 ]
Total events: 83 (High-dose adrenaline), 81 (Standard-dose adrenaline)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.66, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
2 IHCA
Li 1999 3/21 1/22 1.9 % 3.14 [ 0.35, 27.88 ]
Perondi 2004 0/34 4/34 1.1 % 0.11 [ 0.01, 1.99 ]
Sanchez-Mendiola 1998 4/20 0/16 1.1 % 7.29 [ 0.42, 126.07 ]
Stiell 1992 5/147 7/168 7.0 % 0.82 [ 0.26, 2.52 ]
Zhu 2000 2/23 1/20 1.7 % 1.74 [ 0.17, 17.78 ]
Subtotal (95% CI) 245 260 12.7 % 1.22 [ 0.42, 3.59 ]
Total events: 14 (High-dose adrenaline), 13 (Standard-dose adrenaline)
Heterogeneity: Tau2 = 0.41; Chi2 = 5.43, df = 4 (P = 0.25); I2 =26%
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 3127 3079 100.0 % 1.00 [ 0.74, 1.34 ]
Total events: 97 (High-dose adrenaline), 94 (Standard-dose adrenaline)
Heterogeneity: Tau2 = 0.01; Chi2 = 9.17, df = 9 (P = 0.42); I2 =2%
Test for overall effect: Z = 0.03 (P = 0.97)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
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Analysis 2.4. Comparison 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA), Outcome
4 Survival to hospital admission.
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA)
Outcome: 4 Survival to hospital admission
Study or subgroup High dose adrenaline
Standard
dose
adrenaline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brown 1992 145/648 136/632 21.2 % 1.04 [ 0.85, 1.28 ]
Callaham 1992 50/286 27/260 4.7 % 1.68 [ 1.09, 2.61 ]
Choux 1995 65/271 54/265 8.9 % 1.18 [ 0.86, 1.62 ]
Gueugniaud 1998 444/1677 389/1650 65.1 % 1.12 [ 1.00, 1.26 ]
Polglase 1994 1/34 1/41 0.1 % 1.21 [ 0.08, 18.57 ]
Total (95% CI) 2916 2848 100.0 % 1.13 [ 1.03, 1.24 ]
Total events: 705 (High dose adrenaline), 607 (Standard dose adrenaline)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.90, df = 4 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.54 (P = 0.011)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA), Outcome
5 24-hour survival.
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA)
Outcome: 5 24-hour survival
Study or subgroup HDA SDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Choux 1995 40/271 36/265 28.7 % 1.09 [ 0.72, 1.65 ]
Gueugniaud 1998 272/1677 263/1650 50.3 % 1.02 [ 0.87, 1.19 ]
Lipman 1993 4/19 5/16 6.8 % 0.67 [ 0.22, 2.09 ]
Patterson 2005 20/127 7/86 11.9 % 1.93 [ 0.86, 4.38 ]
Perondi 2004 1/34 7/34 2.3 % 0.14 [ 0.02, 1.10 ]
Total (95% CI) 2128 2051 100.0 % 1.04 [ 0.76, 1.43 ]
Total events: 337 (HDA), 318 (SDA)
Heterogeneity: Tau2 = 0.05; Chi2 = 6.52, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA), Outcome
6 Neurological outcome.
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA)
Outcome: 6 Neurological outcome
Study or subgroup High dose adrenaline
Standard
dose
adrenaline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brown 1992 29/648 24/632 38.4 % 1.18 [ 0.69, 2.00 ]
Callaham 1992 0/286 2/260 1.2 % 0.18 [ 0.01, 3.77 ]
Gueugniaud 1998 29/1677 33/1650 44.1 % 0.86 [ 0.53, 1.42 ]
Stiell 1992 9/317 15/333 16.3 % 0.63 [ 0.28, 1.42 ]
Total (95% CI) 2928 2875 100.0 % 0.91 [ 0.65, 1.26 ]
Total events: 67 (High dose adrenaline), 74 (Standard dose adrenaline)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.83, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA), Outcome
7 ROSC (OHCA vs IHCA).
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA)
Outcome: 7 ROSC (OHCA vs IHCA)
Study or subgroup
High Dose
Adrenaline
Standard
Dose
Adrenaline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 OHCA
Brown 1992 217/648 190/632 23.2 % 1.11 [ 0.95, 1.31 ]
Callaham 1992 37/286 22/260 3.5 % 1.53 [ 0.93, 2.52 ]
Choux 1995 96/271 85/265 13.1 % 1.10 [ 0.87, 1.40 ]
Gueugniaud 1998 678/1677 601/1650 43.2 % 1.11 [ 1.02, 1.21 ]
Patterson 2005 32/127 15/86 2.9 % 1.44 [ 0.83, 2.50 ]
Polglase 1994 7/34 6/41 0.9 % 1.41 [ 0.52, 3.79 ]
Schmidbauer 2000 16/25 14/32 3.6 % 1.46 [ 0.90, 2.39 ]
Sherman 1997 15/78 7/62 1.3 % 1.70 [ 0.74, 3.92 ]
Subtotal (95% CI) 3146 3028 91.7 % 1.13 [ 1.06, 1.22 ]
Total events: 1098 (High Dose Adrenaline), 940 (Standard Dose Adrenaline)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.60, df = 7 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 3.50 (P = 0.00046)
2 IHCA
Li 1999 10/21 4/22 0.9 % 2.62 [ 0.97, 7.07 ]
Perondi 2004 20/34 21/34 5.7 % 0.95 [ 0.65, 1.40 ]
Sanchez-Mendiola 1998 7/20 0/16 0.1 % 12.14 [ 0.75, 197.77 ]
Zhu 2000 13/23 6/20 1.6 % 1.88 [ 0.88, 4.03 ]
Subtotal (95% CI) 98 92 8.3 % 1.78 [ 0.82, 3.88 ]
Total events: 50 (High Dose Adrenaline), 31 (Standard Dose Adrenaline)
Heterogeneity: Tau2 = 0.37; Chi2 = 9.41, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 1.45 (P = 0.15)
Total (95% CI) 3244 3120 100.0 % 1.16 [ 1.06, 1.28 ]
Total events: 1148 (High Dose Adrenaline), 971 (Standard Dose Adrenaline)
Heterogeneity: Tau2 = 0.00; Chi2 = 12.69, df = 11 (P = 0.31); I2 =13%
Test for overall effect: Z = 3.09 (P = 0.0020)
Test for subgroup differences: Chi2 = 1.29, df = 1 (P = 0.26), I2 =22%
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Analysis 2.8. Comparison 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA), Outcome
8 ROSC (adults vs children).
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 2 Standard dose adrenaline (SDA) versus high dose adrenaline (HDA)
Outcome: 8 ROSC (adults vs children)
Study or subgroup High dose adrenaline
Standard
dose
adrenaline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ROSC-adults
Brown 1992 217/648 190/632 20.0 % 1.11 [ 0.95, 1.31 ]
Callaham 1992 37/286 22/260 4.9 % 1.53 [ 0.93, 2.52 ]
Choux 1995 96/271 85/265 14.1 % 1.10 [ 0.87, 1.40 ]
Gueugniaud 1998 678/1677 601/1650 26.9 % 1.11 [ 1.02, 1.21 ]
Li 1999 10/21 4/22 1.4 % 2.62 [ 0.97, 7.07 ]
Polglase 1994 7/34 6/41 1.4 % 1.41 [ 0.52, 3.79 ]
Schmidbauer 2000 16/25 14/32 5.0 % 1.46 [ 0.90, 2.39 ]
Sherman 1997 15/78 7/62 2.0 % 1.70 [ 0.74, 3.92 ]
Stiell 1992 56/317 76/333 10.2 % 0.77 [ 0.57, 1.05 ]
Zhu 2000 13/23 6/20 2.3 % 1.88 [ 0.88, 4.03 ]
Subtotal (95% CI) 3380 3317 88.2 % 1.14 [ 1.01, 1.29 ]
Total events: 1145 (High dose adrenaline), 1011 (Standard dose adrenaline)
Heterogeneity: Tau2 = 0.01; Chi2 = 13.96, df = 9 (P = 0.12); I2 =36%
Test for overall effect: Z = 2.12 (P = 0.034)
2 ROSC-children
Patterson 2005 32/127 15/86 4.2 % 1.44 [ 0.83, 2.50 ]
Perondi 2004 20/34 21/34 7.4 % 0.95 [ 0.65, 1.40 ]
Sanchez-Mendiola 1998 7/20 0/16 0.2 % 12.14 [ 0.75, 197.77 ]
Subtotal (95% CI) 181 136 11.8 % 1.31 [ 0.67, 2.56 ]
Total events: 59 (High dose adrenaline), 36 (Standard dose adrenaline)
Heterogeneity: Tau2 = 0.19; Chi2 = 5.40, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 0.78 (P = 0.43)
Total (95% CI) 3561 3453 100.0 % 1.15 [ 1.02, 1.29 ]
Total events: 1204 (High dose adrenaline), 1047 (Standard dose adrenaline)
Heterogeneity: Tau2 = 0.01; Chi2 = 18.30, df = 12 (P = 0.11); I2 =34%
Test for overall effect: Z = 2.23 (P = 0.025)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
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Analysis 3.1. Comparison 3 Standard dose adrenaline (SDA) versus vasopressin, Outcome 1 Survival to
hospital discharge.
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 3 Standard dose adrenaline (SDA) versus vasopressin
Outcome: 1 Survival to hospital discharge
Study or subgroup Vasopressin Adrenaline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Li 1999 7/20 1/22 3.6 % 7.70 [ 1.04, 57.23 ]
Lindner 1997 8/20 3/20 9.5 % 2.67 [ 0.82, 8.62 ]
Mukoyama 2009 10/178 6/158 12.5 % 1.48 [ 0.55, 3.98 ]
Ong 2012 11/374 8/353 14.5 % 1.30 [ 0.53, 3.19 ]
Stiell 2001 12/104 13/96 19.4 % 0.85 [ 0.41, 1.78 ]
Wenzel 2004 57/578 58/588 40.5 % 1.00 [ 0.71, 1.41 ]
Total (95% CI) 1274 1237 100.0 % 1.25 [ 0.84, 1.85 ]
Total events: 105 (Vasopressin), 89 (Adrenaline)
Heterogeneity: Tau2 = 0.07; Chi2 = 7.04, df = 5 (P = 0.22); I2 =29%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Standard dose adrenaline (SDA) versus vasopressin, Outcome 2 Survival to
hospital discharge (OHCA vs IHCA).
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 3 Standard dose adrenaline (SDA) versus vasopressin
Outcome: 2 Survival to hospital discharge (OHCA vs IHCA)
Study or subgroup Vasopressin
Standard
dose
adrenaline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 OHCA
Lindner 1997 8/20 3/20 7.5 % 2.67 [ 0.82, 8.62 ]
Mukoyama 2009 10/178 6/158 10.0 % 1.48 [ 0.55, 3.98 ]
Wenzel 2004 57/578 58/588 35.4 % 1.00 [ 0.71, 1.41 ]
Subtotal (95% CI) 776 766 52.9 % 1.26 [ 0.76, 2.07 ]
Total events: 75 (Vasopressin), 67 (Standard dose adrenaline)
Heterogeneity: Tau2 = 0.07; Chi2 = 2.82, df = 2 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.89 (P = 0.37)
2 IHCA
Li 1999 7/20 1/22 2.8 % 7.70 [ 1.04, 57.23 ]
Stiell 2001 62/104 57/96 44.3 % 1.00 [ 0.80, 1.26 ]
Subtotal (95% CI) 124 118 47.1 % 2.21 [ 0.29, 17.06 ]
Total events: 69 (Vasopressin), 58 (Standard dose adrenaline)
Heterogeneity: Tau2 = 1.76; Chi2 = 4.32, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 0.76 (P = 0.45)
Total (95% CI) 900 884 100.0 % 1.19 [ 0.84, 1.68 ]
Total events: 144 (Vasopressin), 125 (Standard dose adrenaline)
Heterogeneity: Tau2 = 0.06; Chi2 = 7.19, df = 4 (P = 0.13); I2 =44%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Chi2 = 0.28, df = 1 (P = 0.60), I2 =0.0%
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Analysis 3.3. Comparison 3 Standard dose adrenaline (SDA) versus vasopressin, Outcome 3 Survival to
hospital admission.
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 3 Standard dose adrenaline (SDA) versus vasopressin
Outcome: 3 Survival to hospital admission
Study or subgroup Vasopressin Adrenaline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lindner 1997 14/20 7/20 8.0 % 2.00 [ 1.03, 3.88 ]
Ong 2012 83/374 59/353 30.1 % 1.33 [ 0.98, 1.79 ]
Wenzel 2004 214/589 186/597 61.9 % 1.17 [ 0.99, 1.37 ]
Total (95% CI) 983 970 100.0 % 1.27 [ 1.04, 1.54 ]
Total events: 311 (Vasopressin), 252 (Adrenaline)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.74, df = 2 (P = 0.25); I2 =27%
Test for overall effect: Z = 2.38 (P = 0.018)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Standard dose adrenaline (SDA) versus vasopressin, Outcome 4 Neurological
Outcome.
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 3 Standard dose adrenaline (SDA) versus vasopressin
Outcome: 4 Neurological Outcome
Study or subgroup Vasopressin Adrenaline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mukoyama 2009 4/178 0/158 2.0 % 7.99 [ 0.43, 147.33 ]
Ong 2012 5/374 5/353 11.4 % 0.94 [ 0.28, 3.23 ]
Stiell 2001 10/104 13/96 28.7 % 0.71 [ 0.33, 1.54 ]
Wenzel 2004 22/567 28/576 57.9 % 0.80 [ 0.46, 1.38 ]
Total (95% CI) 1223 1183 100.0 % 0.82 [ 0.54, 1.25 ]
Total events: 41 (Vasopressin), 46 (Adrenaline)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.60, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Standard dose adrenaline (SDA) versus vasopressin, Outcome 5 ROSC.
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 3 Standard dose adrenaline (SDA) versus vasopressin
Outcome: 5 ROSC
Study or subgroup Vasopressin Adrenaline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Li 1999 14/20 4/22 3.9 % 3.85 [ 1.52, 9.77 ]
Lindner 1997 16/20 11/20 11.8 % 1.45 [ 0.92, 2.29 ]
Mukoyama 2009 51/178 42/158 15.8 % 1.08 [ 0.76, 1.53 ]
Ong 2012 119/374 106/353 22.5 % 1.06 [ 0.85, 1.32 ]
Stiell 2001 62/104 57/96 21.9 % 1.00 [ 0.80, 1.26 ]
Wenzel 2004 145/589 167/597 24.1 % 0.88 [ 0.73, 1.07 ]
Total (95% CI) 1285 1246 100.0 % 1.10 [ 0.90, 1.33 ]
Total events: 407 (Vasopressin), 387 (Adrenaline)
Heterogeneity: Tau2 = 0.03; Chi2 = 12.70, df = 5 (P = 0.03); I2 =61%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Standard dose adrenaline (SDA) versus vasopressin, Outcome 6 ROSC (OHCA
vs IHCA).
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 3 Standard dose adrenaline (SDA) versus vasopressin
Outcome: 6 ROSC (OHCA vs IHCA)
Study or subgroup Vasopressin
Standard
dose
adrenaline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 OHCA
Lindner 1997 16/20 11/20 21.3 % 1.45 [ 0.92, 2.29 ]
Mukoyama 2009 51/178 42/158 25.0 % 1.08 [ 0.76, 1.53 ]
Wenzel 2004 145/589 167/597 30.3 % 0.88 [ 0.73, 1.07 ]
Subtotal (95% CI) 787 775 76.7 % 1.05 [ 0.80, 1.39 ]
Total events: 212 (Vasopressin), 220 (Standard dose adrenaline)
Heterogeneity: Tau2 = 0.03; Chi2 = 4.53, df = 2 (P = 0.10); I2 =56%
Test for overall effect: Z = 0.35 (P = 0.72)
2 IHCA
Li 1999 14/20 4/22 9.9 % 3.85 [ 1.52, 9.77 ]
Stiell 2001 12/104 13/96 13.5 % 0.85 [ 0.41, 1.78 ]
Subtotal (95% CI) 124 118 23.3 % 1.76 [ 0.40, 7.71 ]
Total events: 26 (Vasopressin), 17 (Standard dose adrenaline)
Heterogeneity: Tau2 = 0.95; Chi2 = 6.21, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 0.75 (P = 0.45)
Total (95% CI) 911 893 100.0 % 1.19 [ 0.84, 1.68 ]
Total events: 238 (Vasopressin), 237 (Standard dose adrenaline)
Heterogeneity: Tau2 = 0.09; Chi2 = 12.79, df = 4 (P = 0.01); I2 =69%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Chi2 = 0.45, df = 1 (P = 0.50), I2 =0.0%
0.01 0.1 1 10 100
Favours SDA Favours vasopressin
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Analysis 4.1. Comparison 4 Standard dose adrenaline (SDA) versus [adrenaline and vasopressin], Outcome
1 Survival to hospital discharge.
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 4 Standard dose adrenaline (SDA) versus [adrenaline and vasopressin]
Outcome: 1 Survival to hospital discharge
Study or subgroup Vaso + Adr Adrenaline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Callaway 2006 5/167 4/158 13.5 % 1.18 [ 0.32, 4.32 ]
Ducros 2011 0/14 2/16 2.6 % 0.23 [ 0.01, 4.36 ]
Gueugniaud 2008 24/1439 33/1448 83.9 % 0.73 [ 0.43, 1.23 ]
Total (95% CI) 1620 1622 100.0 % 0.76 [ 0.47, 1.22 ]
Total events: 29 (Vaso + Adr), 39 (Adrenaline)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.11, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours SDA Favours Vaso+Adr
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Analysis 4.2. Comparison 4 Standard dose adrenaline (SDA) versus [adrenaline and vasopressin], Outcome
2 Survival to hospital admission.
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 4 Standard dose adrenaline (SDA) versus [adrenaline and vasopressin]
Outcome: 2 Survival to hospital admission
Study or subgroup Vaso+Adr SDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Callaway 2006 31/167 37/158 9.7 % 0.79 [ 0.52, 1.21 ]
Ducros 2011 5/14 8/16 2.4 % 0.71 [ 0.30, 1.68 ]
Gueugniaud 2008 299/1442 310/1452 87.9 % 0.97 [ 0.84, 1.12 ]
Total (95% CI) 1623 1626 100.0 % 0.95 [ 0.83, 1.08 ]
Total events: 335 (Vaso+Adr), 355 (SDA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.21, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.40)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours SDA Favours vaso+adr
Analysis 4.3. Comparison 4 Standard dose adrenaline (SDA) versus [adrenaline and vasopressin], Outcome
3 Neurological Outcome.
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 4 Standard dose adrenaline (SDA) versus [adrenaline and vasopressin]
Outcome: 3 Neurological Outcome
Study or subgroup Vaso + Adr SDA Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gueugniaud 2008 13/1439 20/1448 0.65 [ 0.33, 1.31 ]
0.005 0.1 1 10 200
Favours SDA Favours vasop+adr
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Analysis 4.4. Comparison 4 Standard dose adrenaline (SDA) versus [adrenaline and vasopressin], Outcome
4 ROSC.
Review: Adrenaline and vasopressin for cardiac arrest
Comparison: 4 Standard dose adrenaline (SDA) versus [adrenaline and vasopressin]
Outcome: 4 ROSC
Study or subgroup Vaso + Adr SDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Callaway 2006 52/167 48/158 10.6 % 1.02 [ 0.74, 1.42 ]
Ducros 2011 6/14 10/16 2.2 % 0.69 [ 0.34, 1.40 ]
Gueugniaud 2008 413/1442 428/1452 87.2 % 0.97 [ 0.87, 1.09 ]
Total (95% CI) 1623 1626 100.0 % 0.97 [ 0.87, 1.08 ]
Total events: 471 (Vaso + Adr), 486 (SDA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.02, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours SDA Favours vaso+adr
A P P E N D I C E S
Appendix 1. Search strategy
CENTRAL & DARE
#1 MeSH descriptor Epinephrine explode all trees
#2 (adrenalin*)
#3 (epinephrin*)
#4 MeSH descriptor Vasopressins explode all trees
#5 (vasopressin*)
#6 terlipressin
#7 (antidiuretic hormone* or anti diuretic hormone*)
#8 (argipressin)
#9 (pitressin)
#10 pressyn
#11 (petresin)
#12 (glypressin)
#13 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)
#14 MeSH descriptor Heart Arrest explode all trees
#15 MeSH descriptor Ventricular Fibrillation, this term only
#16 MeSH descriptor Cardiopulmonary Resuscitation explode all trees
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#17 (cardiac arrest)
#18 (heart arrest*)
#19 (ventricular fibrillation*)
#20 (acls or als)
#21 resuscitation
#22 (advanced near3 support*)
#23 (#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22)
#24 (#13 AND #23)
MEDLINE Ovid
1 exp Epinephrine/
2 adrenalin$.tw.
3 epinephrin$.tw.
4 exp Vasopressins/
5 vasopressin$.tw.
6 terlipressin.tw.
7 (antidiuretic hormone$ or anti diuretic hormone$).tw.
8 argipressin.tw.
9 pitressin.tw.
10 pressyn.tw.
11 petresin.tw.
12 glypressin.tw.
13 or/1-12
14 exp Heart Arrest/
15 Ventricular Fibrillation/
16 exp Cardiopulmonary Resuscitation/
17 cardiac arrest$.tw.
18 heart arrest$.tw.
19 ventricular fibrillation$.tw.
20 (acls or als).tw.
21 resuscitation.tw.
22 (advanced adj3 support$).tw.
23 or/14-22
24 randomized controlled trial.pt.
25 controlled clinical trial.pt.
26 randomized.ab.
27 placebo.ab.
28 drug therapy.fs.
29 randomly.ab.
30 trial.ab.
31 groups.ab.
32 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31
33 exp animals/ not humans.sh.
34 32 not 33
35 13 and 23 and 34
Embase Ovid
1 exp Epinephrine/
2 adrenalin$.tw.
3 epinephrin$.tw.
4 exp Vasopressins/
5 vasopressin$.tw.
6 terlipressin.tw.
7 (antidiuretic hormone$ or anti diuretic hormone$).tw.
8 argipressin.tw.
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9 pitressin.tw.
10 pressyn.tw.
11 petresin.tw.
12 glypressin.tw.
13 or/1-12
14 exp Heart Arrest/
15 Ventricular Fibrillation/
16 exp Cardiopulmonary Resuscitation/
17 cardiac arrest$.tw.
18 heart arrest$.tw.
19 ventricular fibrillation$.tw.
20 (acls or als).tw.
21 resuscitation.tw.
22 (advanced adj3 support$).tw.
23 or/14-22
24 random$.tw.
25 factorial$.tw.
26 crossover$.tw.
27 cross over$.tw.
28 cross-over$.tw.
29 placebo$.tw.
30 (doubl$ adj blind$).tw.
31 (singl$ adj blind$).tw.
32 assign$.tw.
33 allocat$.tw.
34 volunteer$.tw.
35 crossover procedure/
36 double blind procedure/
37 randomized controlled trial/
38 single blind procedure/
39 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38
40 (animal/ or nonhuman/) not human/
41 39 not 40
42 13 and 23 and 41
Appendix 2. Summary of study characteristics
Presenting rhythm, witnessed cardiac arrests and bystander CPR for the control group (placebo or standard-dose adrenaline
or standard-dose adrenaline and placebo) compared to experimental group (high-dose adrenaline or vasopressin)
Study Number of par-
ticipants
VF % Asystole % PEA % Bystander
Witnessed arrest
%
Bystander CPR %
C Exp C Exp C Exp C Exp C Exp C Exp
Brown
1992
632 648 49.5 45.1 31.7 33.6 18.4 20.5 39 36 24 23
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(Continued)
Calla-
ham
1992
260 286 21 26 48 47 31 26 63 63 22 29
Call-
away
2006
158 167 17 14 51 50 23 22 47 43 35 31
Choux
1995
265 271 16 18 75 72 9 10 - - - -
Ducros
2011
16 14 0 14.3 50 21.4 50 64.3 - - - -
Gueug-
niaud
1998
1650 1667 15.9 18 74.6 72.5 9.5 9.5 78.6 79.1 9.3 10.3
Gueug-
niaud
2008
1452 1442 9.3 9.2 82.4 83.1 8.3 7.7 76.1 74.3 26 27.7
Jacobs
2011
262 272 48.1 43.8 25.2 22.8 26.7 33.5 52.7 44.1 49.2 52.9
Li 1999
a
22 21 - - - - - - - - - -
Li
1999
Lo
Vaspn
22 20 - - - - - - - - - -
Li
1999
Hi
Vaspn
22 20 - - - - - - - - - -
Lind-
ner
1991a
40 28 - - 65 68 35 32 60 57 - -
Lind-
ner
1997
20 20 100 100 -- - - 60 65 25 20
Lip-
man
1993
16 19 100 100
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(Continued)
Mukoyama
2009
158 178 23 25 62 61 15 14 45.6 43.3 16.5 14
Ong
2012
353 374 7.9 5.9 67.4 70.9 20.4 17.6 75.1 70.9 14.2 16.6
Patter-
son
2005
59 95 24 23 37 33
Perkins
2018
3999 4015 17.1 17.8 54.9 53.2 23.4 23.8 49.2 50.1 58.7 59.3
Per-
ondi
2004
34 34 0 12 82 62 18 26 - - - -
Polglase
1994a
41 30 - - - - - - - - - -
Polglase
1994b
41 34 - - - - - - - - - -
Sanchez-
Mendi-
ola
1998
16 20 - 100 100 - - - - -
Schmid-
bauer
2000
32 25 44 60 56 40 - - - - -
Sher-
man
1997
62 78 16 31 84 69 - 74 59 - -
Stiell
1992
333 317 40 43 41 41 16 20 69 69 27 34
Stiell
2001
96 104 16 20 27 34 54 41 84 78 - -
Wenzel
2004
597 589 42 38 45 44 14 18 - - 18 19
Wood-
house
100 94 37 41 63 59 - - - - 33 32
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(Continued)
1995
Zhu
2000
20 23 - - - - - - - - - -
C = Control group; Exp = Experimental group; a 5mg adrenaline; b 10 mg adrenaline
C O N T R I B U T I O N S O F A U T H O R S
IJ and JF contributed equally to the protocol development.
IJ, JF, TW and GP selected studies for inclusion.
IJ, JF and TW extracted data from the studies and entered data into RevMan.
SG provided statistical advice.
IJ, JF, TW and GP drafted the review text.
JF and GP responded to reviewer feedback and amended review text accordingly.
JF, TW, GP and SG approved the final review.
D E C L A R A T I O N S O F I N T E R E S T
GP is the lead investigator (and JF and SG are co-investigators) on the recent RCT of adrenaline versus placebo in OHCA in the UK,
the Paramedic 2 trial (Perkins 2018).
GP has received reimbursement of expenses to attend and speak at CPR conferences and to develop national and international CPR
guidelines. He has received payment from Elsevier Publishing for his role as an editor for the journal Resuscitation. He led a trial of
adrenaline in out of hospital cardiac arrest, for which his employer received funding from the National Institute for Health Research.
IJ and JF were co-authors on another included study (Jacobs 2011).
TW - none known.
S O U R C E S O F S U P P O R T
Internal sources
• Department of Emergency Medicine, University of Western Australia, Australia.
Previous employment (IJ, JF, TW)
• Curtin University, Australia.
Employment - (IJ, JF, TW)
• National Institute for Health Research, UK.
NIHR Senior Investigator
• Intensive Care Foundation, UK.
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External sources
• Australian Resuscitation Council (Western Australian Branch), Australia.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
During the conduct of the review the lead author (IJ) passed away suddenly. Study selection, data extraction, quality assessment
undertaken by IJ were checked by TW, who then acted as the 2nd review author for the completion of the review. We updated the
search strategy to reflect changes in the search terms used in the online databases during the conduct of the review.
Update to protocol: Issue 2, 2003
Vasopressin. Since the protocol, a number of RCTs have been published which compare adrenaline with vasopressin for the treatment
of cardiac arrest. We therefore considered it prudent to include studies of vasopressin, in addition to placebo and high-dose adrenaline.
This provides a more comprehensive review.
The protocol listed the following possible outcomes, that were not reported in the included studies: all-cause mortality; return of a
non-perfusing cardiac rhythm; Presence of organised electrical activity in the heart but producing no cardiac output, also referred to as
pulseless electrical activity (PEA); admission to Intensive Care.
In the Methods section of the protocol it states: “Neurological outcome as assessed using either the Glasgow Outcome Scale (Teasdale
1998, Jennett 1975) or Cerebral Performance Category (Jennett 1975)”. Whilst CPC scores (and to a lesser extent the GOS) are the
most commonly reported methods of reporting neurological outcomes in resuscitation research (because of the relative ease of collection
through medical record review), our intention was not to limit neurological outcomes to only those assessed by CPC or GOS. Our
definition of ‘neurological outcome’ in the protocol should have been stated as follows: Neurological outcome (e.g. as assessed using
either the Glasgow Outcome Scale (Teasdale 1998, Jennett 1975) or Cerebral Performance Category (Jennett 1975). We have therefore
also mentioned other neurological assessments (such as the mini-mental score) in the Results.
We have included GRADE ’Summary of findings’ tables, although they were not planned, to meet the more recent methodological
standards required by Cochrane.
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